Pharmaceutical composition for treating cystic fibrosis

By using Compounds I, Compound II and Compound III to regulate CFTR protein, the problem of defective CFTR protein function in cystic fibrosis is solved, anion transport is improved, and clinical symptoms in CF patients are improved.

CN119033710APending Publication Date: 2024-11-29VERTEX PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411121186.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-04-13
Filing Date
2019-02-04
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Cystic fibrosis leads to functional defects in CFTR proteins, resulting in reduced anion and fluid transport, resulting in lung mucus accumulation and microbial infection. The existing treatment methods have not been effectively cured.

Method used

Using Compound I, Compound II and its pharmaceutically acceptable salts, as well as Compound III-d or Compound III as CFTR regulators, enhances its number and activity on the cell surface by regulating the folding and transport of the CFTR protein, thereby enhancing anions by regulating its volume and activity on the cell surface. transport.

Benefits of technology

It effectively improves the surface expression and function of CFTR protein, reduces lung mucus accumulation and microbial infection, and improves the clinical symptoms of CF patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033710A_ABST
    Figure CN119033710A_ABST
Patent Text Reader

Abstract

The invention relates to a pharmaceutical composition for treating cystic fibrosis. A pharmaceutical composition comprising Compound (I). Methods of treating cystic fibrosis comprise administering to a patient one or more such pharmaceutical compositions. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with application date of February 4, 2019, application number 201980015318.8, and invention name “Pharmaceutical composition for treating cystic fibrosis”. Background Art

[0002] This application claims priority to U.S. Provisional Application No. 62 / 626,567 filed on February 5, 2018 and U.S. Provisional Application No. 62 / 657,522 filed on April 13, 2018. The disclosures of these two provisional applications are incorporated herein by reference in their entirety.

[0003] One aspect of the present invention provides a pharmaceutical composition comprising a modulator of the cystic fibrosis transmembrane conductance regulator (CFTR). Cystic fibrosis (CF) is a recessive genetic disease that affects approximately 70,000 children and adults worldwide. Despite advances in the treatment of CF, there is still no cure.

[0004] In CF patients, mutations in CFTR endogenously expressed in the respiratory epithelium result in reduced apical anion secretion, leading to an imbalance in ion and fluid transport. The resulting reduction in anion transport leads to increased mucus accumulation in the lungs and concomitant microbial infections, ultimately leading to death in CF patients. In addition to respiratory diseases, CF patients often suffer from gastrointestinal problems and pancreatic insufficiency, which, if not treated, will lead to death. In addition, most men with cystic fibrosis are infertile, and women with cystic fibrosis have reduced fertility.

[0005] Sequence analysis of the CFTR gene has revealed a variety of disease-causing mutations (Cutting, GR et al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell 61:863:870; and Kerem, BS et al. (1989) Science 245:1073-1080; Kerem, BS et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, more than 2000 mutations in the CF gene have been identified; currently, the CFTR2 database contains information on only 322 of these identified mutations, with sufficient evidence to define 281 mutations as pathogenic. The most common pathogenic mutation is a phenylalanine deletion at position 508 of the CFTR amino acid sequence, commonly referred to as the F508del mutation. This mutation occurs in approximately 70% of cystic fibrosis cases and is associated with severe disease.

[0006] The deletion of residue 508 in CFTR prevents the new protein from folding correctly. This causes the mutant protein to be unable to leave the endoplasmic reticulum (ER) and be transported to the plasma membrane. Therefore, the number of CFTR channels present in the membrane for anion transport is far less than the number observed in cells expressing wild-type CFTR (i.e., CFTR without mutation). In addition to impaired transport, mutations also cause defective channel gating. The reduction in the number of channels in the membrane and the gating defects together lead to a reduction in transepithelial anion and fluid transport. (Quinton, PM (1990), FASEB J.4: 2709-2727). The defective channels due to the F508del mutation are still functional, although their function is lower than that of wild-type CFTR channels. (Dalemans et al. (1991), Nature Lond. 354: 526-528; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50). In addition to F508del, other disease-causing CFTR mutations that result in defects in trafficking, synthesis, and / or channel gating may be up- or down-regulated to alter anion secretion and modify disease progression and / or severity.

[0007] CFTR is a cAMP / ATP-mediated anion channel that is expressed in a variety of cell types, including absorptive and secretory epithelial cells, where it regulates anion flux across the membrane and the activity of other ion channels and proteins. In epithelial cells, the normal function of CFTR is essential for maintaining the transport of electrolytes throughout the body, including respiratory and digestive tissues. CFTR consists of approximately 1480 amino acids that encode a protein consisting of tandem repeats of transmembrane domains, each of which contains six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are connected by a large polarity regulatory (R)-domain that has multiple phosphorylation sites that regulate channel activity and cellular transport.

[0008] Chloride transport is via ENaC and CFTR present on the apical membrane and Na+ expressed on the basolateral surface of cells. + -K + -ATPase pump and Cl- channels. Secondary active transport of chloride ions from the luminal side leads to intracellular chloride accumulation, which can then passively transport chloride ions via Cl- - channels out of the cell, resulting in vectorial transport. + / 2Cl - / K + Cotransporter, Na + -K + -ATPase pump and basolateral membrane K +The arrangement of the channels and the arrangement of the CFTR on the luminal side coordinates the secretion of chloride ions via the CFTR on the luminal side. Because water itself can never be actively transported, its flow across the epithelium depends on the small transepithelial osmotic gradient created by the bulk flow of sodium and chloride ions.

[0009] Therefore, there is a need for novel methods of treating CFTR-mediated diseases. Summary of the invention

[0010] Disclosed herein are pharmaceutical compositions comprising Compound I and / or a pharmaceutically acceptable salt thereof, Compound II and / or a pharmaceutically acceptable salt thereof, and Compound III-d or Compound III and / or a pharmaceutically acceptable salt thereof. Compound I can be depicted as having the following structure:

[0011]

[0012] The chemical name of Compound I is N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide. PCT Application No. PCT / US2017 / 065425, incorporated herein by reference, discloses Compound I, a method for preparing Compound I, a method for preparing Form A of Compound I, and Compound I is a compound having an EC of 0.07 μM. 50 In some embodiments, Compound 1 is amorphous.

[0013] In some embodiments, Compound I is in Form A. In some embodiments, crystalline Form A is characterized by an X-ray powder diffraction pattern having a signal at at least one 2θ value selected from 6.6±0.2, 7.6±0.2, 9.6±0.2, 12.4±0.2, 13.1±0.2, 15.2±0.2, 16.4±0.2, 18.2±0.2, and 18.6±0.2. In some embodiments, crystalline Form A is characterized by an X-ray powder diffraction pattern having a signal at at least three 2θ values ​​selected from 6.6±0.2, 7.6±0.2, 9.6±0.2, 12.4±0.2, 13.1±0.2, 15.2±0.2, 16.4±0.2, 18.2±0.2, and 18.6±0.2. In some embodiments, the crystalline form A is characterized by an X-ray powder diffraction pattern having signals at at least three 2θ values ​​selected from 6.6±0.2, 9.6±0.2, 13.1±0.2, 15.2±0.2, 18.2±0.2, and 18.6±0.2. In some embodiments, the crystalline form A is characterized by an X-ray powder diffraction pattern having signals at at least three 2θ values ​​selected from 6.6±0.2, 13.1±0.2, 18.2±0.2. In some embodiments, the crystalline form A is characterized by an X-ray powder diffraction pattern having signals at at least six 2θ values ​​of 6.6±0.2, 9.6±0.2, 13.1±0.2, 15.2±0.2, 18.2±0.2, and 18.6±0.2. In some embodiments, crystalline Form A is characterized by an X-ray powder diffraction pattern substantially similar to Figure 4A In some embodiments, crystalline Form A is characterized by an X-ray powder diffraction pattern that is substantially similar to Figure 4B X-ray powder diffraction pattern in. Crystalline Form A was found to be the most thermodynamically stable form and provided good bioavailability.

[0014] Compound II can be depicted as having the following structure:

[0015]

[0016] The chemical name of compound II is (R)-1-(2,2-difluorobenzo[d][1,3]dioxazol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide;

[0017] Compound III-d can be depicted as having the following structure:

[0018]

[0019] The chemical name of compound III-d is N-(2-(tert-butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide;

[0020] Compound III can be depicted as having the following structure:

[0021]

[0022] The chemical name of compound III is N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 A representative list of CFTR gene mutations is shown below.

[0024] Figure 2A This is the dissolution data of Compound I.

[0025] Figure 2B This is the dissolution data of Compound I.

[0026] Figure 2C This is the dissolution data of compound III-d.

[0027] Figure 3A The bioavailability of Compound I in dogs for Tablet 1, Tablet 2, and Tablet 3 is shown.

[0028] Figure 3B The bioavailability of Compound II in dogs for Tablet 1, Tablet 2, and Tablet 3 is shown.

[0029] Figure 3C The bioavailability of Compound III-d for Tablet 1, Tablet 2, and Tablet 3 in dogs is shown.

[0030] Figure 4A This is the XRPD of Form A of Compound 1.

[0031] Figure 4B is the XRPD of a tablet having the composition of Tablet 4.

[0032] Figure 5A This is the dissolution data of Compound I in Tablet 4.

[0033] Figure 5B The dissolution data of Compound II in Tablet 4.

[0034] Figure 5CThe dissolution data of Compound III in Tablet 4.

[0035] Fig. 6A This is the dissolution data of Compound I in Tablet 14.

[0036] Figure 6B The dissolution data of Compound II in Tablet 14.

[0037] Figure 6C The dissolution data of Compound III in Tablet 14. DETAILED DESCRIPTION

[0038] definition

[0039] As used herein, "CFTR" refers to cystic fibrosis transmembrane conductance regulator.

[0040] As used herein, "mutation" may refer to a mutation in the CFTR gene or the CFTR protein. "CFTR gene mutation" refers to a mutation in the CFTR gene, and "CFTR protein mutation" refers to a mutation in the CFTR protein. A genetic defect or mutation or a change in a nucleotide in a gene typically results in a mutation or frameshift in the CFTR protein translated from the gene.

[0041] The term "F508del" refers to a mutant CFTR protein that lacks the amino acid phenylalanine at position 508.

[0042] As used herein, a patient who is "homozygous" for a particular genetic mutation has the same mutation on each allele.

[0043] As used herein, a patient who is "heterozygous" for a particular genetic mutation has that mutation on one allele and a different mutation on the other allele.

[0044] As used herein, the term "modulator" refers to a compound that increases the activity of a biological compound such as a protein. For example, a CFTR modulator is a compound that increases the activity of CFTR. The increase in activity caused by a CFTR modulator includes, but is not limited to, compounds that correct, enhance, stabilize and / or amplify CFTR.

[0045] As used herein, the term "CFTR corrector" refers to a compound that promotes the processing and transport of CFTR to increase the amount of CFTR on the cell surface. Compound I, Compound II, and pharmaceutically acceptable salts thereof disclosed herein are CFTR correctors.

[0046] As used herein, the term "CFTR enhancer" refers to a compound that increases the channel activity of the CFTR protein located on the cell surface and thereby enhances ion transport. Compound III-d and Compound III disclosed herein are CFTR enhancers.

[0047] As used herein, the term "active pharmaceutical ingredient" ("API") refers to a biologically active compound.

[0048] As used herein, the term "pharmaceutically acceptable salt" refers to a salt form of a compound of the present disclosure, wherein the salt is non-toxic. Pharmaceutically acceptable salts of compounds of the present disclosure include those derived from suitable inorganic and organic acids and bases. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19.

[0049] Suitable pharmaceutically acceptable salts are, for example, those disclosed in SM Berge et al. J. Pharmaceutical Sciences, 1977, 66, 1-19. For example, Table 1 of the article provides the following pharmaceutically acceptable salts:

[0050] Table 1:

[0051]

[0052]

[0053] Non-limiting examples of pharmaceutically acceptable acid addition salts include: salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid or perchloric acid; salts formed with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid; and salts formed by using other methods used in the art such as ion exchange. Non-limiting examples of pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, and valerate. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4The present disclosure also contemplates the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Suitable non-limiting examples of alkali metal salts and alkaline earth metal salts include sodium salts, lithium salts, potassium salts, calcium salts, and magnesium salts. Other non-limiting examples of pharmaceutically acceptable salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates. Other suitable non-limiting examples of pharmaceutically acceptable salts include benzenesulfonates and glucosamine salts.

[0054] As used herein, the term "XRPD" refers to the analytical characterization method of X-ray powder diffraction. XRPD patterns are recorded using a diffractometer in transmission or reflection geometry under ambient conditions.

[0055] As used herein, the terms "X-ray powder diffraction pattern", "X-ray powder diffraction pattern", "XRPD pattern" refer interchangeably to an experimentally obtained pattern that plots signal position (abscissa) versus signal intensity (ordinate). For amorphous materials, an X-ray powder diffraction pattern may include one or more broad signals; and for crystalline materials, an X-ray powder diffraction pattern may include one or more signals, each identified by an angle value measured in degrees 2θ (°2θ) depicted on the abscissa of the X-ray powder diffraction pattern, which may be expressed as "a signal at ... degrees 2θ", "a signal at a 2θ value of ...", and / or "a signal at at least ... 2θ values ​​selected from ...".

[0056] As used herein, a "signal" or "peak" refers to a point in an XRPD pattern where the intensity measured in counts is localized. One of ordinary skill in the art will recognize that one or more signals (or peaks) in an XRPD pattern may overlap and may not be apparent, for example, to the naked eye. Indeed, one of ordinary skill in the art will recognize that some art-recognized methods are capable of and suitable for determining whether a signal is present in a pattern, such as Rietveld refinement.

[0057] As used herein, "signal at degrees 2θ", "signal at a 2θ value of", and / or "signal at at least one 2θ value selected from" refers to the X-ray reflection positions (° 2θ) measured and observed in an X-ray powder diffraction experiment.

[0058] The repeatability of the angle value is within the range of ±0.2° 2θ, ie, the angle value can be at the angle value +0.2° 2θ, the angle value −0.2° 2θ, or any value between these two endpoints (angle value +0.2° 2θ and angle value −0.2° 2θ).

[0059] The terms "signal intensity" and "peak intensity" refer interchangeably to the relative signal intensity within a given X-ray powder diffraction pattern. Factors that may affect the relative signal or peak intensity include sample thickness and preferred orientation (e.g., crystalline particles are not randomly distributed).

[0060] As used herein, the term "X-ray powder diffraction pattern having signals at ... 2θ values" refers to an XRPD pattern comprising X-ray reflection positions (° 2θ) measured and observed in an X-ray powder diffraction experiment.

[0061] As used herein, an X-ray powder diffraction pattern is "substantially similar to the X-ray powder diffraction pattern in [a particular] pattern" when at least 90%, such as at least 95%, at least 98%, or at least 99%, of the signals in the two diffraction patterns overlap. In determining "substantially similar", one of ordinary skill in the art will understand that there may be deviations in the intensity and / or signal positions in an XRPD diffraction pattern even for the same crystalline form. Thus, one of ordinary skill in the art will understand that the maximum value of the signal in an XRPD diffraction pattern (in units of degrees 2θ (°2θ) referred to herein) generally refers to the reported value ±0.2 degrees 2θ, which is a deviation recognized in the art.

[0062] As used herein, a crystalline form is "substantially pure" when the amount by weight of the crystalline form is equal to or greater than 90% of the sum of all solid forms in a sample as determined by methods of the art, such as quantitative XRPD. In some embodiments, the solid form is "substantially pure" when the amount by weight of the solid form is equal to or greater than 95% of the sum of all solid forms in a sample. In some embodiments, the solid form is "substantially pure" when the amount by weight of the solid form is equal to or greater than 99% of the sum of all solid forms in a sample.

[0063] As used herein, the term "amorphous" refers to a solid material that has no long-range order in its molecular positions. Amorphous solids are generally supercooled liquids in which molecules are arranged in a random manner, so there is no clear arrangement, such as molecular stacking, and there is no long-range order. For example, an amorphous material is a solid material that does not have sharp characteristic crystalline peaks (i.e., not crystalline as determined by XRPD) in its X-ray powder diffraction (XRPD) pattern. Instead, one or more broad peaks (e.g., halos) appear in its XRPD pattern. Broad peaks are a feature of amorphous solids. See, for example, a comparison of the XRPD of amorphous materials and crystalline materials in US2004 / 0006237.

[0064] As used herein, the term "substantially amorphous" refers to a solid material that has little or no long-range order in its molecular positions. For example, a substantially amorphous material has less than 15% crystallinity (e.g., less than 10% crystallinity or less than 5% crystallinity). It should also be noted that the term "substantially amorphous" includes the descriptor "amorphous," which refers to a material that has no (0%) crystallinity.

[0065] As used herein, the term "dispersion" refers to a dispersed system in which one substance (i.e., the dispersed phase) is distributed throughout a second substance (continuous phase or vehicle) in discrete units. The size of the dispersed phase can vary considerably (e.g., colloidal particles of nanometer size to several micrometers in size). Typically, the dispersed phase can be solid, liquid, or gas. In the case of a solid dispersion, both the dispersed phase and the continuous phase are solid. In pharmaceutical applications, a solid dispersion may include a crystalline drug (dispersed phase) in an amorphous polymer (continuous phase); or alternatively, an amorphous drug (dispersed phase) in an amorphous polymer (continuous phase). In some embodiments, a solid dispersion includes a polymer constituting the dispersed phase and a drug constituting the continuous phase. Alternatively, a solid dispersion includes a drug constituting the dispersed phase and a polymer constituting the continuous phase.

[0066] The terms "patient" and "subject" are used interchangeably and refer to animals, including humans.

[0067] The terms "effective dose" and "effective amount" are used interchangeably herein and refer to the amount of a compound that produces a desired effect (e.g., improving CF or a CF symptom, or reducing the severity of CF or a CF symptom) after administration. The exact amount of an effective dose will depend on the purpose of the treatment and will be determined by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

[0068] As used herein, the terms "treating" and the like generally refer to improving CF or a symptom thereof in a subject or reducing the severity of CF or a symptom thereof. As used herein, "treating" includes, but is not limited to, the following: increased growth, increased weight, reduced mucus in the lungs, improved pancreatic and / or liver function, reduced chest infections, and / or reduced coughing or shortness of breath in a subject. Improvement or reduction of any of these symptoms can be readily assessed according to standard methods and techniques known in the art.

[0069] As used herein, the term "in combination with," when referring to two or more compounds, agents, or additional active pharmaceutical ingredients, means that the two or more compounds, agents, or active pharmaceutical ingredients are administered to a patient before, simultaneously with, or after each other.

[0070] The term "about," when used in conjunction with a dose, amount, or weight percent of an ingredient of a composition or dosage form, includes values ​​recognized by those of ordinary skill in the art as providing a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent.

[0071] Pharmaceutical composition

[0072] Disclosed herein is a pharmaceutical composition comprising a first solid dispersion and a second solid dispersion, wherein the pharmaceutical composition comprises

[0073] (a) 25 mg to 250 mg of Compound I:

[0074]

[0075] (b) a first solid dispersion comprising 20 mg to 150 mg of Compound II:

[0076]

[0077] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[0078] (c) a second solid dispersion comprising 25 mg to 200 mg of compound III-d:

[0079]

[0080] Compound III:

[0081]

[0082] and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion. In some embodiments, the pharmaceutical composition is a single tablet.

[0083] In some embodiments, compound II and compound III-d are each independently substantially amorphous. In some embodiments, compound II and compound III-d are each independently crystalline. In some embodiments, compound II and compound III-d or compound III are each independently a mixture of multiple forms (crystalline and / or amorphous).

[0084] Solid dispersion

[0085] In some embodiments, a pharmaceutical composition (eg, tablet) disclosed herein comprises a first solid dispersion and a second solid dispersion, wherein the first solid dispersion comprises Compound II and the second solid dispersion comprises Compound III-d or Compound III.

[0086] In some embodiments, the first solid dispersion and the second solid dispersion each independently comprise a plurality of particles having an average particle size of 5 to 100 microns. In some embodiments, the first solid dispersion and the second solid dispersion each independently comprise a plurality of particles having an average particle size of 15 to 40 microns. In some embodiments, the first solid dispersion and the second solid dispersion each independently comprise a plurality of particles having an average particle size of 15 microns.

[0087] In some embodiments, the first solid dispersion and the first spray-dried dispersion of the present disclosure independently comprise substantially amorphous Compound II. In some embodiments, the second solid dispersion and the second spray-dried dispersion of the present disclosure independently comprise substantially amorphous Compound III-d or Compound III.

[0088] In some embodiments, the solid dispersions and spray-dried dispersions of the present disclosure may include other excipients, such as polymers and / or surfactants. Any suitable polymers and surfactants known in the art may be used in the present disclosure. Certain exemplary polymers and surfactants are described below.

[0089] Solid dispersions of any one of Compound II, III-d or III can be prepared by any suitable method known in the art, such as spray drying, freeze drying, hot melt or centrifugation / freeze grinding technology. For example, see WO2015 / 160787. Typically, such spray drying, freeze drying, hot melt or centrifugation / freeze grinding technology produces an amorphous form of API (e.g., Compound II, III-d or III).

[0090] Spray drying is the process of converting a liquid feed into a dry particle form. Optionally, a second drying process, such as fluidized bed drying or vacuum drying, can be used to reduce residual solvent to a pharmaceutically acceptable level. Typically, spray drying involves contacting a highly dispersed liquid suspension or solution with a sufficient amount of hot gas to evaporate and dry the droplets. The preparation to be spray dried can be any solution, coarse suspension, slurry, colloidal dispersion or paste that can be atomized using a selected spray drying device. In one method, the preparation is sprayed into a warm filtered gas stream that evaporates the solvent and delivers the dried product to a collector (e.g., a cyclone separator). The exhaust gas is then discharged together with the solvent, or alternatively the exhaust gas is sent to a condenser to capture and potentially recover the solvent. Commercially available equipment can be used for spray drying. For example, commercial spray dryers manufactured by Buchi Ltd. and Niro (e.g., the PSD series of spray dryers manufactured by Niro) (see US2004 / 0105820; US2003 / 0144257).

[0091] Techniques and methods for spray drying can be found in Perry's Chemical Engineering Handbook, 6th edition, RH Perry, DW Green and JO Maloney, eds., McGraw-Hill book co. (1984); and Marshall "Atomization and Spray-Drying" 50, Chem. Eng. Prog. Monogr. Series 2 (1954).

[0092] Removal of the solvent may require a subsequent drying step such as tray drying, fluidized bed drying, vacuum drying, microwave drying, drum drying, or double cone vacuum drying.

[0093] In one embodiment, the solid dispersions and spray-dried dispersions of the present disclosure are fluidized bed dried.

[0094] In one approach, the solvent includes a volatile solvent, such as a solvent having a boiling point of less than 100° C. In some embodiments, the solvent includes a mixture of solvents, such as a mixture of volatile solvents or a mixture of a volatile solvent and a non-volatile solvent. In the case of a mixture of solvents, the mixture may include one or more non-volatile solvents, for example, wherein the non-volatile solvent is present in the mixture in an amount of less than 15%, for example, less than 12%, less than 10%, less than 8%, less than 5%, less than 3%, or less than 2%.

[0095] In some methods, the solvent is one in which the solubility of the API (e.g., Compound II and / or Compound III-d and / or Compound III) is at least 10 mg / ml (e.g., at least 15 mg / ml, 20 mg / ml, 25 mg / ml, 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml or more). In other methods, the solvent includes one in which the solubility of the API (e.g., Compound II and / or Compound III-d and / or Compound III) is at least 20 mg / ml.

[0096] Exemplary solvents that can be tested include acetone, cyclohexane, dichloromethane or methylene chloride (DCM), N,N-dimethylacetamide (DMA), N,N-dimethylformamide (DMF), 1,3-dimethyl-2-imidazolidinone (DMI), dimethyl sulfoxide (DMSO), dioxane, ethyl acetate, ether, glacial acetic acid (HAc), methyl ethyl ketone (MEK), N-methyl-2-pyrrolidone (NMP), methyl tert-butyl ether (MTBE), tetrahydrofuran (THF), pentane, acetonitrile, methanol, ethanol, isopropanol, isopropyl acetate, and toluene. Exemplary co-solvents include DCM / methanol, acetone / DMSO, acetone / DMF, acetone / water, MEK / water, THF / water, dioxane / water. In a two-solvent system, the solvent may be present in an amount of 0.1% to 99.9% w / w. In some preferred embodiments, water is a co-solvent with acetone, wherein the water is present in an amount of 0.1% to 15%, such as 9% to 11%, such as 10%. In some preferred embodiments, water is a co-solvent with MEK, wherein the water is present in an amount of 0.1% to 15%, such as 9% to 11%, such as 10%. In some embodiments, the solvent system includes three solvents. Certain exemplary solvents include those described above, for example, MEK, DCM, water, methanol, IPA, and mixtures thereof.

[0097] The particle size and temperature drying range can be varied to prepare an optimal solid dispersion. As will be appreciated by the skilled artisan, a small particle size will improve solvent removal. However, the applicant has found that smaller particles may result in a lower bulk density, which in some cases may not provide an optimal solid dispersion for downstream processing such as tableting.

[0098] The solid dispersions disclosed herein (e.g., spray-dried dispersions) may optionally include a surfactant. A surfactant or surfactant mixture will typically reduce the interfacial tension between the solid dispersion and the aqueous medium. An appropriate surfactant or surfactant mixture may also enhance the water solubility and bioavailability of the API (e.g., Compound II and / or Compound III-d and / or Compound III) from the solid dispersion. Surfactants used in conjunction with the present disclosure include, but are not limited to, sorbitan fatty acid esters (e.g., ), polyoxyethylene sorbitan fatty acid esters (e.g. ), Sodium Lauryl Sulfate (SLS), Sodium Dodecylbenzene Sulfonate (SDBS), Sodium Octyl Sulfosuccinate (Docusate Sodium), Deoxycholic Acid Sodium Salt (DOSS), Sorbitan Monostearate, Sorbitan Tristearate, Cetyltrimethylammonium Bromide (HTAB), Sodium N-Lauroyl Sarcosinate, Sodium Oleate, Sodium Myristate, Sodium Stearate, Sodium Palmitate, Gelucire 44 / 14, Ethylenediaminetetraacetic Acid (EDTA), Vitamin E d-alpha Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS), Lecithin, Sodium Glutamate Monohydrate, Labrasol, PEG 8 Caprylic / Capric Glycerides, Transcutol, Diethylene Glycol Monoethyl Ether, Solutol HS-15, Polyethylene Glycol / Hydroxystearate, Taurocholic Acid, Pluronic F68, Pluronic F108 and Pluronic F127 (or any other polyoxyethylene-polyoxypropylene copolymer or saturated polyglycol glyceride Specific examples of such surfactants that can be used in conjunction with the present disclosure include, but are not limited to, Span 65, Span 25, Tween 20, Capryol 90, Pluronic F108, sodium lauryl sulfate (SLS), Vitamin E TPGS, pluronic and copolymers.

[0099] In some embodiments, SLS is used as a surfactant in the solid dispersion of compound III-d and / or III.

[0100] The amount of surfactant (e.g., SLS) may be between 0.1%-15% w / w relative to the total weight of the solid dispersion. For example, 0.5% to 10%, such as 0.5% to 5%, for example 0.5% to 4%, 0.5% to 3%, 0.5% to 2%, 0.5% to 1% or 0.5%.

[0101] In certain embodiments, the amount of surfactant is at least 0.1% or at least 0.5% relative to the gross weight of the solid dispersion. In these embodiments, the amount of surfactant is no more than 15% or no more than 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%. In certain embodiments, the amount of surfactant is 0.5% by weight.

[0102] Candidate surfactants (or other components) for use in the present disclosure can be tested for suitability in a manner similar to that described for testing polymers.

[0103] One aspect of the present disclosure provides a method of producing a spray-dried dispersion, the method comprising: (i) providing a mixture of one or more APIs and a solvent; and (ii) forcing the mixture through a nozzle and subjecting the mixture to spray-drying conditions to produce a spray-dried dispersion.

[0104] Another aspect of the present disclosure provides a method of producing a spray-dried dispersion, the method comprising: (i) providing a mixture comprising one or more APIs and a solvent; and (ii) forcing the mixture out of a nozzle under spray-drying conditions to produce a spray-dried dispersion.

[0105] Another aspect of the present disclosure provides a method of producing a spray-dried dispersion, the method comprising: (i) spraying a mixture through a nozzle, wherein the mixture comprises one or more APIs and a solvent; and (ii) forcing the mixture through the nozzle under spray drying conditions to produce particles comprising the API.

[0106] Another aspect of the present disclosure provides a spray-dried dispersion comprising one or more APIs, wherein the dispersion is substantially free of polymer, and wherein the spray-dried dispersion is produced by the following method: (i) providing a mixture consisting essentially of one or more APIs and a solvent; and (ii) forcing the mixture through a nozzle under spray drying conditions to produce the spray-dried dispersion.

[0107] Another aspect of the present disclosure provides a spray-dried dispersion comprising one or more APIs, wherein the dispersion is produced by the following method: (i) providing a mixture comprising one or more APIs, a polymer, and a solvent; and (ii) forcing the mixture through a nozzle under spray drying conditions to produce the spray-dried dispersion.

[0108] Another aspect of the present disclosure provides a spray-dried dispersion comprising particles, wherein the particles comprise one or more APIs and a polymer, and wherein the spray-dried dispersion is produced by: (i) spraying a mixture through a nozzle, wherein the mixture comprises one or more APIs and a solvent; and (ii) forcing the mixture through the nozzle under spray drying conditions to produce the spray-dried dispersion.

[0109] Another aspect of the present disclosure provides a spray-dried dispersion comprising particles, wherein the particles comprise one or more APIs and the particles are substantially free of polymer, and wherein the spray-dried dispersion is produced by: (i) spraying a mixture through a nozzle, wherein the mixture comprises one or more APIs and a solvent; and (ii) forcing the mixture through the nozzle under spray drying conditions to produce the spray-dried dispersion.

[0110] In some embodiments, the one or more APIs are selected from Compound II, Compound III-d, and Compound III.

[0111] Some embodiments further include further drying the spray-dried dispersion. For example, the spray-dried dispersion is dried under reduced pressure. In other examples, the spray-dried dispersion is dried at a temperature of 50°C to 100°C.

[0112] In some embodiments, the solvent includes a polar organic solvent. Examples of polar organic solvents include methyl ethyl ketone, THF, DCM, methanol or IPA or any combination thereof, such as DCM / methanol. In other examples, the solvent also includes water. For example, the solvent can be methyl ethyl ketone / water, THF / water or methyl ethyl ketone / water / IPA. For example, the ratio of the polar organic solvent to water is 70:30 to 95:5 by volume. In other cases, the ratio of the polar organic solvent to water is 90:10 by volume.

[0113] Some embodiments further include filtering the mixture prior to forcing the mixture through the nozzle. Such filtering can be accomplished using any suitable filter media having a suitable pore size.

[0114] Some embodiments further include applying heat to the mixture as it enters the nozzle. The heating can be accomplished using any suitable heating element.

[0115] In some embodiments, the nozzle includes an inlet and an outlet, and the inlet is heated to a temperature less than the boiling point of the solvent.

[0116] In some embodiments, the mixture is pushed through the nozzle by a pressurized gas. Examples of suitable pressurized gases include those that are inert to the first reagent, the second reagent, and the solvent. In one example, the pressurized gas includes elemental nitrogen.

[0117] In some embodiments, the pressurized gas has a positive pressure of 90 psi to 150 psi.

[0118] In some embodiments, the pharmaceutically acceptable compositions of the present disclosure comprising substantially amorphous API (e.g., Compound II, Compound III-d, and Compound III) can be prepared by non-spray drying techniques such as centrifugation / freeze grinding techniques. Compositions comprising substantially amorphous API (e.g., Compound II, Compound III-d, and Compound III) can also be prepared by hot melt extrusion techniques.

[0119] In some embodiments, the solid dispersion of the present disclosure (e.g., spray-dried dispersion) comprises a polymer. Any suitable polymer known in the art can be used in the present disclosure. Exemplary suitable polymers include polymers selected from cellulose-based polymers, polyoxyethylene polymers, polyethylene-propylene glycol copolymers, vinyl-based polymers, PEO-polyvinyl caprolactam-based polymers, and polymethacrylate-based polymers.

[0120] Cellulose-based polymers include methylcellulose, hydroxypropyl methylcellulose (HPMC) (hydroxypropyl methylcellulose), hydroxypropyl methylcellulose phthalate (HPMC-P), hydroxypropyl methylcellulose acetate succinate, and copolymers thereof. Polyoxyethylene polymers include polyethylene-propylene glycol, polyethylene glycol, poloxamer, and copolymers thereof. Vinyl-based polymers include polyvinyl pyrrolidine (PVP) and PVP / VA. PEO-polyvinyl caprolactam-based polymers include polyethylene glycol, polyvinyl acetate, and polyvinyl caprolactam-based graft copolymers (e.g., ). Polymethacrylate-based polymers are cationic and anionic polymers synthesized from dimethylaminoethyl methacrylate, methacrylic acid, and methacrylate in different ratios. Several types are commercially available and can be obtained as dry powders, aqueous dispersions, or organic solutions. Examples of such polymethacrylate-based polymers include poly(methacrylic acid, ethyl acrylate) (1:1), dimethylaminoethyl methacrylate-methyl methacrylate copolymer, and

[0121] In some embodiments, the cellulose-based polymer is hydroxypropyl methylcellulose acetate succinate (also known as hydroxypropyl methylcellulose acetate succinate or HMPCAS) and hydroxypropyl methylcellulose (also known as hydroxypropyl methylcellulose or HPMC), or a combination of hydroxypropyl methylcellulose acetate succinate and hydroxypropyl methylcellulose. Based on the content (weight %) of acetyl groups and succinyl groups in the HPMCAS molecule and the particle size, various grades of HPMCAS can be obtained. For example, HPMCAS L grade, M grade, and H grade can be obtained. HPMCAS-H is a grade containing about 10 wt%-14 wt% acetyl groups and about 4 wt%-8 wt% succinyl groups. Each HPMCAS grade can be obtained in two particle sizes, namely F (fine powder grade) and G (granular grade). HPMC has various types (e.g., HPMC E type, F type, J type, and K type). HPMC E type means that there are about 28%-30% methoxy groups and about 7%-12% hydroxypropoxy groups. There are various E grades from low viscosity to high viscosity. For example, E3 indicates that the viscosity of HPMC measured in a 2% aqueous solution at 20°C is about 2.4-3.6 millipascal seconds (mPa·s); E15 indicates that the viscosity of HPMC measured in a 2% aqueous solution at 20°C is about 12-18 mPa·s; and E50 indicates that the viscosity of HPMC measured in a 2% aqueous solution at 20°C is about 40-60 mPa·s.

[0122] In some embodiments, the cellulose-based polymer is hypromellose acetate succinate and hypromellose, or a combination of hypromellose acetate succinate and hypromellose.

[0123] In some embodiments, the cellulose-based polymer is hypromellose E15, hypromellose acetate succinate L, or hypromellose acetate succinate H.

[0124] In some embodiments, the polyoxyethylene polymer or polyethylene glycol-propylene glycol copolymer is polyethylene glycol or pluronic.

[0125] In some embodiments, the polyoxyethylene polymer or polyethylene glycol-propylene glycol copolymer is polyethylene glycol 3350 or poloxamer 407.

[0126] In some embodiments, the vinyl-based polymer is a vinyl polyvinylpyrrolidone polymer, such as polyvinylpyrrolidone K30 or polyvinylpyrrolidone VA 64.

[0127] In some embodiments, the polymethacrylate polymer is Eudragit L100-55 or EPO.

[0128] In some embodiments, the polymer is selected from cellulosic polymers, such as HPMC and / or HPMCAS.

[0129] In one embodiment, the polymer is soluble in an aqueous medium. The solubility of the polymer can be pH-independent or pH-dependent. The latter includes one or more enteric polymers. The term "enteric polymer" refers to a polymer that preferentially dissolves in the weaker acidic environment of the intestine relative to the more acidic environment of the stomach, for example, a polymer that is insoluble in acidic aqueous media but soluble when the pH is above 5-6. Suitable polymers are chemically and biologically inert. In order to improve the physical stability of the solid dispersion, the glass transition temperature (Tg) of the polymer is as high as possible. For example, a polymer having a glass transition temperature at least equal to or greater than the glass transition temperature of the API. The glass transition temperature of other polymers is within 10 to 15°C of the API.

[0130] In addition, the hygroscopicity of the polymer is low, for example, less than 10%. For comparison in the present application, the hygroscopicity of the polymer or composition is characterized at 60% relative humidity. In some preferred embodiments, the polymer has a water absorption rate of less than 10%, for example, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3% or less than 2%. Hygroscopicity can also affect the physical stability of the solid dispersion. Generally, the moisture adsorbed in the polymer can greatly reduce the Tg of the polymer and the resulting solid dispersion, which will further reduce the physical stability of the solid dispersion as described above.

[0131] In one embodiment, the polymer is one or more water-soluble polymers or partially water-soluble polymers. Water-soluble or partially water-soluble polymers include, but are not limited to, cellulose derivatives (e.g., hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC)) or ethyl cellulose; polyvinyl pyrrolidone (PVP); polyethylene glycol (PEG); polyvinyl alcohol (PVA); acrylates, such as polymethacrylates (e.g., E); cyclodextrins (eg, β-cyclodextrin) and their copolymers and derivatives, including, for example, PVP-VA (polyvinylpyrrolidone-vinyl acetate).

[0132] In some embodiments, the polymer is hydroxypropyl methylcellulose (HPMC), such as HPMC E50, HPMC E15, or HPMC E3.

[0133] As described herein, the polymer can be a pH-dependent enteric polymer. Such pH-dependent enteric polymers include, but are not limited to, cellulose derivatives (e.g., cellulose acetate hydroxypropyl methylcellulose acetate (CAP)), hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), carboxymethylcellulose (CMC) or its salts (e.g., sodium salts, such as (CMC-Na)); cellulose acetate trimellitate (CAT), hydroxypropyl cellulose acetate phthalate (HPCAP), hydroxypropyl methylcellulose acetate phthalate (HPMCAP) and methylcellulose acetate phthalate (MCAP) or polymethacrylates (e.g., S). In some embodiments, the polymer is hydroxypropyl methylcellulose acetate succinate (HPMCAS). In some embodiments, the polymer is hydroxypropyl methylcellulose acetate succinate HG grade (HPMCAS-HG).

[0134] In another embodiment, the polymer is a polyvinylpyrrolidone copolymer, for example, vinylpyrrolidone / vinyl acetate copolymer (PVP / VA).

[0135] In the embodiment of compound II, compound III-d or compound III and polymer (for example, with HPMC, HPMCAS or PVP / VA polymer) forming solid dispersion, the amount of polymer ranges from 0.1 wt % to 99 wt % relative to the gross weight of solid dispersion. Unless otherwise indicated, the percentage of drugs, polymers and other excipients as described in the dispersion is given in weight percentage. The amount of polymer is generally at least 20%, and preferably at least 30%, for example, at least 35%, at least 40%, at least 45% or 50% (for example, 49.5%). The amount is generally 99% or less, and preferably 80% or less, for example, 75% or less, 70% or less, 65% or less, 60% or less or 55% or less. In one embodiment, the amount of polymer is at most 50% (and even more specifically, between 40% and 50%, such as 49%, 49.5% or 50%) of the gross weight of dispersion.

[0136] In some embodiments, API (e.g., Compound II, Compound III-d, or Compound III) and polymer are present in approximately equal amounts by weight, for example, each of the polymer and the drug accounts for half of the weight percentage of the dispersion. For example, the polymer is present in an amount of 49.5% by weight, and Compound II, Compound III-d, or Compound III is present in an amount of 50% by weight. In another embodiment, Compound II, Compound III-d, or Compound III is present in an amount greater than half of the weight percentage of the dispersion. For example, the polymer is present in an amount of 20% by weight, and Compound II, Compound III-d, or Compound III is present in an amount of 80% by weight. In other embodiments, the polymer is present in an amount of 19.5% by weight, and Compound II, Compound III-d, or Compound III is present in an amount of 80% by weight.

[0137] In some embodiments, the combination of API (e.g., Compound II, Compound III-d, or Compound III) and a polymer represents 1% to 20% w / w total solids content of the spray-dried solution before spray drying. In some embodiments, the combination of Compound II, Compound III-d, or Compound III and a polymer represents 5% to 15% w / w total solids content of the spray-dried solution before spray drying. In some embodiments, the combination of Compound II, Compound III-d, or Compound III and a polymer represents 11% w / w total solids content of the spray-dried solution before spray drying.

[0138] In some embodiments, the dispersion further comprises other minor ingredients, such as a surfactant (e.g., SLS). In some embodiments, the surfactant is present in an amount less than 10% of the dispersion, e.g., less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, or less than 0.5%.

[0139] In the embodiment comprising polymer, polymer is present in the amount of effectively stabilizing solid dispersion.Stabilizing includes suppressing or preventing the crystallization of API (for example, compound II, compound III-d or compound III).This stabilization will suppress the conversion of API from amorphous to crystalline form.For example, polymer will prevent at least a portion of API (for example, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or more) from amorphous to crystalline form.Stability can be measured by, for example, measuring the glass transition temperature of solid dispersion, measuring the amount of crystalline material, measuring the relaxation rate of amorphous material or by measuring the solubility or bioavailability of API.

[0140] In some embodiments, the glass transition temperature of the polymer used in the present disclosure is no less than 10-15°C lower than the glass transition temperature of the API. In some cases, the glass transition temperature of the polymer is higher than the glass transition temperature of the API, and is generally at least 50°C higher than the desired storage temperature of the drug product. For example, at least 100°C, at least 105°C, at least 105°C, at least 110°C, at least 120°C, at least 130°C, at least 140°C, at least 150°C, at least 160°C, at least 160°C or higher.

[0141] In some embodiments, the polymers used in the present disclosure have similar or better solubility in solvents suitable for the spray drying process relative to the API (e.g., Compound II, Compound III-d, or Compound III). In some embodiments, the polymer will dissolve in the same solvent system or systems as the API.

[0142] In some embodiments, the polymers used in the present disclosure can increase the solubility of the API (e.g., Compound II, Compound III-d, or Compound III) in aqueous and physiologically relevant media relative to the solubility of the API in the absence of the polymer or relative to the solubility of the API when combined with a reference polymer. For example, the polymer can increase the solubility of Compound II, Compound III-d, or Compound III by reducing the amount of amorphous Compound II, Compound III-d, or Compound III that is converted to a crystalline form from a solid amorphous dispersion or from a liquid suspension.

[0143] In some embodiments, polymers used in the present disclosure can reduce the relaxation rate of an amorphous material.

[0144] In some embodiments, the polymers used in the present disclosure can increase the physical and / or chemical stability of the API (eg, Compound II, Compound III-d, or Compound III).

[0145] In some embodiments, the polymers used in the present disclosure can improve the manufacturability of an API (eg, Compound II, Compound III-d, or Compound III).

[0146] In some embodiments, polymers for use in the present disclosure can improve one or more handling, administration, or storage properties of an API (eg, Compound II, Compound III-d, or Compound III).

[0147] In some embodiments, the polymers used in the present disclosure have little or no adverse interactions with other drug components (eg, excipients).

[0148] The suitability of a candidate polymer (or other component) can be tested using a spray drying method (or other methods) as described herein to form an amorphous composition. Candidate compositions can be compared in terms of stability, resistance to crystal formation or other properties, and compared with reference preparations such as preparations of pure amorphous compound I, compound II, compound III-d or compound III. For example, a candidate composition can be tested to determine the time at which it inhibits solvent-mediated crystallization from starting under controlled conditions or the conversion percentage at a given time of at least 50%, 75% or 100%, and a reference preparation, or a candidate composition can be tested to determine whether it has improved bioavailability or solubility relative to crystalline compound I, compound II, compound III-d or compound III.

[0149] In some embodiments, the first solid dispersion comprises a cellulose polymer. For example, the first solid dispersion comprises hydroxypropyl methylcellulose (HPMC). In some embodiments, the first solid dispersion comprises HPMC and compound II in a weight ratio of 1:10 to 1:1. In some cases, the weight ratio of HPMC to compound II is 1:3 to 1:5.

[0150] In some embodiments, the second solid dispersion comprises a cellulose polymer. For example, the second solid dispersion comprises hydroxypropylmethylcellulose acetate succinate or (HPMCAS).

[0151] In some embodiments, the first solid dispersion and the second solid dispersion each comprise a plurality of particles having an average particle size of 5 to 100 microns. In some embodiments, the average particle size of the particles is 5 to 30 microns. In some embodiments, the average particle size of the particles is 15 microns.

[0152] In some embodiments, the first solid dispersion comprises 70 wt % to 90 wt % (eg, 75 wt % to 85 wt %) of Compound II.

[0153] In some embodiments, the second solid dispersion comprises 70 wt % to 90 wt % (eg, 75 wt % to 85 wt %) of Compound III-d or III.

[0154] In some embodiments, both the first solid dispersion and the second solid dispersion are spray-dried dispersions.

[0155] In some embodiments, the pharmaceutical compositions disclosed herein further comprise one or more pharmaceutically acceptable excipients, such as a pharmaceutically acceptable vehicle, adjuvant, or carrier.

[0156] Remington: The Science and Practice of Pharmacy, 21st edition, 2005, editors DB Troy, Lippincott Williams and Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, editors J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New York, the contents of each of these two documents are incorporated herein by reference, and disclose a variety of carriers for preparing pharmaceutically acceptable compositions and known techniques for their preparation. Unless any conventional carrier medium is incompatible with the compounds of the present disclosure, such as by producing any undesirable biological effect or interacting in a harmful manner with any other component of the pharmaceutically acceptable composition, its use is considered to be within the scope of the present disclosure.

[0157] In one embodiment, a pharmaceutical composition of the present disclosure comprises one or more of a filler, a disintegrant, and a lubricant.

[0158] Fillers suitable for use in pharmaceutical compositions disclosed herein are compatible with other ingredients of the pharmaceutical composition, i.e., they do not substantially reduce the solubility, hardness, chemical stability, physical stability or biological activity of the pharmaceutical composition. Exemplary fillers include: cellulose, modified cellulose (e.g., sodium carboxymethylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose), cellulose acetate, microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, starch (e.g., corn starch, potato starch), sugar (e.g., mannitol, lactose, sucrose, etc.), or any combination thereof. In one embodiment, the filler is microcrystalline cellulose.

[0159] In some embodiments, the pharmaceutical composition comprises one or more fillers, the amount of the one or more fillers is at least 5% by weight (e.g., at least 20%, at least 30% by weight, or at least 40% by weight) by weight of the pharmaceutical composition. For example, the pharmaceutical composition comprises 10% to 60% by weight (e.g., 20% to 55%, 25% to 50% by weight, or 27% to 45% by weight) of filler by weight of the pharmaceutical composition. In another example, the pharmaceutical composition comprises at least 20% by weight (e.g., at least 30% by weight or at least 40% by weight) of microcrystalline cellulose, such as MCC Avicel PH102 or Avicel PH101, by weight of the pharmaceutical composition. In yet another example, the pharmaceutical composition comprises 10% to 60% by weight (e.g., 20% to 55% by weight or 25% to 45% by weight) of microcrystalline cellulose by weight of the pharmaceutical composition.

[0160] Disintegrants suitable for use in the pharmaceutical compositions disclosed herein can enhance the dispersion of the pharmaceutical composition and are compatible with the other ingredients of the pharmaceutical composition, i.e., they do not substantially reduce the chemical stability, physical stability, hardness, or biological activity of the pharmaceutical composition. Exemplary disintegrants include crosslinked sodium carboxymethylcellulose, sodium starch glycolate, crosslinked polyvinylpyrrolidone, or a combination thereof. In one embodiment, the disintegrant is crosslinked sodium carboxymethylcellulose.

[0161] In some embodiments, the pharmaceutical compositions disclosed herein include a disintegrant in an amount of 10% by weight or less (e.g., 7% by weight or less, 6% by weight or less, or 5% by weight or less) by weight of the pharmaceutical composition. For example, the pharmaceutical composition includes 1% to 10% by weight (e.g., 1.5% to 7.5% by weight or 2.5% to 6% by weight) of the disintegrant by weight of the pharmaceutical composition. In another example, the pharmaceutical composition includes 10% or less by weight (e.g., 7% or less, 6% or less, or 5% or less) of cross-linked sodium carboxymethyl cellulose by weight of the pharmaceutical composition. In yet another example, the pharmaceutical composition includes 1% to 10% by weight (e.g., 1.5% to 7.5% by weight or 2.5% to 6% by weight) of cross-linked sodium carboxymethyl cellulose by weight of the pharmaceutical composition. In some examples, the pharmaceutical composition comprises 0.1 wt % to 10 wt % (e.g., 0.5 wt % to 7.5 wt % or 1.5 wt % to 6 wt %) of a disintegrant by weight of the pharmaceutical composition. In other embodiments, the pharmaceutical composition comprises 0.5 wt % to 10 wt % (e.g., 1.5 wt % to 7.5 wt % or 2.5 wt % to 6 wt %) of a disintegrant by weight of the pharmaceutical composition.

[0162] In some embodiments, the pharmaceutical composition disclosed herein comprises a lubricant. Lubricants can prevent the mixture components from adhering to surfaces (e.g., surfaces of mixing bowls, granulation rollers, compression molds and / or punches). Lubricants can also reduce intergranular friction within the particles, and improve the compression and discharge of compressed pharmaceutical compositions from granulators and / or molding presses. Suitable lubricants for pharmaceutical compositions disclosed herein are compatible with other ingredients of the pharmaceutical composition, that is, they do not substantially reduce the solubility, hardness or biological activity of the pharmaceutical composition. Exemplary lubricants include magnesium stearate, sodium stearyl fumarate, calcium stearate, zinc stearate, sodium stearate, stearic acid, aluminum stearate, leucine, glyceryl behenate, hydrogenated vegetable oil or any combination thereof. In embodiments, the lubricant is magnesium stearate.

[0163] In one embodiment, the pharmaceutical composition comprises a lubricant in an amount of 5% by weight or less (e.g., 4.75% by weight, 4.0% by weight or less, or 3.00% by weight or less, or 2.0% by weight or less) by weight of the pharmaceutical composition. For example, the pharmaceutical composition comprises a lubricant in an amount of 5% by weight to 0.10% by weight (e.g., 4.5% by weight to 0.5% by weight or 3% by weight to 1% by weight) by weight of the pharmaceutical composition. In another example, the pharmaceutical composition comprises magnesium stearate in an amount of 5% by weight to 0.10% by weight (e.g., 4.0% by weight or less, 3.0% by weight or less, or 2.0% by weight or less, or 1.0% by weight or less) by weight of the pharmaceutical composition. In yet another example, the pharmaceutical composition comprises magnesium stearate in an amount of 5% by weight to 0.10% by weight (e.g., 4.5% by weight to 0.15% by weight or 3.0% by weight to 0.50% by weight) by weight of the pharmaceutical composition.

[0164] In some embodiments, the pharmaceutical compositions disclosed herein are tablets.

[0165] Any suitable spray-dried dispersion of compound II, compound III-d and compound III can be used in the pharmaceutical compositions disclosed herein. Some examples of compound II and its pharmaceutically acceptable salts can be found in WO 2011 / 119984 and WO2014 / 015841, all of which are incorporated herein by reference. Some examples of compound III and its pharmaceutically acceptable salts can be found in WO 2007 / 134279, WO 2010 / 019239, WO 2011 / 019413, WO 2012 / 027731 and WO2013 / 130669, all of which are incorporated herein by reference.

[0166] Pharmaceutical compositions comprising Compound II and Compound III are disclosed in PCT Publication No. WO 2015 / 160787, which is incorporated herein by reference. Table 2 below shows an exemplary embodiment:

[0167] Table 2. Exemplary tablets containing 100 mg Compound II and 150 mg Compound III.

[0168]

[0169] Pharmaceutical compositions comprising Compound III are disclosed in PCT Publication No. WO 2010 / 019239, which is incorporated herein by reference. Table 3 below shows an exemplary embodiment:

[0170] Table 3: Composition of an exemplary tablet of Compound III.

[0171]

[0172]

[0173] Additional pharmaceutical compositions comprising Compound III are disclosed in PCT Publication No. WO 2013 / 130669, which is incorporated herein by reference. Exemplary mini-tablets (about 2 mm in diameter, about 2 mm in thickness, and 6.9 mg per mini-tablet) are formulated to have 50 mg of Compound III per 26 mini-tablets and 75 mg of Compound III per 39 mini-tablets using the amounts of the ingredients described in Table 4 below.

[0174] Table 4: Composition of mini-tablets with 50 mg and 75 mg potency

[0175]

[0176] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0177]

[0178]

[0179] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0180]

[0181] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0182]

[0183]

[0184] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0185]

[0186] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0187]

[0188] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0189]

[0190]

[0191] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0192]

[0193] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0194]

[0195] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0196]

[0197] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0198]

[0199] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0200]

[0201]

[0202] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0203]

[0204] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0205]

[0206] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0207]

[0208] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0209]

[0210] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0211]

[0212]

[0213] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0214]

[0215] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0216]

[0217] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0218]

[0219] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0220]

[0221] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0222]

[0223] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0224]

[0225] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0226]

[0227] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0228]

[0229]

[0230] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0231]

[0232] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0233]

[0234] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0235]

[0236]

[0237] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0238]

[0239] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0240]

[0241] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0242]

[0243]

[0244] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0245]

[0246] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0247]

[0248] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0249]

[0250] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0251]

[0252]

[0253] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0254]

[0255] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0256]

[0257] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0258]

[0259] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0260]

[0261] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0262]

[0263] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0264]

[0265] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0266]

[0267] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0268]

[0269] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0270]

[0271] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0272]

[0273] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0274]

[0275] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0276]

[0277]

[0278] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0279]

[0280] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0281]

[0282] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0283]

[0284] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0285] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0286] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0287] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0288]

[0289] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0290] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0291]

[0292] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0293]

[0294] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0295]

[0296] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0297]

[0298] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0299]

[0300]

[0301] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0302]

[0303] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0304]

[0305] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0306]

[0307]

[0308] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0309] (A) an intragranular portion, the intragranular portion comprising:

[0310] (a) 10 mg to 110 mg of Compound I;

[0311] (b) 25 mg to 70 mg of a first solid dispersion, the first solid dispersion comprising 80 wt % of Compound II relative to the total weight of the first solid dispersion; and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion; and

[0312] (c) 85 mg to 195 mg of a second solid dispersion, the second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion; 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt % of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[0313] (d) 10 mg to 45 mg croscarmellose sodium; and

[0314] (e) 40 mg to 115 mg microcrystalline cellulose; and

[0315] (B) an extragranular portion, the extragranular portion comprising:

[0316] (f) 55 mg to 165 mg microcrystalline cellulose; and

[0317] (g) 2 mg to 7 mg magnesium stearate.

[0318] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0319] (A) an intragranular portion, the intragranular portion comprising:

[0320] (a) 95 mg to 105 mg of Compound I;

[0321] (b) 60 mg to 65 mg of a first solid dispersion, the first solid dispersion comprising 80 wt % of Compound II relative to the total weight of the first solid dispersion, and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion;

[0322] (c) 185 mg to 190 mg of a second solid dispersion, the second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion; 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt % of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[0323] (d) 35 mg to 45 mg croscarmellose sodium;

[0324] (e) 105 mg to 115 mg microcrystalline cellulose; and

[0325] (B) an extragranular portion, the extragranular portion comprising:

[0326] (f) 155 mg to 165 mg of said microcrystalline cellulose; and

[0327] (g) 2 mg to 7 mg magnesium stearate.

[0328] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0329] (A) an intragranular portion, the intragranular portion comprising:

[0330] (a) 45 mg to 55 mg of Compound I;

[0331] (b) 25 mg to 55 mg of a first solid dispersion, the first solid dispersion comprising 80 wt % of Compound II relative to the total weight of the first solid dispersion, and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion;

[0332] (c) 90 mg to 100 mg of a second solid dispersion, the second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion; 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt % of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[0333] (d) 15 mg to 25 mg croscarmellose sodium;

[0334] (e) 50 mg to 60 mg microcrystalline cellulose; and

[0335] (B) an extragranular portion, the extragranular portion comprising:

[0336] (f) 75 mg to 85 mg microcrystalline cellulose; and

[0337] (g) 2 mg to 7 mg magnesium stearate.

[0338] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0339] (A) an intragranular portion, the intragranular portion comprising:

[0340] (a) 45 mg to 55 mg of Compound I;

[0341] (b) 60 mg to 65 mg of a first solid dispersion, the first solid dispersion comprising 80 wt % of Compound II relative to the total weight of the first solid dispersion, and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion;

[0342] (c) 185 mg to 190 mg of a second solid dispersion, the second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion; 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt % of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[0343] (d) 30 mg to 40 mg croscarmellose sodium;

[0344] (e) 90 mg to 100 mg microcrystalline cellulose; and

[0345] (B) an extragranular portion, the extragranular portion comprising:

[0346] (f) 130 mg to 145 mg microcrystalline cellulose; and

[0347] (g) 2 mg to 7 mg magnesium stearate.

[0348] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0349] (A) an intragranular portion, the intragranular portion comprising:

[0350] (a) 20 mg to 30 mg of Compound I;

[0351] (b) 30 mg to 35 mg of a first solid dispersion, the first solid dispersion comprising 80 wt % of Compound II relative to the total weight of the first solid dispersion, and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion;

[0352] (c) 90 mg to 100 mg of a second solid dispersion, the second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion; 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt % of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[0353] (d) 15 mg to 25 mg croscarmellose sodium;

[0354] (e) 45 mg to 50 mg microcrystalline cellulose; and

[0355] (B) an extragranular portion, the extragranular portion comprising:

[0356] (f) 65 mg to 70 mg microcrystalline cellulose; and

[0357] (g) 2 mg to 7 mg magnesium stearate.

[0358] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0359] (A) an intragranular portion, the intragranular portion comprising:

[0360] (a) 20 mg to 30 mg of Compound I;

[0361] (b) 60 mg to 65 mg of a first solid dispersion, the first solid dispersion comprising 80 wt % of Compound II relative to the total weight of the first solid dispersion, and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion;

[0362] (c) 185 mg to 190 mg of a second solid dispersion, the second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion; 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt % of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[0363] (d) 35 mg to 45 mg croscarmellose sodium;

[0364] (e) 80 mg to 90 mg microcrystalline cellulose; and

[0365] (B) an extragranular portion, the extragranular portion comprising:

[0366] (f) 120 mg to 130 mg microcrystalline cellulose; and

[0367] (g) 2 mg to 7 mg magnesium stearate.

[0368] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0369] (A) an intragranular portion, the intragranular portion comprising:

[0370] (a) 10 mg to 15 mg of Compound I;

[0371] (b) 25 mg to 35 mg of a first solid dispersion, the first solid dispersion comprising 80 wt % of Compound II relative to the total weight of the first solid dispersion, and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion;

[0372] (c) 90 mg to 100 mg of a second solid dispersion, the second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion; 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt % of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[0373] (d) 10 mg to 20 mg croscarmellose sodium;

[0374] (e) 40 mg to 50 mg microcrystalline cellulose; and

[0375] (B) an extragranular portion, the extragranular portion comprising:

[0376] (f) 60 mg to 65 mg microcrystalline cellulose; and

[0377] (g) 2 mg to 7 mg magnesium stearate.

[0378] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0379]

[0380] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0381]

[0382] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0383]

[0384]

[0385] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0386]

[0387] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0388]

[0389]

[0390] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0391]

[0392] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0393]

[0394] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0395]

[0396] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0397]

[0398] In some embodiments, the pharmaceutical compositions disclosed herein comprise:

[0399]

[0400]

[0401] In some embodiments, the pharmaceutical compositions disclosed herein are tablets.

[0402] Method for preparing tablets

[0403] Tablets of the present disclosure can be produced by compacting or pressing a mixture or composition (e.g., powder or granules) under pressure to form a stable three-dimensional shape (e.g., tablet). As used herein, "tablet" includes compressed drug dosage unit forms of all shapes and sizes, whether coated or uncoated. In some embodiments, the method for preparing a tablet disclosed herein includes: (a) mixing Compound I with a first solid dispersion and a second solid dispersion to form a first mixture; and (b) pressing a tablet mixture containing the first mixture into a tablet. As used herein, the term "mixing" includes mixing, blending and combining. In some embodiments, the tablet mixture also includes one or more pharmaceutically acceptable excipients, and the method also includes mixing the first mixture with the one or more excipients to form a tablet mixture. Mixing the first mixture with one or more excipients can be performed in one or more steps. In one embodiment, one or more excipients are mixed to form a second mixture; and before the compression step, the first mixture is mixed with the second mixture to form a tablet mixture. In one embodiment, one or more excipients can be mixed with the first mixture in more than one portion, for example, some excipients are first mixed with the first mixture and then other excipients are mixed. In some embodiments, the tablet disclosed herein comprises an intragranular portion and an extragranular portion as described above, and one or more excipients contained in the intragranular portion are mixed to form a second mixture, and one or more excipients contained in the extragranular portion are mixed to form a third mixture, and the first mixture is combined with the second mixture, and the combined first and second mixtures are combined with the third mixture to form a tablet mixture.

[0404] In some embodiments, methods of preparing a tablet disclosed herein include: (a) mixing Compound 1 with a first solid dispersion and a second solid dispersion to form a first mixture; (b) mixing the first mixture with one or more of microcrystalline cellulose, cross-linked sodium carboxymethyl cellulose, and magnesium stearate to form a tablet mixture; and (c) compressing the tablet mixture into a tablet.

[0405] In some embodiments, the method of preparing a tablet disclosed herein comprises:

[0406] (a) Compound I is mixed with the above-mentioned first solid dispersion and the second solid dispersion to form a first mixture; (b) one or more of microcrystalline cellulose, cross-linked carboxymethyl cellulose sodium and magnesium stearate in the intragranular part are mixed to form a second mixture; (c) one or more of microcrystalline cellulose, cross-linked carboxymethyl cellulose sodium and magnesium stearate in the extragranular part are mixed to form a third mixture; (d) the first mixture, the second mixture and the third mixture are mixed to form a tablet mixture; and (e) the tablet mixture containing the first mixture, the second mixture and the third mixture is compressed into a tablet. Note that steps (a), (b) and (c) can be performed in any order.

[0407] In some embodiments, the methods disclosed herein further comprise coating the tablet.

[0408] In some embodiments, the method disclosed herein further comprises granulating the first mixture, the second mixture and / or the third mixture before compressing the tablet mixture. Any suitable method known in the art for granulating and compressing the pharmaceutical composition can be used. Note that step (a) can be performed before step (b), or step (b) can be performed before step (a).

[0409] Granulation and compression

[0410] In some embodiments, solid forms, including powders comprising one or more APIs (e.g., Compound I, Compound II, Compound III-d, and / or Compound III) and pharmaceutically acceptable excipients (e.g., fillers, diluents, disintegrants, surfactants, glidants, binders, lubricants, or any combination thereof), can be subjected to a dry granulation process. The dry granulation process aggregates the powder into larger particles, the size of which is suitable for further processing. Dry granulation can improve the flowability of the mixture to produce tablets that meet the requirements of mass variation or content uniformity.

[0411] In some embodiments, one or more mixing and dry granulation steps can be used to produce the formulation. The order and number of times of granulation mixing. Before being pressed into tablets, at least one of the excipient and the API can be subjected to dry granulation or wet high shear granulation or twin screw wet granulation. Dry granulation can be performed by mechanical methods, which, compared with the wet granulation method, transfers energy to the mixture without using any liquid substance (whether in the form of an aqueous solution, a solution based on an organic solute, or a mixture thereof), and mechanical methods are also contemplated herein. Generally, mechanical methods require compaction, such as the compaction provided by roller compaction. An example of an alternative method for dry granulation is impact compression. In some embodiments, wet granulation can be used instead of dry granulation.

[0412] In some embodiments, roller compaction is a granulation method that involves mechanical compaction of one or more substances. In some embodiments, a pharmaceutical composition comprising a powder mixture is pressed between two rotating rollers (i.e., roller compaction) to produce a solid sheet, which is then crushed in a sieve to form a granular material. In such a granular material, intimate mechanical contact between the ingredients can be obtained. An example of a roller compaction device is It is Gerteis 3W-Polygran from Gerteis Maschinen+Processengineering AG.

[0413] In some embodiments, tablet compression according to the present disclosure can be performed without the use of any liquid substance (whether in the form of an aqueous solution, an organic solute-based solution, or a mixture thereof), i.e., a dry granulation process. In typical embodiments, the resulting core or tablet has a tensile strength in the range of 0.5 MPa to 3.0 MPa; such as 1.0 to 2.5 MPa, such as in the range of 1.5 to 2.0 MPa.

[0414] In some embodiments, the ingredients are weighed according to the formula set forth herein. Next, all the intragranular ingredients are screened and thoroughly mixed. These ingredients can be lubricated with a suitable lubricant, such as magnesium stearate. The next step can include compacting / striking the powder mixture and the screened ingredients. Next, the compacted or pressed blend is ground into particles and can be optionally sieved to obtain the desired size. Next, these particles can be further blended or lubricated with, for example, magnesium stearate. Next, the granular composition of the present disclosure can be pressed into a variety of pharmaceutical preparations according to the present disclosure on a suitable punch. Optionally, tablets can be coated with a film coating.

[0415] Another aspect of the present disclosure provides a method for preparing a pharmaceutical composition and compressing the composition into a tablet, wherein the pharmaceutical composition comprises a mixture of compositions comprising one or more APIs (e.g., Compound I, Compound II, Compound III-d and / or Compound III); and one or more excipients selected from the following: one or more fillers, diluents, binders, glidants, surfactants, lubricants, disintegrants.

[0416] Coating

[0417] In some embodiments, tablets disclosed herein can be coated with film coatings and optionally marked with logos, other images and / or text using suitable inks. In other embodiments, tablets disclosed herein can be coated with film coatings, waxed, and optionally marked with logos, other images and / or text using suitable inks. Suitable film coatings and inks are compatible with other ingredients of tablets, for example, they do not substantially reduce the solubility, chemical stability, physical stability, hardness or biological activity of the tablets. Suitable colorants and inks can be any color and are water-based or solvent-based. In one embodiment, tablets disclosed herein are coated with colorants and then marked with logos, other images and / or text using suitable inks.

[0418] In some embodiments, the tablets disclosed herein are coated with a film that accounts for 2% to 6% by weight of the weight of the uncoated tablet. In some embodiments, the film comprises one or more colorants and / or pigments. In some embodiments, the tablets disclosed herein are coated with a film comprising one or more colorants and / or pigments, and wherein the film accounts for 2% to 5% by weight of the weight of the uncoated tablet. In some embodiments, the tablets disclosed herein are coated with a film comprising one or more colorants and / or pigments, and wherein the film accounts for 2% to 4% by weight of the weight of the uncoated tablet. Colored tablets can be marked with logos and text indicating the strength of the active ingredient in the tablet using suitable inks.

[0419] Treatment

[0420] Tablets disclosed herein can be administered once a day, twice a day, or three times a day. In some embodiments, one or more tablets are administered per administration. In some embodiments, two tablets are administered per administration. In some embodiments, two tablets are administered per administration, once a day. In some embodiments, two tablets are administered per administration, twice a day. An effective amount of API (e.g., compound (I)) is administered to a patient together with one or more tablets disclosed herein or using one or more tablets disclosed herein.

[0421] The tablets disclosed herein can be used to treat cystic fibrosis.

[0422] In some aspects, the tablets disclosed herein can be used in combination therapy. In some embodiments, the tablets disclosed herein can be administered simultaneously with, before, or after at least one active pharmaceutical ingredient or medical procedure.

[0423] In some embodiments, the pharmaceutical composition is a tablet. In some embodiments, the tablet is suitable for oral administration.

[0424] The tablets disclosed herein are used, optionally together with an additional active pharmaceutical ingredient or medical procedure, to treat cystic fibrosis in a patient.

[0425] Compounds I, II, III-d and III are as described above. Compound IV is depicted as having the following structure:

[0426]

[0427] The chemical name of compound IV is 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid.

[0428] A CFTR mutation may affect CFTR quantity, which is the number of CFTR channels on the cell surface, or it may affect CFTR function, which is the ability of each channel to open and transport ions. Mutations that affect CFTR quantity include those that result in synthesis defects (class I defects), those that result in processing and transport defects (class II defects), those that result in reduced CFTR synthesis (class V defects), and those that reduce the surface stability of CFTR (class VI defects). Mutations that affect CFTR function include those that result in gating defects (class III defects) and those that result in conductance defects (class IV defects). Some CFTR mutations exhibit features from more than one class.

[0429] In some embodiments, disclosed herein is a method for treating cystic fibrosis of a patient, reducing its severity, or treating it symptomatically, the method comprising administering to a patient such as a human an effective amount of a compound disclosed herein, a pharmaceutically acceptable salt thereof, or a deuterated analog of any of the foregoing; or a pharmaceutical composition, wherein the patient suffers from cystic fibrosis. In some embodiments, the patient has a F508del / minimal function (MF) genotype, a F508del / F508del genotype (homozygous for the F508del mutation), a F508del / gating genotype, or a F508del / residual function (RF) genotype. In some embodiments, the patient is heterozygous and has one F508del mutation.

[0430] As used herein, "minimal function (MF) mutations" refer to CFTR gene mutations associated with minimal CFTR function (little to no functional CFTR protein), and include, for example, mutations associated with severe defects in the ability of the CFTR channel to open and close, known as defective channel gating or "gating mutations"; mutations associated with severe defects in CFTR cellular processing and its delivery to the cell surface; mutations associated with no (or minimal) CFTR synthesis; and mutations associated with severe defects in channel conductance. Table C below includes a non-exclusive list of CFTR minimal function mutations detectable by FDA-approved genotyping assays. In some embodiments, a mutation is considered a MF mutation if it meets at least one of the following two criteria:

[0431] (1) biological plausibility of the untranslated protein (the genetic sequence predicts the complete absence of CFTR protein), or

[0432] (2) In vitro testing supporting the lack of responsiveness to Compound II, Compound III, or the combination of Compound II and Compound III, and population-based evidence of clinical severity (as reported in a large patient registry).

[0433] In some embodiments, minimal function mutations are those that result in little to no functional CFTR protein and are unresponsive to Compound II, Compound III, or a combination of Compound II and Compound III in vitro.

[0434] In some embodiments, minimal functional mutations are those that are not responsive to Compound II, Compound III, or a combination of Compound II and Compound III in vitro. In some embodiments, minimal functional mutations are mutations tested in vitro based on in vitro experiments that meet the following criteria:

[0435] Baseline chloride transport <10% of wild-type CFTR, and

[0436] • In this assay, chloride transport is increased by <10% over baseline following the addition of TEZ, IVA, or TEZ / IVA.

[0437] In some embodiments, patients with at least one minimal function mutation show evidence of clinical severity as defined below:

[0438] Mean sweat chloride >86 mmol / L and

[0439] ●Prevalence of pancreatic insufficiency (PI) >50%.

[0440] Patients with the F508del / minimal function genotype are defined as patients with heterozygous F508del-CFTR whose second CFTR allele comprises a minimal function mutation. In some embodiments, patients with the F508del / minimal function genotype are patients with heterozygous F508del-CFTR whose second CFTR allele comprises a mutation that results in a CFTR protein with minimal CFTR function (little to no functional CFTR protein) and is unresponsive to Compound II, Compound III, or a combination of Compound II and Compound III in vitro.

[0441] In some embodiments, minimal functional mutations can be determined using 3 main sources:

[0442] The biological plausibility of the mutation for the response (ie, mutation class)

[0443] ● Population-based evidence of clinical severity (from the CFTR2 Patient Registry; accessed February 15, 2016)

[0444] ○ Mean sweat chloride > 86 mmol / L, and

[0445] ○ Prevalence of pancreatic insufficiency (PI) > 50%

[0446] In vitro testing

[0447] ○ Mutations that result in baseline chloride transport < 10% of wild-type CFTR are considered minimally functional

[0448] o Mutations that resulted in chloride transport <10% of wild-type CFTR following addition of Compound II and / or Compound III were considered non-responsive.

[0449] As used herein, "residual function mutations" refer to class II to V mutations, which have some residual chloride transport and result in a less severe clinical phenotype. Residual function mutations are mutations in the CFTR gene that result in reduced protein amount or function on the cell surface, which can produce partial CFTR activity.

[0450] Non-limiting examples of CFTR gene mutations known to cause residual function phenotypes include CFTR residual function mutations selected from the group consisting of 2789+5G→A, 3849+10kbC→T, 3272-26A→G, 711+3A→G, E56K, P67L, R74W, D110E, D110H, R117C, L206W, R347H, R352Q, A455E, D579G, E831X, S945L, S977F, F1052V, R1070W, F1074L, D1152H, D1270N, E193K, and K1060T. For example, CFTR mutations such as 2789+507A that cause defective mRNA splicing result in reduced protein synthesis, but some functional CFTR is delivered to the cell surface to provide residual function. Other CFTR mutations that reduce conductance and / or gating, such as R117H, produce a normal amount of CFTR channels on the cell surface, but at a low level of function, resulting in residual function. In some embodiments, the CFTR residual function mutation is selected from R117H, S1235R, I1027T, R668C, G576A, M470V, L997F, R75Q, R1070Q, R31C, D614G, G1069R, R1162L, E56K, A1067T, E193K and K1060T. In some embodiments, the CFTR residual function mutation is selected from R117H, S1235R, I1027T, R668C, G576A, M470V, L997F, R75Q, R1070Q, R31C, D614G, G1069R, R1162L, E56K, and A1067T.

[0451] Residual CFTR function can be characterized at the cell (in vitro) level using cell-based assays, such as the FRT assay (Van Goar, F. et al. (2009) PNAS Vol. 106 No. 44, 18825-18830; and Van Goor, F. et al. (2011) PNAS Vol. 108 No. 46, 18843-18846), to measure the amount of chloride ions transported by the mutant CFTR channel. Residual functional mutations cause CFTR-dependent ion transport to be reduced but not completely eliminated. In some embodiments, residual functional mutations cause CFTR activity to be reduced by at least about 10% in the FRT assay. In some embodiments, residual functional mutations cause CFTR activity to be reduced by up to about 90% in the FRT assay.

[0452] Patients with the F508del / residual function genotype are defined as patients with heterozygous F508del-CFTR whose second CFTR allele contains a mutation that results in a reduction in the amount or function of the protein on the cell surface, which results in partial CFTR activity.

[0453] Patients with the F508del / gating mutation genotype are defined as patients with heterozygous F508del-CFTR whose second CFTR allele contains a mutation associated with a gating defect and clinically demonstrated to be responsive to Compound III. Examples of such mutations include: G178R, S549N, S549R, G551D, G551S, G1244E, S1251N, S1255P, and G1349D.

[0454] In some embodiments, the methods of treating, lessening the severity of, or treating symptomatically of cystic fibrosis disclosed herein each independently increase chloride transport above the patient's baseline chloride transport.

[0455] In some embodiments, in the methods disclosed herein for treating cystic fibrosis, reducing its severity, or treating it symptomatically, the patient is heterozygous for F508del, and another CFTR gene mutation is any mutation that causes CF. In some embodiments, the patient is heterozygous for F508del, and another CFTR gene mutation is any mutation that causes CF, and based on in vitro and / or clinical data, it is expected to be and / or respond to any novel compound disclosed herein, such as Compound I, Compound II, Compound III, and / or Compound IV genotype. In some embodiments, the patient is heterozygous for F508del, and another CFTR gene mutation is any mutation that causes CF, and based on in vitro and / or clinical data, it is expected to be and / or respond to any combination of the following: (i) novel compounds disclosed herein, such as Compound I, and (ii) Compound II, and / or Compound III and / or Compound IV genotype.

[0456] In some embodiments, in the methods of treating, lessening the severity of, or treating symptomatically cystic fibrosis disclosed herein, the patient possesses a CFTR gene mutation selected from any mutation listed in Table A.

[0457] Table A. CF mutations

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient has a gene selected from the group consisting of G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G->A, 621+1G->T, 31 20+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4 005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A , 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, 3849+10kbC->T, 327 2-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A->G, 1898+3A->G , 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T , 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C, 621+3A->G, 1949d el84, 3141del9, 3195del6, 3199del6, 3905InsT, 4209TGTT->A, A1006E, A120T, A234D, A349V, A613T, C524R, D192G, D443Y, D513G, D836Y, D924N, D979V , E116K, E403D, E474K, E588V, E60K, E822K, F1016S, F1099L, F191V, F311de l, F311L, F508C, F575Y, G1061R, G1249R, G126D, G149R, G194R, G194V, G27R, G314E, G458V, G463V, G480C, G622D, G628R, G628R(G->A), G91R, G970D, H10 54D, H1085P, H1085R, H1375P, H139R, H199R, H609R, H939R, I1005R, I1234V,I1269N, I1366N, I175V, I502T, I506S, I506T, I601F, I618T, I807M, I980K, L102R, L1324P, L1335P, L138ins, L1480P, L15P, L165S, L320V, L346P, L453S, L571S, L967S, M1101R, M152V, M1T, M1V, M265R, M952I, M952T, P574H, P5L, P750L, P99L, Q1100P, Q1291H, Q1291R, Q237E, Q2 37H, Q452P, Q98R, R1066C, R1066H, R117G, R117L, R117P, R1283M, R1283S, R170H, R258G, R31 L, R334L, R334Q, R347L, R352W, R516G, R553Q, R751L, R792G, R933G, S1118F, S1159F, S1159P , S13F, S549R(A->C), S549R(T->G), S589N, S737F, S912L, T1036N, T1053I, T1246I, T604I, V CFTR gene mutations of 1153E, V1240G, V1293G, V201M, V232D, V456A, V456F, V562I, W1098C, W1098R, W1282R, W361R, W57G, W57R, Y1014C, Y1032C, Y109N, Y161D, Y161S, Y563D, Y563N, Y569C, and Y913C.

[0470] In some embodiments, the patient has at least one combination of mutations selected from the group consisting of G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455 E. D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G->A, 621+1G-> T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A ,1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G- >T, 3850-1G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+ 1.6kbA->G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 181 1+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C and 621+3A->G.

[0471] In some embodiments,Patients have at least one combination of mutations selected from the following: 1949del84, 3141del9, 3195del6, 3199del6, 3905InsT, 4209TGTT->A, A1006E, A120T, A234D, A349V, A613T, C524R, D192G, D443Y, D513G, D836Y, D924N, D979V, E116K, E403D, E474K, E588V, E60K, E822K, F1016S, F1099L, F191V, F311del, F311L, F508C, F575Y, G1061R, G1249R, G126D , G149R, G194R, G194V, G27R, G314E, G458V, G463V, G480C, G622D, G628R, G6 28R(G->A), G91R, G970D, H1054D, H1085P, H1085R, H1375P, H139R, H199R, H 609R, H939R, I1005R, I1234V, I1269N, I1366N, I175V, I502T, I506S, I506T , I601F, I618T, I807M, I980K, L102R, L1324P, L1335P, L138ins, L1480P, L15 P, L165S, L320V, L346P, L453S, L571S, L967S, M1101R, M152V, M1T, M1V, M26 5R, M952I, M952T, P574H, P5L, P750L, P99L, Q1100P, Q1291H, Q1291R, Q237E , Q237H, Q452P, Q98R, R1066C, R1066H, R117G, R117L, R117P, R1283M, R1283 S, R170H, R258G, R31L, R334L, R334Q, R347L, R352W, R516G, R553Q, R751L, R7 92G, R933G, S1118F, S1159F, S1159P, S13F, S549R(A->C), S549R(T->G), S5 89N, S737F, S912L, T1036N, T1053I, T1246I, T604I, V1153E, V1240G, V1293 G, V201M, V232D, V456A, V456F, V562I, W1098C, W1098R, W1282R, W361R, W57 G, W57R, Y1014C, Y1032C, Y109N, Y161D, Y161S, Y563D, Y563N, Y569C and Y913C. ,

[0472] In some embodiments, in the methods disclosed herein for treating cystic fibrosis, reducing its severity, or treating it symptomatically, the patient has a CFTR gene mutation G551D. In some embodiments, the patient is homozygous for the G551D gene mutation. In some embodiments, the patient is heterozygous for the G551D gene mutation. In some embodiments, the patient is heterozygous for the G551D gene mutation, has a G551D mutation on one allele, and has any other mutation causing CF on the other allele. In some embodiments, the patient is heterozygous for the G551D gene mutation on one allele, and another CF-causing gene mutation on the other allele is any one of F508del, G542X, N1303K, W1282X, R117H, R553X, 1717-1G->A, 621+1G->T, 2789+5G->A, 3849+10kbC->T, R1162X, G85E, 3120+1G->A, ΔI507, 1898+1G->A, 3659delC, R347P, R560T, R334W, A455E, 2184delA, or 711+1G->T. In some embodiments, the patient is heterozygous for the G551D gene mutation, and another CFTR gene mutation is F508del. In some embodiments, the patient is heterozygous for the G551D gene mutation and the other CFTR gene mutation is R117H.

[0473] In some embodiments, in the methods disclosed herein for treating cystic fibrosis, reducing its severity, or treating it symptomatically, the patient has a CFTR gene mutation F508del. In some embodiments, the patient is homozygous for the F508del gene mutation. In some embodiments, the patient is heterozygous for the F508del gene mutation, wherein the patient has the F508del gene mutation on one allele and any gene mutation that causes CF on the other allele. In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is any mutation that causes CF, including but not limited to G551D, G542X, N1303K, W1282X, R117H, R553X, 1717-1G->A, 621+1G->T, 2789+5G->A, 3849+10kbC->T, R1162X, G85E, 3120+1G->A, ΔI507, 1898+1G->A, 3659delC, R347P, R560T, R334W, A455E, 2184delA, or 711+1G->T. In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is G551D. In some embodiments, the patient is heterozygous for F508del and the other CFTR gene mutation is R117H.

[0474] In some embodiments, the patient has at least one combination of mutations selected from:

[0475] D443Y; G576A; R668C,

[0476] F508C; S1251N,

[0477] G576A; R668C,

[0478] G970R; M470V,

[0479] R74W; D1270N,

[0480] R74W; V201M, and

[0481] R74W;V201M;D1270N.

[0482] In some embodiments, in the methods disclosed herein for treating cystic fibrosis, reducing its severity, or treating it symptomatically, the patient has a CFTR gene mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, and G1069R. In some embodiments, the patient has a CFTR gene mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, and S1251N. In some embodiments, the patient has a CFTR gene mutation selected from E193K, F1052V, and G1069R. In some embodiments, the method increases chloride transport relative to the patient's baseline chloride transport.

[0483] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient possesses a CFTR gene mutation selected from R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, and D1152H.

[0484] In some embodiments, the patient has a gene selected from 1717-1G->A, 621+1G->T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, CFTR gene mutations include 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C and 621+3A->G. In some embodiments, the patient has a CFTR gene mutation selected from 1717-1G->A, 1811+1.6kbA->G, 2789+5G->A, 3272-26A->G, and 3849+10kbC->T. In some embodiments, the patient has a CFTR gene mutation selected from 2789+5G->A and 3272-26A->G.

[0485] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient has a gene selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R352Q, E56K, P67L, L2 06W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G->A, 621+1G-> T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G ->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 27 89+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A->G, 1898 +3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C and 621+3A->G CFTR gene mutations, and human CFTR mutations are selected from F508del, R117H and G551D.

[0486] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient has a gene selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455 E. D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G->A, 621+1G->T, 3120+1G->A , 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, 3849+10kbC ->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342 -2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C, 621+3A->G, and the CFTR mutation is selected from F508del, R117H and G551D; and the CFTR mutation is selected from F508del, R117H and G551D.

[0487] In some embodiments, the patient has a CFTR gene mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V and G1069R, and the human CFTR mutation is selected from F508del, R117H and G551D. In some embodiments, the patient has a CFTR gene mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251N, and the human CFTR mutation is selected from F508del, R117H and G551D. In some embodiments, the patient possesses a CFTR gene mutation selected from E193K, F1052V, and G1069R, and the human CFTR mutation is selected from F508del, R117H, and G551D.

[0488] In some embodiments, the patient possesses a CFTR gene mutation selected from R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, and D1152H, and the human CFTR mutation is selected from F508del, R117H, and G551D.

[0489] In some embodiments, the patient has a gene selected from the group consisting of 1717-1G->A, 621+1G->T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, 3849+10kbC->T, 3 CFTR gene mutations 272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C and 621+3A->G, and the human CFTR mutation is selected from F508del, R117H and G551D. In some embodiments, the patient has a CFTR gene mutation selected from 1717-1G->A, 1811+1.6kbA->G, 2789+5G->A, 3272-26A->G, and 3849+10kbC->T, and the human CFTR mutation is selected from F508del, R117H, and G551D. In some embodiments, the patient has a CFTR gene mutation selected from 2789+5G->A and 3272-26A->G, and the human CFTR mutation is selected from F508del, R117H.

[0490] In some embodiments, the patient has a mutation that causes CF on one allele and a mutation that causes CF on the other allele. In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is any mutation that causes CF, including but not limited to F508del on one CFTR allele and a CFTR mutation on a second CFTR allele that is associated with minimal CFTR function, residual CFTR function, or CFTR channel gating activity defects.

[0491] In some embodiments, the CF-causing mutation is selected from Table A. In some embodiments, the CF-causing mutation is selected from Table B. In some embodiments, the CF-causing mutation is selected from Table C. In some embodiments, the CF-causing mutation is selected from Figure 3. In some embodiments, the patient is heterozygous with a CF-causing mutation on one CFTR allele selected from the mutations listed in the table of Figure 3 and a CF-causing mutation on the other CFTR allele selected from the CFTR mutations listed in Table B: Table B: CFTR mutations

[0492] Table C: CFTR mutations

[0493]

[0494]

[0495] In some embodiments, the patient is: having a F508del / MF (F / MF) genotype (heterozygous for F508del and a MF mutation that is not expected to respond to CFTR modulators such as Compound III); having a F508del / F508del (F / F) genotype (homozygous for F508del); and / or having a F508del / gating (F / G) genotype (heterozygous for F508del and a gating mutation known to be CFTR modulator-responsive (e.g., Compound III-responsive). In some embodiments, a patient with a F508del / MF (F / MF) genotype has a MF mutation that is not expected to respond to Compound II, Compound III, and both Compound II and Compound III. In some embodiments, a patient with a F508del / MF (F / MF) genotype has any one of the MF mutations in Table C.

[0496] In some embodiments, the patient is heterozygous for F508del and the other CFTR gene mutation is any CF-causing mutation, including truncating mutations, splicing mutations, small (≤3 nucleotides) insertion or deletion frameshift mutations; non-small (>3 nucleotides) insertion or deletion frameshift mutations; and Class II, Class III, Class IV mutations that are unresponsive to Compound III alone or in combination with Compound II or Compound IV.

[0497] In some embodiments, the patient is heterozygous for F508del, and another CFTR gene mutation is a truncating mutation. In some specific embodiments, the truncating mutation is a truncating mutation listed in Table C.

[0498] In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is a splicing mutation. In some specific embodiments, the splicing mutation is a splicing mutation listed in Table C.

[0499] In some embodiments, the patient is heterozygous for F508del, and another CFTR gene mutation is a small (≤3 nucleotides) insertion or deletion frameshift mutation. In some specific embodiments, a small (≤3 nucleotides) insertion or deletion frameshift mutation is a small (≤3 nucleotides) insertion or deletion frameshift mutation listed in Table C.

[0500] In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is any CF-causing mutation that is expected to be and / or respond to any combination of: (i) a novel compound selected from those disclosed herein (e.g., compounds of Formula (I), (II), (III), (IV) or (V), and pharmaceutically acceptable salts thereof, and deuterated derivatives thereof); and (ii) Compound II, and / or Compound III, and / or Compound IV, based on in vitro and / or clinical data.

[0501] In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is any CF-causing mutation that, based on in vitro and / or clinical data, is expected to be and / or respond to the following triple combination: a novel compound selected from those disclosed herein (e.g., compounds of Formula (I), (II), (III), (IV) or (V), and pharmaceutically acceptable salts thereof, and deuterated derivatives thereof); and Compound II and Compound III.

[0502] In some embodiments, the patient is heterozygous for F508del, and another CFTR gene mutation is a non-small (>3 nucleotides) insertion or deletion frameshift mutation. In some specific embodiments, the non-small (>3 nucleotides) insertion or deletion frameshift mutation is a non-small (>3 nucleotides) insertion or deletion frameshift mutation listed in Table 5B.

[0503] In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is a Class II, Class III, Class IV mutation that is unresponsive to Compound III alone or in combination with Compound II or Compound IV. In some specific embodiments, the Class II, Class III, Class IV mutation that is unresponsive to Compound III alone or in combination with Compound II or Compound IV is a Class II, Class III, Class IV mutation that is unresponsive to Compound III alone or in combination with Compound II or Compound IV listed in Table C.

[0504] In some embodiments, the patient is heterozygous for F508del and the other CFTR gene mutation is any mutation listed in Table C.

[0505] In some embodiments, the patient is heterozygous for F508del and the other CFTR gene mutation is any mutation listed in Table A, Table B, Table C, and Figure 3, but is not F508del.

[0506] In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is any mutation listed in Table A. In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is any mutation listed in Table B. In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is any mutation listed in Table C. In some embodiments, the patient is heterozygous for F508del, and the other CFTR gene mutation is any mutation listed in Figure 3.

[0507] In some embodiments, the patient is homozygous for F508del.

[0508] In some embodiments, the patient is heterozygous for a CF-causing mutation on one CFTR allele selected from the mutations listed in the table of FIG. 3 and for another CF-causing mutation on the other CFTR allele selected from the CFTR mutations listed in Table C.

[0509] In some embodiments, the compositions disclosed herein can be used to treat, reduce the severity of, or treat symptomatically cystic fibrosis in patients who exhibit residual CFTR activity in the apical membrane of respiratory and non-respiratory epithelia. Residual CFTR activity on epithelial surfaces can be readily detected using methods known in the art, such as standard electrophysiological, biochemical, or histochemical techniques. These methods use in vivo or ex vivo electrophysiological techniques, sweat or saliva Cl - Concentration measurement or in vitro biochemical or histochemical techniques to monitor cell surface density to identify CFTR activity. Using these methods, for patients with various different mutations that are heterozygous or homozygous, including the most common mutation F508del and other mutations such as G551D mutation or R117H mutation that are heterozygous patients, residual CFTR activity can be easily detected. In some embodiments, the compositions disclosed herein can be used to treat cystic fibrosis in patients who show little or no residual CFTR activity, reduce its severity, or treat it symptomatically. In some embodiments, the compositions disclosed herein can be used to treat cystic fibrosis in patients who show little or no residual CFTR activity in the apical membrane of the respiratory epithelium, reduce its severity, or treat it symptomatically.

[0510] In some embodiments, the compositions disclosed herein can be used to treat or reduce the severity of cystic fibrosis in patients exhibiting residual CFTR activity using pharmacological methods. These methods increase the amount of CFTR present on the cell surface, thereby inducing CFTR activity in patients that was not present heretofore or increasing the existing level of residual CFTR activity in patients.

[0511] In some embodiments, the compositions disclosed herein can be used to treat or lessen the severity of cystic fibrosis in patients with certain genotypes that exhibit residual CFTR activity.

[0512] In some embodiments, the compositions disclosed herein can be used to treat, reduce the severity of, or symptomatically treat cystic fibrosis in patients with certain clinical phenotypes (e.g., mild to moderate clinical phenotypes that are generally associated with the amount of residual CFTR activity in the epithelial apical membrane. These phenotypes include patients who exhibit pancreatic sufficiency.

[0513] In some embodiments, the compositions disclosed herein can be used to treat, lessen the severity of, or symptomatically treat patients diagnosed with pancreatic sufficiency, idiopathic pancreatitis, and congenital bilateral absence of the vas deferens, or mild lung disease, wherein the patients exhibit residual CFTR activity.

[0514] In some embodiments, the disclosure relates to a method for enhancing or inducing anion channel activity in vitro or in vivo, comprising contacting the channel with a composition disclosed herein. In some embodiments, the anion channel is a chloride channel or a bicarbonate channel. In some embodiments, the anion channel is a chloride channel.

[0515] In some embodiments of the methods for treating cystic fibrosis disclosed herein, the absolute change in the patient's percentage of predicted forced expiratory volume in one second (ppFEV1) relative to the patient's ppFEV1 before administration 15 days after administration of at least one compound selected from Compound I and a pharmaceutically acceptable salt thereof, at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof, and at least one compound selected from Compound III or III-d and a pharmaceutically acceptable salt thereof ranges from 3% to 40%.

[0516] In some embodiments of the methods for treating cystic fibrosis disclosed herein, the absolute change in the patient's percentage of predicted forced expiratory volume in one second (ppFEV1) 29 days after administration of at least one compound selected from Compound I and a pharmaceutically acceptable salt thereof, at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof, and at least one compound selected from Compound III and a pharmaceutically acceptable salt thereof relative to the patient's ppFEV1 before said administration ranges from 3% to 40%.

[0517] In some embodiments of the methods of treating cystic fibrosis disclosed herein, the patient's sweat chloride has an absolute change range from baseline (i.e., relative to the patient's sweat chloride before the administration) of -2 to -65 mmol / L 15 days after administration of at least one compound selected from Compound I and a pharmaceutically acceptable salt thereof, at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof, and at least one compound selected from Compound III or III-d and a pharmaceutically acceptable salt thereof. In some embodiments, the patient's sweat chloride has an absolute change range from -5 to -65 mmol / L. In some embodiments, the patient's sweat chloride has an absolute change range from -10 to -65 mmol / L. In some embodiments, the patient's sweat chloride has an absolute change range from -2 to -65 mmol / L.

[0518] In some embodiments of the methods of treating cystic fibrosis disclosed herein, the patient's sweat chloride 29 days after administration of at least one compound selected from Compound I and a pharmaceutically acceptable salt thereof, at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof, and at least one compound selected from Compound III and a pharmaceutically acceptable salt thereof, has an absolute change in sweat chloride from baseline (i.e., relative to the patient's sweat chloride before the administration) ranging from -2 to -65 mmol / L. In some embodiments, the patient's sweat chloride has an absolute change in range of -5 to -65 mmol / L. In some embodiments, the patient's sweat chloride has an absolute change in range of -10 to -65 mmol / L. In some embodiments, the patient's sweat chloride has an absolute change in range of -2 to -65 mmol / L.

[0519] In some embodiments, the triple combination is administered to a patient who has one F508del mutation and one minimal function mutation and is not taking any of the at least one compound selected from Compound I and a pharmaceutically acceptable salt thereof, at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof, and at least one compound selected from Compound III or III-d and a pharmaceutically acceptable salt thereof.

[0520] In some embodiments, the triple combination is administered to a patient with two copies of the F508del mutation, wherein the patient is taking at least one compound selected from Compound II and a pharmaceutically acceptable salt thereof and at least one compound selected from Compound III or III-d and a pharmaceutically acceptable salt thereof, but is not taking any of the at least one compound selected from Compound I and a pharmaceutically acceptable salt thereof.

[0521] In some embodiments, the absolute change in the patient's ppFEV1 in one second 15 days after administration of at least one compound selected from Compound I and pharmaceutically acceptable salts thereof, at least one compound selected from Compound II and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound III or III-d and pharmaceutically acceptable salts thereof relative to the patient's ppFEV1 before said administration ranges from 3% to 35%.

[0522] In some embodiments, the absolute change in the patient's ppFEV1 in one second 29 days after administration of at least one compound selected from Compound I and pharmaceutically acceptable salts thereof, at least one compound selected from Compound II and pharmaceutically acceptable salts thereof, and at least one compound selected from Compound III and pharmaceutically acceptable salts thereof relative to the patient's ppFEV1 before said administration ranges from 3% to 35%.

[0523] In some embodiments, the absolute change in a patient's ppFEV1 relative to the patient's ppFEV1 prior to administration of the triple combination can be calculated as (post-baseline value - baseline value). The baseline value is defined as the most recent non-missing measurement collected before the first dose of study drug in the treatment period (Day 1).

[0524] The exact amount of API and tablets containing such API required will vary from subject to subject, depending on the species, age and general condition of the subject, the severity of the disease, the specific medicament, its mode of administration, etc. The compounds of the present disclosure can be formulated in dosage unit form to facilitate administration and maintain dosage uniformity. As used herein, the expression "dosage unit form" refers to physically discrete units of a medicament suitable for the patient to be treated. However, it should be understood that the total daily usage of the API of the present disclosure and tablets containing such API will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dosage level for any particular patient or organism will depend on a variety of factors, including the condition being treated and the severity of the condition; the activity of the specific API administered; the specific composition used; the age, weight, health, sex and diet of the patient; the time of administration; the route of administration; the excretion rate of the specific compound used; the duration of treatment; drugs used in combination with or incidentally used with the specific compound used and similar factors well known in the medical field. As used herein, the term "patient" refers to an animal, such as a mammal, and even such as a human.

[0525] In some embodiments, the present disclosure also relates to methods of treatment using isotopically labeled compounds of the aforementioned compounds, wherein the isotopically labeled compounds have the same structure as disclosed herein, except that one or more atoms therein have been replaced (isotopically labeled) with one or more atoms having an atomic mass or mass number different from the atomic mass or mass number of the atoms normally found in nature. Examples of isotopes that are commercially available and suitable for use in the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as respectively 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl.

[0526] Isotope-labeled compounds and salts can be used in a variety of beneficial ways. They can be used in pharmaceutical and / or various types of assays, such as substrate tissue distribution assays. For example, tritium ( 3 H) and / or carbon-14 ( 14 C) labeled compounds are particularly useful in many types of assays, such as substrate tissue distribution assays, due to their relatively simple preparation and excellent detectability. 2 H) The labeled compounds are useful in therapy and have advantages over non 2 Potential therapeutic advantages of H-labeled compounds. Generally, deuterium ( 2 H) labeled compounds and salts may have higher metabolic stability than non-isotope labeled compounds and salts. Higher metabolic stability is directly converted into longer in vivo half-life or lower dosage, which may be desirable. Isotope labeled compounds and salts can generally be prepared by performing the procedures disclosed in the synthetic schemes and related descriptions, the examples section and the preparation section herein, replacing non-isotope labeled reactants with readily available isotope labeled reactants.

[0527] In some embodiments, isotopically labeled compounds and salts are deuterated ( 2 In some specific embodiments, the isotope-labeled compounds and salts are deuterated ( 2 H) in which one or more hydrogen atoms have been replaced by deuterium. In chemical structures, deuterium is represented by “ 2 "H" or "D".

[0528] deuterium( 2H) labeled compounds and salts can manipulate the oxidative metabolism of compounds through the primary kinetic isotope effect. The primary kinetic isotope effect is a change in the rate of a chemical reaction caused by the exchange of isotopic nuclei, which in turn is caused by a change in the ground state energy necessary to form a covalent bond following this isotope exchange. Exchange of heavier isotopes generally lowers the ground state energy of a chemical bond, thereby reducing the breaking of rate-limiting bonds. If bond breaking occurs in or near a saddle point region along the coordinates of a multi-product reaction, the product distribution ratio can be significantly altered. Explanation: If deuterium is bonded to a carbon atom at a non-exchangeable position, the rate difference k M / k D = 2-7 ​​is typical. For further discussion, see SL Harbeson and RD Tung, Deuterium In Drug Discovery and Development, Ann. Rep. Med. Chem. 2011, 46, 403-417; and TG Gant "Using deuterium in drug discovery: leaving the label in the drug" J. Med. Chem. 2014, 57, 3595-3611, the relevant parts of which are independently incorporated herein by reference.

[0529] The concentration of an isotope (eg, deuterium) incorporated into the isotopically labeled compounds and salts of the present disclosure can be defined by an isotopic enrichment factor. As used herein, the term "isotopic enrichment factor" refers to the ratio between the isotopic abundance and the natural abundance of a particular isotope. In some embodiments, where a substituent in a compound of the present disclosure represents deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

[0530] When discovering and developing therapeutic agents, one skilled in the art attempts to optimize pharmacokinetic parameters while retaining desired in vitro properties. It is reasonable to assume that many compounds with poor pharmacokinetic properties are susceptible to oxidative metabolism.

[0531] Those of ordinary skill in the art will appreciate that, compared to the corresponding hydrogen analogs, deuteration of one or more metabolically unstable positions on a compound or active metabolite can result in improvements in one or more excellent DMPK properties while maintaining biological activity. One or more excellent DMPK properties can affect exposure, half-life, clearance, metabolism and / or even food requirements for optimal absorption of the drug product. Deuteration can also change the metabolism of the deuterated compound at other non-deuterated positions.

[0532] Compound III-d as used herein includes deuterated compounds disclosed in US Pat. No. 8,865,902 (which is incorporated herein by reference) and CTP-656.

[0533] As mentioned above, compound III-d is:

[0534]

[0535] Exemplary embodiments of the present disclosure include:

[0536] 1. A single tablet comprising

[0537] (a) 25 mg to 150 mg of Compound I:

[0538]

[0539] (b) a first solid dispersion comprising 20 mg to 150 mg of Compound II:

[0540]

[0541] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[0542] (c) a second solid dispersion comprising 25 mg to 200 mg of compound III-d:

[0543] and 10 to 30 wt % of a polymer relative to the total weight of the second solid dispersion.

[0544] 2. A single tablet as described in embodiment 1, wherein at least one of the first solid dispersion or the second solid dispersion is a spray-dried dispersion.

[0545] 3. A single tablet according to embodiment 1, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[0546] 4. A single tablet according to embodiment 1, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[0547] 5. The single tablet of embodiment 1, wherein the polymer in the first solid dispersion is HPMC E15; and the polymer in the second solid dispersion is hydroxypropylmethylcellulose acetate succinate H.

[0548] 6. The single tablet of embodiment 1, wherein the polymer in the first solid dispersion is HPMC E15; and the polymer in the second solid dispersion is hydroxypropylmethylcellulose acetate succinate HG.

[0549] 6a. A single tablet according to embodiment 1, wherein Compound I is in crystalline Form A.

[0550] 6b. A single tablet as described in embodiment 6a, wherein Compound I crystalline Form A is in substantially pure form.

[0551] 6c. A single tablet as described in embodiment 6a, wherein Compound 1 crystalline Form A is characterized by an X-ray powder diffraction pattern having signals at at least three 2θ values ​​selected from 6.6±0.2, 7.6±0.2, 9.6±0.2, 12.4±0.2, 13.1±0.2, 15.2±0.2, 16.4±0.2, 18.2±0.2 and 18.6±0.2.

[0552] 6d. A single tablet as described in embodiment 6a, wherein Compound I crystalline Form A is characterized by an X-ray powder diffraction pattern having signals at at least three 2θ values ​​selected from 6.6±0.2, 9.6±0.2, 7.6±0.2, 15.2±0.2, 12.4±0.2 and 16.4±0.2.

[0553] 6e. A single tablet as described in embodiment 6a, wherein Compound I crystalline Form A is characterized by an X-ray powder diffraction pattern having signals at three 2θ values ​​of 6.6±0.2, 9.6±0.2, and 15.2±0.2.

[0554] 6f. A single tablet as described in embodiment 6a, wherein Compound I crystalline Form A is characterized by an X-ray powder diffraction pattern having signals at six 2θ values ​​of 6.6±0.2, 9.6±0.2, 7.6±0.2, 15.2±0.2, 12.4±0.2 and 16.4±0.2.

[0555] 6g. A single tablet as described in embodiment 6a, wherein Compound I crystalline Form A is characterized by an X-ray powder diffraction pattern that is substantially similar to Figure 4A X-ray powder diffraction pattern of .

[0556] 6h. A single tablet as described in embodiment 6a, wherein Compound I crystalline Form A is characterized by an X-ray powder diffraction pattern that is substantially similar to Figure 4B X-ray powder diffraction pattern of .

[0557] 7. A single tablet as described in any of embodiments 1-6g, comprising 80 mg to 120 mg of Compound I.

[0558] 8. A single tablet as described in any of embodiments 1-6g, comprising 80 mg to 120 mg, 85 mg to 115 mg, 90 mg to 110 mg or 95 mg to 105 mg of Compound I.

[0559] 9. A single tablet as described in any one of embodiments 1-6g, comprising 100 mg of Compound I.

[0560] 10. A single tablet as described in any of embodiments 1-6g, comprising 75 mg to 125 mg of Compound I.

[0561] 11. A single tablet as described in any one of embodiments 1-10, wherein the first solid dispersion comprises 25 mg to 75 mg of Compound II.

[0562] 12. A single tablet as described in any one of embodiments 1-10, wherein the first solid dispersion comprises 50 mg of Compound II.

[0563] 13. A single tablet as described in any one of embodiments 1-12, wherein the second solid dispersion contains 25 mg to 50 mg, 25 mg to 75 mg, 50 mg to 100 mg, or 75 mg to 125 mg of Compound III-d.

[0564] 14. A single tablet as described in any one of embodiments 1-12, wherein the second solid dispersion comprises 75 mg of Compound III-d.

[0565] 15. A single tablet as described in any one of embodiments 1-6, comprising

[0566] 50 mg to 125 mg of Compound I; and wherein

[0567] The first solid dispersion comprises 25 mg to 75 mg of Compound II; and

[0568] The second solid dispersion contains 75 mg to 125 mg of Compound III-d.

[0569] 16. A single tablet as described in any one of embodiments 1-6, comprising

[0570] 75 mg to 125 mg of Compound I; and wherein

[0571] The first solid dispersion comprises 50 mg of Compound II; and

[0572] The second solid dispersion contained 75 mg of Compound III-d.

[0573] 17. A single tablet as described in any one of embodiments 1-6, comprising

[0574] 100 mg of Compound I; and wherein

[0575] The first solid dispersion comprises 50 mg of Compound II; and

[0576] The second solid dispersion contained 75 mg of Compound III-d.

[0577] 18. A single tablet as described in any one of embodiments 1-17, wherein the second solid dispersion further comprises 0.5% sodium lauryl sulfate relative to the total weight of the second solid dispersion.

[0578] 19. A single tablet as described in any one of embodiments 1-18, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, lubricants and glidants.

[0579] 20. A single tablet as described in embodiment 19, wherein the filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, starch, maltodextrin, agar and guar gum.

[0580] 21. A single tablet according to embodiment 19, wherein the disintegrant is selected from cross-linked sodium carboxymethylcellulose, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose and microcrystalline cellulose.

[0581] 22. A single tablet as described in embodiment 19, wherein the lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc.

[0582] 23. A single tablet as described in embodiment 19, wherein the glidant is colloidal silicon dioxide.

[0583] 24. A single tablet as described in any one of embodiments 1-23, wherein Compound I is substantially crystalline, and wherein Compounds II and III-d are each independently substantially amorphous.

[0584] 25. A pharmaceutical composition comprising:

[0585] (a) 10% to 30% by weight of Compound I relative to the total weight of the pharmaceutical composition:

[0586]

[0587] (b) 10% to 30% by weight of the first solid dispersion relative to the total weight of the pharmaceutical composition;

[0588] The first solid dispersion comprises 70% to 90% by weight of Compound II relative to the total weight of the first solid dispersion:

[0589]

[0590] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[0591] (c) 10% to 30% by weight of a second solid dispersion relative to the total weight of the pharmaceutical composition;

[0592] The second solid dispersion comprises 70 wt % to 90 wt % of compound III-d relative to the total weight of the second solid dispersion:

[0593] and 10 to 30 wt % of a polymer relative to the total weight of the second solid dispersion.

[0594] 26. The pharmaceutical composition of embodiment 25, wherein at least one of the first solid dispersion or the second solid dispersion is a spray-dried dispersion.

[0595] 27. The pharmaceutical composition of embodiment 25, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[0596] 28. The pharmaceutical composition of embodiment 25, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[0597] 29. The pharmaceutical composition of embodiment 25, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose (HPMC E15); and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate H.

[0598] 30. The pharmaceutical composition according to embodiment 25, wherein:

[0599] The first solid dispersion comprises 70 wt % to 85 wt % of Compound II relative to the total weight of the first solid dispersion, and the polymer is hydroxypropyl methylcellulose in an amount of 15 wt % to 30 wt % relative to the total weight of the first solid dispersion; and

[0600] The second solid dispersion comprises 70 to 85 wt % of compound III-d relative to the total weight of the second solid dispersion, 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and the polymer is hydroxypropyl methylcellulose acetate succinate in an amount of 14.5 to 29.5 wt % relative to the total weight of the second solid dispersion.

[0601] 31. The pharmaceutical composition of any one of embodiments 25-30, wherein the first solid dispersion comprises 75 wt% to 85 wt% of Compound II relative to the total weight of the first solid dispersion.

[0602] 32. A pharmaceutical composition as described in any one of embodiments 25-31, wherein the first solid dispersion comprises 80 weight % of Compound II relative to the total weight of the first solid dispersion; and 20 weight % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion.

[0603] 33. The pharmaceutical composition of any one of embodiments 25-32, wherein the second solid dispersion comprises 75 wt% to 85 wt% of compound III-d relative to the total weight of the second solid dispersion.

[0604] 34. A pharmaceutical composition as described in any of embodiments 25-33, wherein the second solid dispersion comprises 80 wt% of Compound III-d, relative to the total weight of the second solid dispersion; 0.5% of sodium lauryl sulfate, relative to the total weight of the second solid dispersion, and 19.5 wt% of hydroxypropyl methylcellulose acetate succinate, relative to the total weight of the second solid dispersion.

[0605] 35. The pharmaceutical composition of any one of embodiments 25-34, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, lubricants and glidants.

[0606] 36. A pharmaceutical composition as described in embodiment 35, wherein the filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, starch, maltodextrin, agar and guar gum.

[0607] 37. A pharmaceutical composition as described in embodiment 35, wherein the disintegrant is selected from cross-linked carboxymethylcellulose sodium, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose and microcrystalline cellulose.

[0608] 38. The pharmaceutical composition of embodiment 35, wherein the lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc.

[0609] 39. The pharmaceutical composition of embodiment 35, wherein the glidant is colloidal silicon dioxide.

[0610] 40. The pharmaceutical composition of any one of embodiments 25-39, wherein Compound I is substantially crystalline, and wherein Compounds II and III-d are each independently substantially amorphous.

[0611] 41. The pharmaceutical composition of any one of embodiments 25-40, wherein the pharmaceutical composition is a tablet.

[0612] 42. The pharmaceutical composition of any one of embodiments 25-40, wherein the pharmaceutical composition is in the form of particles.

[0613] 43. A pharmaceutical composition comprising:

[0614] (a) Compound I:

[0615]

[0616] (b) a first solid dispersion,

[0617] The first solid dispersion comprises 70% to 90% by weight of Compound II relative to the total weight of the first solid dispersion:

[0618]

[0619] and 10 to 30 wt % of a polymer; and

[0620] (c) a second solid dispersion;

[0621] The second solid dispersion comprises 70 wt % to 90 wt % of compound III-d relative to the total weight of the second solid dispersion:

[0622] and 10 to 30 wt % of a polymer, wherein

[0623] The weight ratio of compound I in (a): compound II in (b): compound III-d in (c) is in the range of 1-4:2:3.

[0624] 43a. A pharmaceutical composition as described in embodiment 43, wherein the weight ratio of compound I in (a): compound II in (b): compound III-d in (c) is 2:2:3.

[0625] 43b. A pharmaceutical composition as described in embodiment 43, wherein the weight ratio of compound I in (a): compound II in (b): compound III-d in (c) is 1:2:3.

[0626] 43c. A pharmaceutical composition as described in Embodiment 43, wherein the weight ratio of Compound I in (a): Compound II in (b): Compound III-d in (c) is 4:2:3.

[0627] 44. The pharmaceutical composition of embodiment 43, wherein at least one of the second solid dispersion or the third solid dispersion is a spray-dried dispersion.

[0628] 45. The pharmaceutical composition of embodiment 43, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[0629] 46. ​​A pharmaceutical composition as described in embodiment 43, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[0630] 47. A pharmaceutical composition as described in embodiment 43, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose (HPMC E15); and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate H.

[0631] 48. The pharmaceutical composition according to embodiment 43, wherein:

[0632] The first solid dispersion comprises 70 wt % to 85 wt % of Compound II relative to the total weight of the first solid dispersion, and the polymer is hydroxypropyl methylcellulose in an amount of 15 wt % to 30 wt % relative to the total weight of the first solid dispersion; and

[0633] The second solid dispersion comprises 70 to 85 wt % of compound III-d relative to the total weight of the second solid dispersion, 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and the polymer is hydroxypropyl methylcellulose acetate succinate in an amount of 14.5 to 29.5 wt % relative to the total weight of the second solid dispersion.

[0634] 49. The pharmaceutical composition of any one of embodiments 43-48, wherein the first solid dispersion comprises 75 wt% to 85 wt% of Compound II relative to the total weight of the first solid dispersion.

[0635] 50. A pharmaceutical composition as described in any one of embodiments 43-49, wherein the first solid dispersion comprises 80 weight % of Compound II relative to the total weight of the first solid dispersion; and 20 weight % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion.

[0636] 51. The pharmaceutical composition of any one of embodiments 43-50, wherein the second solid dispersion comprises 75 wt% to 85 wt% of Compound III-d relative to the total weight of the second solid dispersion.

[0637] 52. A pharmaceutical composition as described in any of embodiments 43-51, wherein the second solid dispersion comprises 80 wt% of Compound III-d, relative to the total weight of the second solid dispersion; 0.5% of sodium lauryl sulfate, relative to the total weight of the second solid dispersion, and 19.5 wt% of hydroxypropyl methylcellulose acetate succinate, relative to the total weight of the second solid dispersion.

[0638] 53. The pharmaceutical composition of any one of embodiments 43-42, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, lubricants and glidants.

[0639] 54. A pharmaceutical composition as described in embodiment 53, wherein the filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, starch, maltodextrin, agar and guar gum.

[0640] 55. The pharmaceutical composition of embodiment 53, wherein the disintegrant is selected from cross-linked sodium carboxymethylcellulose, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose and microcrystalline cellulose.

[0641] 56. The pharmaceutical composition of embodiment 53, wherein the lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc.

[0642] 57. The pharmaceutical composition of embodiment 53, wherein the glidant is colloidal silicon dioxide.

[0643] 58. The pharmaceutical composition of any one of embodiments 43-57, wherein Compound I is substantially crystalline, and wherein Compounds II and III-d are each independently substantially amorphous.

[0644] 59. The pharmaceutical composition of any one of embodiments 43-58, wherein the pharmaceutical composition is a tablet.

[0645] 60. The pharmaceutical composition of any one of embodiments 43-58, wherein the pharmaceutical composition is in the form of particles.

[0646] 61. A single tablet comprising:

[0647] (a) 25 mg to 125 mg of Compound I:

[0648]

[0649] (b) 60 mg to 65 mg of a first solid dispersion, wherein the first solid dispersion comprises 80 wt % of Compound II relative to the total weight of the first solid dispersion:

[0650]

[0651] and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion; and

[0652] (c) 90 mg to 95 mg of a second solid dispersion, wherein the second solid dispersion comprises 80 wt % of Compound III-d relative to the total weight of the second solid dispersion:

[0653]

[0654] 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt% of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[0655] (d) 75 mg to 230 mg microcrystalline cellulose;

[0656] (e) 20 mg to 45 mg croscarmellose sodium; and

[0657] (f) 2 mg to 7 mg magnesium stearate.

[0658] 62. A single tablet according to embodiment 61, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0659] (A) wherein the intra-particle portion comprises:

[0660] (a) 90 mg to 110 mg of Compound I;

[0661] (b) 60 mg to 65 mg of the first solid dispersion;

[0662] (c) 90 mg to 95 mg of the second solid dispersion;

[0663] (d) 75 mg to 85 mg of said microcrystalline cellulose;

[0664] (e) 25 mg to 35 mg of croscarmellose sodium; and

[0665] (B) wherein the extragranular portion comprises:

[0666] (a) 115 mg to 120 mg of said microcrystalline cellulose; and

[0667] (b) 3 mg to 7 mg magnesium stearate.

[0668] 63. A single tablet according to embodiment 61, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0669] (A) wherein the intra-particle portion comprises:

[0670] (a) 90 mg to 110 mg of Compound I;

[0671] (b) 60 mg to 65 mg of the first solid dispersion;

[0672] (c) 90 mg to 95 mg of the second solid dispersion;

[0673] (d) 20 mg to 25 mg of said croscarmellose sodium; and (B) wherein said extragranular portion comprises:

[0674] (a) 85 mg to 95 mg of said microcrystalline cellulose; and

[0675] (b) 2 mg to 6 mg magnesium stearate.

[0676] 64. A single tablet according to embodiment 61, comprising (a) 90 mg to 110 mg of Compound I;

[0677] (b) 60 mg to 65 mg of the first solid dispersion;

[0678] (c) 90 mg to 95 mg of the second solid dispersion;

[0679] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 200 mg of said microcrystalline cellulose; and (f) 3 mg to 7 mg of magnesium stearate.

[0680] 65. A single tablet according to embodiment 61, comprising (a) 90 mg to 110 mg of Compound I;

[0681] (b) 60 mg to 65 mg of the first solid dispersion;

[0682] (c) 90 mg to 95 mg of the second solid dispersion;

[0683] (d) 20 mg to 25 mg of the cross-linked sodium carboxymethyl cellulose; (e) 85 mg to 95 mg of the microcrystalline cellulose; and

[0684] (f) 2 mg to 6 mg magnesium stearate.

[0685] 66. A single tablet according to embodiment 61, comprising (a) 90 mg to 110 mg of Compound I;

[0686] (b) 60 mg to 65 mg of the first solid dispersion;

[0687] (c) 90 mg to 95 mg of the second solid dispersion;

[0688] (d) 20 mg to 30 mg of said croscarmellose sodium; (e) 135 mg to 145 mg of said microcrystalline cellulose; and (f) 2 mg to 6 mg of magnesium stearate.

[0689] 67. A single tablet according to embodiment 61, comprising (a) 90 mg to 110 mg of Compound I;

[0690] (b) 60 mg to 65 mg of the first solid dispersion;

[0691] (c) 90 mg to 95 mg of the second solid dispersion;

[0692] (d) 35 mg to 40 mg of croscarmellose sodium;

[0693] (e) 105 mg to 115 mg lactose monohydrate;

[0694] (f) 220 mg to 230 mg of said microcrystalline cellulose;

[0695] (g) 1 mg to 5 mg colloidal silicon dioxide; and

[0696] (h) 4 mg to 7 mg magnesium stearate.

[0697] 68. A single tablet according to embodiment 61, comprising (a) 90 mg to 110 mg of Compound I;

[0698] (b) 60 mg to 65 mg of the first solid dispersion;

[0699] (c) 90 mg to 95 mg of the second solid dispersion;

[0700] (d) 20 mg to 30 mg of croscarmellose sodium;

[0701] (e) 40 mg to 50 mg lactose monohydrate;

[0702] (f) 90 mg to 100 mg of said microcrystalline cellulose;

[0703] (g) 1 mg to 5 mg colloidal silicon dioxide; and

[0704] (h) 2 mg to 7 mg magnesium stearate.

[0705] 69. A single tablet according to embodiment 61, comprising (a) 90 mg to 110 mg of Compound I;

[0706] (b) 60 mg to 65 mg of the first solid dispersion;

[0707] (c) 90 mg to 95 mg of the second solid dispersion;

[0708] (d) 20 mg to 30 mg of the cross-linked sodium carboxymethyl cellulose; (e) 135 mg to 145 mg of the microcrystalline cellulose;

[0709] (f) 1 mg to 5 mg colloidal silicon dioxide; and

[0710] (g) 2 mg to 7 mg magnesium stearate.

[0711] 70. A single tablet according to embodiment 61, comprising (a) 90 mg to 110 mg of Compound I;

[0712] (b) 60 mg to 65 mg of the first solid dispersion;

[0713] (c) 90 mg to 95 mg of the second solid dispersion;

[0714] (d) 20 mg to 30 mg of said croscarmellose sodium; (e) 135 mg to 145 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[0715] 71. A single tablet comprising

[0716] (a) 25 mg to 150 mg of Compound I:

[0717]

[0718] (b) a first solid dispersion comprising 20 mg to 150 mg of Compound II:

[0719]

[0720] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[0721] (c) a second solid dispersion comprising 25 mg to 200 mg of Compound III:

[0722] and 10 to 30 wt % of a polymer relative to the total weight of the second solid dispersion.

[0723] 72. A single tablet as described in embodiment 71, wherein at least one of the first solid dispersion or the second solid dispersion is a spray-dried dispersion.

[0724] 73. A single tablet as described in embodiment 71, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[0725] 74. A single tablet as described in embodiment 71, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[0726] 75. A single tablet according to embodiment 71, wherein the polymer in the first solid dispersion is HPMC E15; and the polymer in the second solid dispersion is hydroxypropylmethylcellulose acetate succinate H.

[0727] 76. A single tablet according to embodiment 71, wherein the polymer in the first solid dispersion is HPMC E15; and the polymer in the second solid dispersion is hydroxypropylmethylcellulose acetate succinate HG.

[0728] 77. A single tablet as described in any of embodiments 71-76, comprising 80 mg to 120 mg of Compound I.

[0729] 78. A single tablet as described in any of embodiments 71-76, comprising 80 mg to 120 mg, 85 mg to 115 mg, 90 mg to 110 mg or 95 mg to 105 mg of Compound I.

[0730] 79. A single tablet as described in any one of embodiments 71-76, comprising 100 mg of Compound I.

[0731] 80. A single tablet as described in any of embodiments 71-76, comprising 75 mg to 125 mg of Compound I.

[0732] 81. A single tablet as described in any one of embodiments 71-80, wherein the first solid dispersion comprises 25 mg to 75 mg of Compound II.

[0733] 82. A single tablet as described in any one of embodiments 71-80, wherein the first solid dispersion comprises 50 mg of Compound II.

[0734] 83. A single tablet as described in any one of embodiments 71-82, wherein the second solid dispersion contains 25 mg to 50 mg, 25 mg to 75 mg, 50 mg to 100 mg, or 75 mg to 125 mg of Compound III.

[0735] 84. A single tablet as described in any one of embodiments 71-82, wherein the second solid dispersion comprises 75 mg of Compound III.

[0736] 85. A single tablet as described in any one of embodiments 71-76, comprising

[0737] 50 mg to 125 mg of Compound I; and wherein

[0738] The first solid dispersion comprises 25 mg to 75 mg of Compound II; and

[0739] The second solid dispersion contains 75 mg to 125 mg of Compound III.

[0740] 86. A single tablet as described in any one of embodiments 71-82, comprising

[0741] 75 mg to 125 mg of Compound I; and wherein

[0742] The first solid dispersion comprises 50 mg of Compound II; and

[0743] The second solid dispersion contained 75 mg of Compound III.

[0744] 87. A single tablet as described in any one of embodiments 71-82, comprising

[0745] 100 mg of Compound I; and wherein

[0746] The first solid dispersion comprises 50 mg of Compound II; and

[0747] The second solid dispersion contained 75 mg of Compound III.

[0748] 88. A single tablet as described in any one of embodiments 71-87, wherein the second solid dispersion further comprises 0.5% of sodium lauryl sulfate relative to the total weight of the second solid dispersion.

[0749] 89. A single tablet as described in any of embodiments 71-88, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, lubricants and glidants.

[0750] 90. The single tablet of embodiment 89, wherein the filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, starch, maltodextrin, agar, and guar gum.

[0751] 91. The single tablet of embodiment 89, wherein the disintegrant is selected from croscarmellose sodium, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, and microcrystalline cellulose.

[0752] 92. A single tablet as described in embodiment 89, wherein the lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc.

[0753] 93. The single tablet of embodiment 89, wherein the glidant is colloidal silicon dioxide.

[0754] 94. A single tablet as described in any one of embodiments 71-93, wherein Compound I is substantially crystalline, and wherein Compounds II and III are each independently substantially amorphous.

[0755] 95. A pharmaceutical composition comprising:

[0756] (a) 10% to 30% by weight of Compound I relative to the total weight of the pharmaceutical composition:

[0757]

[0758] (b) 8 to 30 weight % of the first solid dispersion relative to the total weight of the pharmaceutical composition;

[0759] The first solid dispersion comprises 70% to 90% by weight of Compound II relative to the total weight of the first solid dispersion:

[0760]

[0761] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[0762] (c) 10% to 30% by weight of a second solid dispersion relative to the total weight of the pharmaceutical composition;

[0763] The second solid dispersion comprises 70% to 90% by weight of compound III relative to the total weight of the second solid dispersion:

[0764] and 10 to 30 wt % of a polymer relative to the total weight of the second solid dispersion.

[0765] 96. The pharmaceutical composition of embodiment 95, wherein at least one of the second solid dispersion or the third solid dispersion is a spray-dried dispersion.

[0766] 97. The pharmaceutical composition of embodiment 95, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[0767] 98. A pharmaceutical composition as described in embodiment 95, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[0768] 99. A pharmaceutical composition as described in embodiment 95, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose (HPMC E15); and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate H.

[0769] 100. The pharmaceutical composition of embodiment 95, wherein:

[0770] The first solid dispersion comprises 70 wt % to 85 wt % of Compound II relative to the total weight of the first solid dispersion, and the polymer is hydroxypropyl methylcellulose in an amount of 15 wt % to 30 wt % relative to the total weight of the first solid dispersion; and

[0771] The second solid dispersion comprises 70 to 85 wt% of Compound III relative to the total weight of the second solid dispersion, 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and the polymer is hydroxypropylmethylcellulose acetate succinate in an amount of 14.5 to 29.5 wt% relative to the total weight of the second solid dispersion.

[0772] 101. The pharmaceutical composition of any one of embodiments 95-100, wherein the first solid dispersion comprises 75 wt% to 85 wt% of Compound II relative to the total weight of the first solid dispersion.

[0773] 102. A pharmaceutical composition as described in any of embodiments 95-100, wherein the first solid dispersion comprises 80 weight % of Compound II, relative to the total weight of the first solid dispersion; and 20 weight % of hydroxypropyl methylcellulose, relative to the total weight of the first solid dispersion.

[0774] 103. The pharmaceutical composition of any one of embodiments 95-102, wherein the second solid dispersion comprises 75 wt% to 85 wt% of Compound III relative to the total weight of the second solid dispersion.

[0775] 104. A pharmaceutical composition as described in any of embodiments 95-103, wherein the second solid dispersion comprises 80 weight % of Compound III relative to the total weight of the second solid dispersion; 0.5 weight % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and 19.5 weight % of hydroxypropyl methylcellulose acetate succinate relative to the total weight of the second solid dispersion.

[0776] 105. The pharmaceutical composition of any one of embodiments 95-104, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, and lubricants.

[0777] 106. A pharmaceutical composition as described in embodiment 105, wherein the filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, starch, maltodextrin, agar and guar gum.

[0778] 107. The pharmaceutical composition of embodiment 105, wherein the disintegrant is selected from cross-linked sodium carboxymethylcellulose, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose and microcrystalline cellulose.

[0779] 108. The pharmaceutical composition of embodiment 105, wherein the lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc.

[0780] 109. The pharmaceutical composition of any one of embodiments 95-108, wherein Compound I is substantially crystalline, and wherein Compounds II and III are each independently substantially amorphous.

[0781] 110. The pharmaceutical composition of any one of embodiments 95-109, wherein the composition is a tablet.

[0782] 111. The pharmaceutical composition of any one of embodiments 95-109, wherein the pharmaceutical composition is in the form of particles.

[0783] 112. A pharmaceutical composition comprising:

[0784] (a) Compound I:

[0785]

[0786] (b) a first solid dispersion, the first solid dispersion comprising 70 wt % to 90 wt % of Compound II relative to the total weight of the first solid dispersion:

[0787]

[0788] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[0789] (c) a second solid dispersion, the second solid dispersion comprising 70 wt % to 90 wt % of Compound III relative to the total weight of the second solid dispersion:

[0790] and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion, wherein

[0791] The weight ratio of compound I in (a): compound II in (b): compound III-d in (c) ranges from 2:4:5 to 6:1:1.

[0792] 113. The pharmaceutical composition of embodiment 112, wherein at least one of the second solid dispersion or the third solid dispersion is a spray-dried dispersion.

[0793] 114. The pharmaceutical composition of embodiment 112, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[0794] 115. The pharmaceutical composition of embodiment 112, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[0795] 116. A pharmaceutical composition as described in embodiment 112, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose (HPMC E15); and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate H.

[0796] 117. The pharmaceutical composition according to embodiment 112, wherein:

[0797] The first solid dispersion comprises 70 wt % to 85 wt % of Compound II relative to the total weight of the first solid dispersion, and the polymer is hydroxypropyl methylcellulose in an amount of 15 wt % to 30 wt % relative to the total weight of the first solid dispersion; and

[0798] The second solid dispersion comprises 70 to 85 wt% of Compound III relative to the total weight of the second solid dispersion, 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and the polymer is hydroxypropylmethylcellulose acetate succinate in an amount of 14.5 to 29.5 wt% relative to the total weight of the second solid dispersion.

[0799] 118. The pharmaceutical composition of any one of embodiments 112-117, wherein the first solid dispersion comprises 75 wt% to 85 wt% of Compound II relative to the total weight of the first solid dispersion.

[0800] 119. A pharmaceutical composition as described in any one of embodiments 112-117, wherein the first solid dispersion comprises 80 weight % of Compound II, relative to the total weight of the first solid dispersion; and 20 weight % of hydroxypropyl methylcellulose, relative to the total weight of the first solid dispersion.

[0801] 120. The pharmaceutical composition of any one of embodiments 112-119, wherein the second solid dispersion comprises 75% to 85% by weight of Compound III relative to the total weight of the second solid dispersion.

[0802] 121. A pharmaceutical composition as described in any of embodiments 112-120, wherein the second solid dispersion comprises 80 weight % of Compound III relative to the total weight of the second solid dispersion; 0.5 weight % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and 19.5 weight % of hydroxypropyl methylcellulose acetate succinate relative to the total weight of the second solid dispersion.

[0803] 122. The pharmaceutical composition of any one of embodiments 112-121, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, and lubricants.

[0804] 123. A pharmaceutical composition as described in embodiment 122, wherein the filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, starch, maltodextrin, agar and guar gum.

[0805] 124. The pharmaceutical composition of embodiment 122, wherein the disintegrant is selected from cross-linked sodium carboxymethylcellulose, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose and microcrystalline cellulose.

[0806] 125. The pharmaceutical composition of embodiment 122, wherein the lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc.

[0807] 126. The pharmaceutical composition of any one of embodiments 112-125, wherein Compound I is substantially crystalline, and wherein Compounds II and III are each independently substantially amorphous.

[0808] 127. The pharmaceutical composition of any one of embodiments 112-126, wherein the pharmaceutical composition is a tablet.

[0809] 128. The pharmaceutical composition of any one of embodiments 112-126, wherein the pharmaceutical composition is in the form of particles.

[0810] 129. A single tablet comprising:

[0811] (a) 25 mg to 125 mg of Compound I:

[0812]

[0813] (b) 60 mg to 65 mg of a first solid dispersion, wherein the first solid dispersion comprises 80 wt % of Compound II relative to the total weight of the first solid dispersion:

[0814]

[0815] and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion; and

[0816] (c) 90 mg to 95 mg of a second solid dispersion, wherein the second solid dispersion comprises 80 wt % of Compound III relative to the total weight of the second solid dispersion:

[0817]

[0818] 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt% of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[0819] (d) 85 mg to 275 mg microcrystalline cellulose;

[0820] (e) 10 mg to 35 mg croscarmellose sodium; and

[0821] (f) 2 mg to 7 mg magnesium stearate.

[0822] 130. A single tablet as described in embodiment 129, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0823] (A) wherein the intra-particle portion comprises:

[0824] (a) 90 mg to 110 mg of Compound I;

[0825] (b) 60 mg to 65 mg of the first solid dispersion;

[0826] (c) 90 mg to 95 mg of the second solid dispersion;

[0827] (d) 25 mg to 35 mg of croscarmellose sodium;

[0828] (e) 75 mg to 85 mg of said microcrystalline cellulose; and

[0829] (B) wherein the extragranular portion comprises:

[0830] (a) 115 mg to 120 mg of said microcrystalline cellulose; and

[0831] (b) 3 mg to 7 mg magnesium stearate.

[0832] 131. A single tablet as described in embodiment 129, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0833] (A) wherein the intra-particle portion comprises:

[0834] (a) 90 mg to 110 mg of Compound I;

[0835] (b) 60 mg to 65 mg of the first solid dispersion;

[0836] (c) 90 mg to 95 mg of the second solid dispersion;

[0837] (d) 20 mg to 25 mg of croscarmellose sodium;

[0838] (e) 85 mg to 90 mg of said microcrystalline cellulose; and

[0839] (B) wherein the extragranular portion comprises:

[0840] (a) 115 mg to 120 mg microcrystalline cellulose; and

[0841] (b) 2 mg to 7 mg magnesium stearate.

[0842] 132. A single tablet as described in embodiment 129, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0843] (A) wherein the intra-particle portion comprises:

[0844] (a) 90 mg to 110 mg of Compound I;

[0845] (b) 60 mg to 65 mg of the first solid dispersion;

[0846] (c) 90 mg to 95 mg of the second solid dispersion;

[0847] (d) 20 mg to 25 mg of croscarmellose sodium; and

[0848] (B) wherein the extragranular portion comprises:

[0849] (a) 85 mg to 95 mg microcrystalline cellulose; and

[0850] (b) 2 mg to 6 mg magnesium stearate.

[0851] 133. A single tablet as described in embodiment 129, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0852] (A) wherein the intra-particle portion comprises:

[0853] (a) 90 mg to 110 mg of Compound I;

[0854] (b) 60 mg to 65 mg of the first solid dispersion;

[0855] (c) 90 mg to 95 mg of the second solid dispersion;

[0856] (d) 20 mg to 25 mg of croscarmellose sodium; and

[0857] (B) wherein the extragranular portion comprises:

[0858] (a) 270 mg to 275 mg microcrystalline cellulose; and

[0859] (b) 2 mg to 7 mg magnesium stearate.

[0860] 134. A single tablet as described in embodiment 129, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0861] (A) wherein the intra-particle portion comprises:

[0862] (a) 90 mg to 110 mg of Compound I;

[0863] (b) 60 mg to 65 mg of the first solid dispersion;

[0864] (c) 90 mg to 95 mg of the second solid dispersion;

[0865] (d) 20 mg to 25 mg of croscarmellose sodium;

[0866] (e) 85 mg to 90 mg of said microcrystalline cellulose; and

[0867] (B) wherein the extragranular portion comprises:

[0868] (a) 5 mg to 10 mg of cross-linked sodium carboxymethyl cellulose;

[0869] (b) 105 mg to 115 mg microcrystalline cellulose; and

[0870] (c) 2 mg to 7 mg magnesium stearate.

[0871] 135. A single tablet as described in embodiment 129, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0872] (A) wherein the intra-particle portion comprises:

[0873] (a) 90 mg to 110 mg of Compound I;

[0874] (b) 60 mg to 65 mg of the first solid dispersion;

[0875] (c) 90 mg to 95 mg of the second solid dispersion;

[0876] (d) 105 mg to 115 mg of said microcrystalline cellulose; and

[0877] (B) wherein the extragranular portion comprises:

[0878] (a) 25 mg to 35 mg of croscarmellose sodium;

[0879] (b) 85 mg to 90 mg microcrystalline cellulose; and

[0880] (c) 2 mg to 7 mg magnesium stearate.

[0881] 136. A single tablet as described in embodiment 129, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0882] (A) wherein the intra-particle portion comprises:

[0883] (a) 90 mg to 110 mg of Compound I;

[0884] (b) 60 mg to 65 mg of the first solid dispersion;

[0885] (c) 90 mg to 95 mg of the second solid dispersion;

[0886] (d) 195 mg to 200 mg of said microcrystalline cellulose; and

[0887] (B) wherein the extragranular portion comprises:

[0888] (a) 25 mg to 35 mg of croscarmellose sodium; and

[0889] (b) 2 mg to 7 mg magnesium stearate.

[0890] 137. A single tablet as described in embodiment 129, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0891] (A) wherein the intra-particle portion comprises:

[0892] (a) 60 mg to 65 mg of the first solid dispersion;

[0893] (b) 90 mg to 95 mg of the second solid dispersion;

[0894] (c) 12 mg to 17 mg of croscarmellose sodium;

[0895] (d) 60 mg to 70 mg of said microcrystalline cellulose; and

[0896] (B) wherein the extragranular portion comprises:

[0897] (a) 90 mg to 110 mg of Compound I;

[0898] (b) 95 mg to 105 mg microcrystalline cellulose; and

[0899] (c) 2 mg to 7 mg magnesium stearate.

[0900] 138. A single tablet as described in embodiment 129, wherein the tablet comprises an intragranular portion and an extragranular portion, and

[0901] (A) wherein the intra-particle portion comprises:

[0902] (a) 60 mg to 65 mg of the first solid dispersion;

[0903] (b) 90 mg to 95 mg of the second solid dispersion;

[0904] (c) 10 mg to 20 mg of said croscarmellose sodium; (d) 60 mg to 70 mg of said microcrystalline cellulose; and (B) wherein said extragranular portion comprises:

[0905] (a) 90 mg to 110 mg of Compound I;

[0906] (b) 195 mg to 205 mg microcrystalline cellulose; and

[0907] (c) 2 mg to 7 mg magnesium stearate.

[0908] 139. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[0909] (b) 60 mg to 65 mg of the first solid dispersion;

[0910] (c) 90 mg to 95 mg of the second solid dispersion;

[0911] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[0912] 140. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[0913] (b) 60 mg to 65 mg of the first solid dispersion;

[0914] (c) 90 mg to 95 mg of the second solid dispersion;

[0915] (d) 20 mg to 25 mg of said croscarmellose sodium; (e) 200 mg to 210 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[0916] 141. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[0917] (b) 60 mg to 65 mg of the first solid dispersion;

[0918] (c) 90 mg to 95 mg of the second solid dispersion;

[0919] (d) 20 mg to 25 mg of the cross-linked sodium carboxymethyl cellulose; (e) 85 mg to 95 mg of the microcrystalline cellulose; and

[0920] (f) 2 mg to 6 mg magnesium stearate.

[0921] 142. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[0922] (b) 60 mg to 65 mg of the first solid dispersion;

[0923] (c) 90 mg to 95 mg of the second solid dispersion;

[0924] (d) 20 mg to 25 mg of said croscarmellose sodium; (e) 270 mg to 275 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[0925] 143. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[0926] (b) 60 mg to 65 mg of the first solid dispersion;

[0927] (c) 90 mg to 95 mg of the second solid dispersion;

[0928] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[0929] 144. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[0930] (b) 60 mg to 65 mg of the first solid dispersion;

[0931] (c) 90 mg to 95 mg of the second solid dispersion;

[0932] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[0933] 145. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[0934] (b) 60 mg to 65 mg of the first solid dispersion;

[0935] (c) 90 mg to 95 mg of the second solid dispersion;

[0936] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 200 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[0937] 146. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[0938] (b) 60 mg to 65 mg of the first solid dispersion;

[0939] (c) 90 mg to 95 mg of the second solid dispersion;

[0940] (d) 12 mg to 17 mg of croscarmellose sodium;

[0941] (e) 160 mg to 170 mg of said microcrystalline cellulose; and

[0942] (f) 2 mg to 7 mg magnesium stearate.

[0943] 147. A single tablet as described in embodiment 129, comprising

[0944] (a) 90 mg to 110 mg of Compound I;

[0945] (b) 60 mg to 65 mg of the first solid dispersion;

[0946] (c) 90 mg to 95 mg of the second solid dispersion;

[0947] (d) 10 mg to 20 mg of the cross-linked sodium carboxymethyl cellulose;

[0948] (e) 260 mg to 270 mg of said microcrystalline cellulose; and

[0949] (f) 2 mg to 7 mg magnesium stearate.

[0950] 148. A pharmaceutical composition comprising:

[0951] (a) 10% to 30% by weight of Compound I relative to the total weight of the pharmaceutical composition:

[0952]

[0953] (b) 5 to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[0954]

[0955] (c) 10% to 25% by weight of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition:

[0956]

[0957] (d) 20% to 45% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[0958] (e) 3% to 8% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[0959] (f) 0.5 to 2 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[0960] 149. The pharmaceutical composition of embodiment 148, wherein the pharmaceutical composition comprises:

[0961] (a) 18 wt % to 23 wt % of Compound I relative to the total weight of the pharmaceutical composition;

[0962] (b) 8 to 12 wt% of Compound II relative to the total weight of the pharmaceutical composition;

[0963] (c) 13% to 18% by weight of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[0964] (d) 35% to 45% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[0965] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[0966] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[0967] 150. The pharmaceutical composition of embodiment 148, wherein the pharmaceutical composition comprises:

[0968] (a) 15% to 25% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[0969] (b) 5 to 10 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[0970] (c) 7 to 15 wt % of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[0971] (d) 30% to 50% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[0972] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[0973] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[0974] 151. The pharmaceutical composition of embodiment 148, wherein the pharmaceutical composition comprises:

[0975] (a) 20% to 25% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[0976] (b) 7 to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[0977] (c) 15 to 20 wt % of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[0978] (d) 15 to 25 weight % of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[0979] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[0980] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[0981] 152. The pharmaceutical composition of embodiment 148, wherein the pharmaceutical composition comprises:

[0982] (a) 20% to 25% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[0983] (b) 7 to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[0984] (c) 15 to 20 wt % of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[0985] (d) 25% to 35% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[0986] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[0987] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[0988] 153. The pharmaceutical composition of embodiment 148, wherein the pharmaceutical composition comprises:

[0989] (a) 22% to 28% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[0990] (b) 10% to 15% by weight of Compound II relative to the total weight of the pharmaceutical composition:

[0991] (c) 15% to 25% by weight of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[0992] (d) 15 to 25 weight % of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[0993] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[0994] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[0995] 154. The pharmaceutical composition of embodiment 148, wherein the pharmaceutical composition comprises:

[0996] (a) 15% to 20% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[0997] (b) 7 to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[0998] (c) 10% to 15% by weight of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[0999] (d) 45% to 55% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[1000] (e) 3% to 5% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[1001] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[1002] 155. The pharmaceutical composition of any one of embodiments 148-154, wherein the pharmaceutical composition is a tablet.

[1003] 156. A method of treating cystic fibrosis in a patient, the method comprising orally administering to the patient one or more single tablets or pharmaceutical compositions as described in any one of embodiments 1-155.

[1004] 157. The method of embodiment 156, wherein one or more of the single tablets or pharmaceutical compositions are administered once daily.

[1005] 158. The method of embodiment 156, wherein one or more of the single tablets or pharmaceutical compositions are administered twice daily.

[1006] 159. The method of embodiment 156, wherein two tablets are administered once daily.

[1007] 160. The method of any one of embodiments 156-159, wherein the patient with cystic fibrosis is selected from a patient with a F508del / minimal function genotype, a patient with a F508del / F508del genotype, a patient with a F508del / gating genotype, and a patient with a F508del / residual function genotype.

[1008] 161. The method of embodiment 160, wherein the patient with the F508del / minimal functional genotype has a minimal functional mutation selected from:

[1009]

[1010] 162. The method of embodiment 160, wherein the patient with the F508del / gating genotype has a gating mutation selected from G178R, S549N, S549R, G551D, G551S, G1244E, S1251N, S1255P, and G1349D.

[1011] 163. The method of embodiment 160, wherein the patient with the F508del / residual function genotype has a gene selected from 2789+5G→A, 3849+10kbC→T, 3272-26A→G, 711+3A→G, E56K, P67L, R74W, D110E, D110H, R117C, L206W, R347H, R352Q, A455E, D579G, E831X, S945L, S Residual function mutations of 977F, F1052V, R1070W, F1074L, D1152H, D1270N, E193K, K1060T, R117H, S1235R, I1027T, R668C, G576A, M470V, L997F, R75Q, R1070Q, R31C, D614G, G1069R, R1162L, E56K, A1067T, E193K, and K1060T.

[1012] 164. A method of preparing a single tablet as described in any one of embodiments 1, 41, 59, 61, 71, 110, 127, 129 or 155, comprising

[1013] (a) mixing Compound 1 with the first solid dispersion and the second solid dispersion to form a first mixture; and

[1014] (b) compressing a tablet mixture comprising the first mixture into tablets.

[1015] 165. The method of embodiment 164, wherein the tablet mixture further comprises one or more pharmaceutically acceptable excipients, and the method further comprises mixing the first mixture with the one or more excipients to form the tablet mixture.

[1016] 166. The method of embodiment 164 or 165, further comprising coating the tablet.

[1017] 167. A method of preparing a single tablet as described in embodiment 61 or 129, comprising

[1018] (a) mixing Compound 1 with the first solid dispersion and the second solid dispersion to form a first mixture;

[1019] (b) mixing the first mixture with the microcrystalline cellulose, croscarmellose sodium and magnesium stearate to form a tablet mixture; and (c) compressing the tablet mixture into tablets.

[1020] 168. The method of embodiment 167, further comprising coating the tablet.

[1021] Additional exemplary embodiments of the present disclosure include:

[1022] 1. A pharmaceutical composition comprising:

[1023] (a) 25 mg to 250 mg of Compound I:

[1024]

[1025] (b) a first solid dispersion comprising 20 mg to 150 mg of Compound II:

[1026]

[1027] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[1028] (c) a second solid dispersion comprising 25 mg to 200 mg of compound II-d:

[1029] and 10 to 30 wt % of a polymer relative to the total weight of the second solid dispersion.

[1030] 2. The pharmaceutical composition of embodiment 1, wherein at least one of the first solid dispersion or the second solid dispersion is a spray-dried dispersion.

[1031] 3. The pharmaceutical composition of embodiment 1, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[1032] 4. The pharmaceutical composition of embodiment 1, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[1033] 5. The pharmaceutical composition according to embodiment 1, wherein the polymer in the first solid dispersion is HPMC E15; and the polymer in the second solid dispersion is hydroxypropylmethylcellulose acetate succinate H.

[1034] 6. The pharmaceutical composition according to embodiment 1, wherein the polymer in the first solid dispersion is HPMC E15; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate HG.

[1035] 7. A pharmaceutical composition as described in any of embodiments 1-6, comprising 25 mg to 75 mg or 80 mg to 120 mg of Compound I.

[1036] 8. A pharmaceutical composition as described in any of embodiments 1-6, comprising 80 mg to 120 mg, 85 mg to 115 mg, 90 mg to 110 mg or 95 mg to 105 mg of Compound I.

[1037] 9. A pharmaceutical composition as described in any of embodiments 1-6, comprising 25 mg, 50 mg or 100 mg of Compound I.

[1038] 10. The pharmaceutical composition of any one of embodiments 1-6, comprising 75 mg to 125 mg of Compound I.

[1039] 11. The pharmaceutical composition of any one of embodiments 1-10, wherein the first solid dispersion comprises 25 mg to 75 mg of Compound II.

[1040] 12. A single tablet as described in any one of embodiments 1-10, wherein the first solid dispersion comprises 50 mg of Compound II.

[1041] 13. The pharmaceutical composition of any one of embodiments 1-12, wherein the second solid dispersion comprises 25 mg to 50 mg, 25 mg to 75 mg, 50 mg to 100 mg, 75 mg to 125 mg, or 125 mg to 175 mg of Compound III-d.

[1042] 14. A single tablet as described in any one of embodiments 1-12, wherein the second solid dispersion comprises 75 mg or 150 mg of Compound III-d.

[1043] 15. A pharmaceutical composition as described in any one of embodiments 1-6, comprising

[1044] 50 mg to 125 mg of Compound I; and wherein

[1045] The first solid dispersion comprises 25 mg to 75 mg of Compound II; and

[1046] The second solid dispersion contains 75 mg to 125 mg of Compound III-d.

[1047] 16. A pharmaceutical composition as described in any one of embodiments 1-6, comprising

[1048] (a) 75 mg to 125 mg of Compound I; and wherein

[1049] The first solid dispersion comprises 50 mg of Compound II; and

[1050] The second solid dispersion comprises 75 mg of compound III-d; or (b) 100 mg of compound I;

[1051] The first solid dispersion comprises 50 mg of Compound II; and

[1052] The second solid dispersion contained 75 mg of Compound III-d.

[1053] 17. The pharmaceutical composition of any one of embodiments 1-17, wherein the second solid dispersion further comprises 0.5% sodium lauryl sulfate relative to the total weight of the second solid dispersion.

[1054] 18. The pharmaceutical composition of any one of embodiments 1-18, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, lubricants and glidants.

[1055] 19. The pharmaceutical composition according to embodiment 19, wherein:

[1056] The filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, starch, maltodextrin, agar and guar gum;

[1057] disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, and microcrystalline cellulose;

[1058] The lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc; and

[1059] The glidant is colloidal silicon dioxide.

[1060] 20. The pharmaceutical composition of any one of embodiments 1-19, wherein Compound I is substantially crystalline, and wherein Compounds II and III-d are each independently substantially amorphous.

[1061] 21. The pharmaceutical composition of any one of embodiments 1-20, wherein the pharmaceutical composition is a tablet or in the form of granules.

[1062] 22. The pharmaceutical composition of embodiment 1, further comprising microcrystalline cellulose; croscarmellose sodium; and optionally magnesium stearate.

[1063] 23. A pharmaceutical composition as described in embodiment 22, wherein the pharmaceutical composition comprises 50 mg to 250 mg microcrystalline cellulose; 10 mg to 45 mg croscarmellose sodium; and optionally 1 mg to 10 mg magnesium stearate.

[1064] 24. A pharmaceutical composition as described in any of embodiments 1-23, wherein the weight ratio of compound I in (a): compound II in (b): compound III-d in (c) is 4:2:3, 2:2:3 or 1:2:3.

[1065] 25. A pharmaceutical composition comprising:

[1066] (a) 10% to 30% by weight of Compound I relative to the total weight of the pharmaceutical composition:

[1067]

[1068] (b) 10% to 30% by weight of the first solid dispersion relative to the total weight of the pharmaceutical composition;

[1069] The first solid dispersion comprises 70% to 90% by weight of Compound II relative to the total weight of the first solid dispersion:

[1070]

[1071] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[1072] (c) 10% to 30% by weight of a second solid dispersion relative to the total weight of the pharmaceutical composition;

[1073] The second solid dispersion comprises 70 wt % to 90 wt % of compound III-d relative to the total weight of the second solid dispersion:

[1074] and 10 to 30 wt % of a polymer relative to the total weight of the second solid dispersion.

[1075] 26. The pharmaceutical composition of embodiment 25, wherein at least one of the first solid dispersion or the second solid dispersion is a spray-dried dispersion.

[1076] 27. The pharmaceutical composition of embodiment 25, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[1077] 28. The pharmaceutical composition of embodiment 25, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[1078] 29. The pharmaceutical composition of embodiment 25, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose (HPMC E15); and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate H.

[1079] 30. The pharmaceutical composition according to embodiment 25, wherein:

[1080] The first solid dispersion comprises 70 wt % to 85 wt % of Compound II relative to the total weight of the first solid dispersion, and the polymer is hydroxypropyl methylcellulose in an amount of 15 wt % to 30 wt % relative to the total weight of the first solid dispersion; and

[1081] The second solid dispersion comprises 70 to 85 wt % of compound III-d relative to the total weight of the second solid dispersion, 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and the polymer is hydroxypropyl methylcellulose acetate succinate in an amount of 14.5 to 29.5 wt % relative to the total weight of the second solid dispersion.

[1082] 31. The pharmaceutical composition of any one of embodiments 25-30, wherein the first solid dispersion comprises 75 wt% to 85 wt% of Compound II relative to the total weight of the first solid dispersion.

[1083] 32. A pharmaceutical composition as described in any one of embodiments 25-31, wherein the first solid dispersion comprises 80 weight % of Compound II relative to the total weight of the first solid dispersion; and 20 weight % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion.

[1084] 33. The pharmaceutical composition of any one of embodiments 25-32, wherein the second solid dispersion comprises 75 wt% to 85 wt% of compound III-d relative to the total weight of the second solid dispersion.

[1085] 34. A pharmaceutical composition as described in any of embodiments 25-33, wherein the second solid dispersion comprises 80 wt% of Compound III-d, relative to the total weight of the second solid dispersion; 0.5% of sodium lauryl sulfate, relative to the total weight of the second solid dispersion, and 19.5 wt% of hydroxypropyl methylcellulose acetate succinate, relative to the total weight of the second solid dispersion.

[1086] 35. The pharmaceutical composition of any one of embodiments 25-34, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, lubricants and glidants.

[1087] 36. The pharmaceutical composition according to embodiment 35, wherein:

[1088] The filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, starch, maltodextrin, agar and guar gum;

[1089] disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, and microcrystalline cellulose;

[1090] The lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc; and

[1091] The glidant is colloidal silicon dioxide.

[1092] 37. The pharmaceutical composition of any one of embodiments 25-36, wherein Compound I is substantially crystalline, and wherein Compounds II and III-d are each independently substantially amorphous.

[1093] 38. The pharmaceutical composition of any one of embodiments 25-37, wherein the pharmaceutical composition is a tablet or in the form of granules.

[1094] 39. The pharmaceutical composition of embodiment 35, further comprising microcrystalline cellulose; croscarmellose sodium; and magnesium stearate.

[1095] 40. The pharmaceutical composition of embodiment 39, wherein the pharmaceutical composition comprises 50 mg to 250 mg microcrystalline cellulose; 10 mg to 45 mg croscarmellose sodium; and 1 mg to 10 mg magnesium stearate.

[1096] 41. A pharmaceutical composition as described in embodiment 39, wherein the pharmaceutical composition comprises 15% to 45% by weight of microcrystalline cellulose; 1% to 10% by weight of croscarmellose sodium; and optionally 0.5% to 3% by weight of magnesium stearate, relative to the total weight of the pharmaceutical composition.

[1097] 42. A pharmaceutical composition as described in any of embodiments 25-41, wherein the weight ratio of Compound I in (a): Compound II in (b): Compound III-d in (c) is 4:2:3, 2:2:3 or 1:2:3.

[1098] 43. A pharmaceutical composition comprising:

[1099] (a) Compound I:

[1100]

[1101] (b) a first solid dispersion,

[1102] The first solid dispersion comprises 70% to 90% by weight of Compound II relative to the total weight of the first solid dispersion:

[1103]

[1104] and 10 to 30 wt % of a polymer; and

[1105] (c) a second solid dispersion;

[1106] The second solid dispersion comprises 70 wt % to 90 wt % of compound III-d relative to the total weight of the second solid dispersion:

[1107] and 10 to 30 wt % of a polymer, wherein

[1108] The weight ratio of compound I in (a): compound II in (b): compound III-d in (c) is in the range of 1-4:2:3.

[1109] 44. The pharmaceutical composition of embodiment 43, wherein at least one of the second solid dispersion or the third solid dispersion is a spray-dried dispersion.

[1110] 45. The pharmaceutical composition of embodiment 43, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[1111] 46. ​​A pharmaceutical composition as described in embodiment 43, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[1112] 47. A pharmaceutical composition as described in embodiment 43, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose (HPMC E15); and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate H.

[1113] 48. The pharmaceutical composition according to embodiment 43, wherein:

[1114] The first solid dispersion comprises 70 wt % to 85 wt % of Compound II relative to the total weight of the first solid dispersion, and the polymer is hydroxypropyl methylcellulose in an amount of 15 wt % to 30 wt % relative to the total weight of the first solid dispersion; and

[1115] The second solid dispersion comprises 70 to 85 wt % of compound III-d relative to the total weight of the second solid dispersion, 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and the polymer is hydroxypropyl methylcellulose acetate succinate in an amount of 14.5 to 29.5 wt % relative to the total weight of the second solid dispersion.

[1116] 49. The pharmaceutical composition of any one of embodiments 43-48, wherein the first solid dispersion comprises 75 wt% to 85 wt% of Compound II relative to the total weight of the first solid dispersion.

[1117] 50. A pharmaceutical composition as described in any one of embodiments 43-49, wherein the first solid dispersion comprises 80 weight % of Compound II relative to the total weight of the first solid dispersion; and 20 weight % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion.

[1118] 51. The pharmaceutical composition of any one of embodiments 43-50, wherein the second solid dispersion comprises 75 wt% to 85 wt% of Compound III-d relative to the total weight of the second solid dispersion.

[1119] 52. A pharmaceutical composition as described in any of embodiments 43-51, wherein the second solid dispersion comprises 80 wt% of Compound III-d, relative to the total weight of the second solid dispersion; 0.5% of sodium lauryl sulfate, relative to the total weight of the second solid dispersion, and 19.5 wt% of hydroxypropyl methylcellulose acetate succinate, relative to the total weight of the second solid dispersion.

[1120] 53. The pharmaceutical composition of any one of embodiments 43-52, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, lubricants and glidants.

[1121] 54. The pharmaceutical composition according to embodiment 53, wherein:

[1122] The filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, starch, maltodextrin, agar and guar gum;

[1123] disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, and microcrystalline cellulose;

[1124] The lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc; and

[1125] The glidant is colloidal silicon dioxide.

[1126] 55. The pharmaceutical composition of any one of embodiments 43-54, wherein Compound I is substantially crystalline, and wherein Compounds II and III-d are each independently substantially amorphous.

[1127] 56. The pharmaceutical composition of any one of embodiments 43-55, wherein the pharmaceutical composition is a tablet or in the form of granules.

[1128] 57. A pharmaceutical composition as described in any of embodiments 43-56, wherein the weight ratio of Compound I in (a): Compound II in (b): Compound III-d in (c) is 4:2:3, 2:2:3 or 1:2:3.

[1129] 58. The pharmaceutical composition of embodiment 43, further comprising microcrystalline cellulose; croscarmellose sodium; and magnesium stearate.

[1130] 59. The pharmaceutical composition of embodiment 58, wherein the pharmaceutical composition comprises 50 mg to 250 mg microcrystalline cellulose; 10 mg to 45 mg croscarmellose sodium; and optionally 1 mg to 10 mg magnesium stearate.

[1131] 60. A pharmaceutical composition as described in embodiment 58, wherein the pharmaceutical composition comprises 15% to 45% by weight of microcrystalline cellulose; 1% to 10% by weight of croscarmellose sodium; and optionally 0.5% to 3% by weight of magnesium stearate, relative to the total weight of the pharmaceutical composition.

[1132] 61. A single tablet comprising:

[1133] (a) 25 mg to 125 mg of Compound I:

[1134]

[1135] (b) 60 mg to 65 mg of a first solid dispersion, wherein the first solid dispersion comprises 80 wt % of Compound II relative to the total weight of the first solid dispersion:

[1136]

[1137] and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion; and

[1138] (c) 90 mg to 95 mg of a second solid dispersion, wherein the second solid dispersion comprises 80 wt % of Compound III-d relative to the total weight of the second solid dispersion:

[1139]

[1140] 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt% of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[1141] (d) 75 mg to 230 mg microcrystalline cellulose;

[1142] (e) 20 mg to 45 mg croscarmellose sodium; and

[1143] (f) 2 mg to 7 mg magnesium stearate.

[1144] 62. A single tablet according to embodiment 61, comprising:

[1145] (a) 90 mg to 110 mg or 35 mg to 75 mg of Compound I;

[1146] (b) 60 mg to 65 mg of the first solid dispersion;

[1147] (c) 90 mg to 95 mg of the second solid dispersion;

[1148] (d) 190 mg to 205 mg of said microcrystalline cellulose;

[1149] (e) 25 mg to 35 mg of croscarmellose sodium; and

[1150] (f) 3 mg to 7 mg magnesium stearate.

[1151] 63. A single tablet according to embodiment 61, comprising:

[1152] (a) 90 mg to 110 mg of Compound I;

[1153] (b) 60 mg to 65 mg of the first solid dispersion;

[1154] (c) 90 mg to 95 mg of the second solid dispersion;

[1155] (d) 20 mg to 25 mg of croscarmellose sodium;

[1156] (e) 85 mg to 95 mg of said microcrystalline cellulose; and

[1157] (f) 2 mg to 6 mg magnesium stearate.

[1158] 64. A single tablet according to embodiment 61, comprising:

[1159] (a) 90 mg to 110 mg of Compound I;

[1160] (b) 60 mg to 65 mg of the first solid dispersion;

[1161] (c) 90 mg to 95 mg of the second solid dispersion;

[1162] (d) 25 mg to 35 mg of croscarmellose sodium;

[1163] (e) 195 mg to 200 mg of said microcrystalline cellulose; and

[1164] (f) 3 mg to 7 mg magnesium stearate.

[1165] 65. A single tablet according to embodiment 61, comprising:

[1166] (a) 90 mg to 110 mg of Compound I;

[1167] (b) 60 mg to 65 mg of the first solid dispersion;

[1168] (c) 90 mg to 95 mg of the second solid dispersion;

[1169] (d) 20 mg to 25 mg of the cross-linked sodium carboxymethyl cellulose; (e) 85 mg to 95 mg of the microcrystalline cellulose; and

[1170] (f) 2 mg to 6 mg magnesium stearate.

[1171] 66. A single tablet according to embodiment 61, comprising: (a) 90 mg to 110 mg of Compound I;

[1172] (b) 60 mg to 65 mg of the first solid dispersion;

[1173] (c) 90 mg to 95 mg of the second solid dispersion;

[1174] (d) 20 mg to 30 mg of said croscarmellose sodium; (e) 135 mg to 145 mg of said microcrystalline cellulose; and (f) 2 mg to 6 mg of magnesium stearate.

[1175] 67. A single tablet according to embodiment 61, comprising: (a) 90 mg to 110 mg of Compound I;

[1176] (b) 60 mg to 65 mg of the first solid dispersion;

[1177] (c) 90 mg to 95 mg of the second solid dispersion;

[1178] (d) 35 mg to 40 mg of croscarmellose sodium;

[1179] (e) 105 mg to 115 mg lactose monohydrate;

[1180] (f) 220 mg to 230 mg of said microcrystalline cellulose;

[1181] (g) 1 mg to 5 mg colloidal silicon dioxide; and

[1182] (h) 4 mg to 7 mg magnesium stearate.

[1183] 68. A single tablet according to embodiment 61, comprising: (a) 90 mg to 110 mg of Compound I;

[1184] (b) 60 mg to 65 mg of the first solid dispersion;

[1185] (c) 90 mg to 95 mg of the second solid dispersion;

[1186] (d) 20 mg to 30 mg of croscarmellose sodium;

[1187] (e) 40 mg to 50 mg lactose monohydrate;

[1188] (f) 90 mg to 100 mg of said microcrystalline cellulose;

[1189] (g) 1 mg to 5 mg colloidal silicon dioxide; and

[1190] (h) 2 mg to 7 mg magnesium stearate.

[1191] 69. A single tablet according to embodiment 61, comprising: (a) 90 mg to 110 mg of Compound I;

[1192] (b) 60 mg to 65 mg of the first solid dispersion;

[1193] (c) 90 mg to 95 mg of the second solid dispersion;

[1194] (d) 20 mg to 30 mg of the cross-linked sodium carboxymethyl cellulose; (e) 135 mg to 145 mg of the microcrystalline cellulose;

[1195] (f) 1 mg to 5 mg colloidal silicon dioxide; and

[1196] (g) 2 mg to 7 mg magnesium stearate.

[1197] 70. A single tablet according to embodiment 61, comprising:

[1198] (a) 90 mg to 110 mg of Compound I;

[1199] (b) 60 mg to 65 mg of the first solid dispersion;

[1200] (c) 90 mg to 95 mg of the second solid dispersion;

[1201] (d) 20 mg to 30 mg of croscarmellose sodium;

[1202] (e) 135 mg to 145 mg of said microcrystalline cellulose; and

[1203] (f) 2 mg to 7 mg magnesium stearate.

[1204] 71. A pharmaceutical composition comprising:

[1205] (a) 15 mg to 250 mg of Compound I:

[1206]

[1207] (b) a first solid dispersion comprising 10 mg to 150 mg of Compound II:

[1208]

[1209] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[1210] (c) a second solid dispersion comprising 25 mg to 200 mg of Compound III:

[1211] and 10 to 30 wt % of a polymer relative to the total weight of the second solid dispersion.

[1212] 72. The pharmaceutical composition of embodiment 71, wherein at least one of the first solid dispersion or the second solid dispersion is a spray-dried dispersion.

[1213] 73. The pharmaceutical composition of embodiment 71, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[1214] 74. The pharmaceutical composition of embodiment 71, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[1215] 75. The pharmaceutical composition of embodiment 71, wherein the polymer in the first solid dispersion is HPMC E15; and the polymer in the second solid dispersion is hydroxypropylmethylcellulose acetate succinate H.

[1216] 76. The pharmaceutical composition of embodiment 71, wherein the polymer in the first solid dispersion is HPMC E15; and the polymer in the second solid dispersion is hydroxypropylmethylcellulose acetate succinate HG.

[1217] 77. The pharmaceutical composition of any one of embodiments 71-76, comprising 25 mg to 75 mg or 80 mg to 120 mg of Compound I.

[1218] 78. A pharmaceutical composition as described in any of embodiments 71-76, comprising 80 mg to 120 mg, 85 mg to 115 mg, 90 mg to 110 mg or 95 mg to 105 mg of Compound I.

[1219] 79. The pharmaceutical composition of any one of embodiments 71-76, comprising 25 mg, 50 mg or 100 mg of Compound I.

[1220] 80. The pharmaceutical composition of any one of embodiments 71-76, comprising 75 mg to 125 mg of Compound I.

[1221] 81. The pharmaceutical composition of any one of embodiments 71-80, wherein the first solid dispersion comprises 25 mg to 75 mg of Compound II.

[1222] 82. A single tablet as described in any one of embodiments 71-80, wherein the first solid dispersion comprises 50 mg of Compound II.

[1223] 83. A pharmaceutical composition as described in any one of embodiments 71-82, wherein the second solid dispersion comprises 25 mg to 50 mg, 25 mg to 75 mg, 50 mg to 100 mg, 75 mg to 125 mg, or 125 mg to 175 mg of Compound III.

[1224] 84. A single tablet as described in any one of embodiments 71-82, wherein the second solid dispersion comprises 75 mg of Compound III.

[1225] 85. A pharmaceutical composition as described in any one of embodiments 71-76, comprising

[1226] (a) 50 mg to 125 mg of Compound I; and wherein

[1227] The first solid dispersion comprises 25 mg to 75 mg of Compound II; and

[1228] The second solid dispersion comprises 50 mg to 175 mg of Compound III; or

[1229] (b) 70 mg to 240 mg of Compound I; and wherein

[1230] The first solid dispersion comprises 30 mg to 120 mg of Compound II; and

[1231] The second solid dispersion comprises 50 mg to 170 mg of Compound III; or

[1232] (c) 30 mg to 120 mg of Compound I; and wherein

[1233] The first solid dispersion comprises 15 mg to 60 mg of Compound II; and

[1234] The second solid dispersion comprises 20 mg to 90 mg of Compound III; or

[1235] (d) 30 mg to 120 mg of Compound I; and wherein

[1236] The first solid dispersion comprises 15 mg to 60 mg of Compound II; and

[1237] The second solid dispersion comprises 50 mg to 170 mg of Compound III; or

[1238] (e) 15 mg to 55 mg of Compound I; and wherein

[1239] The first solid dispersion comprises 10 mg to 50 mg of Compound II; and

[1240] The second solid dispersion contains 20 mg to 90 mg of Compound III.

[1241] 86. A pharmaceutical composition as described in any one of embodiments 71-76, comprising

[1242] (a) 75 mg to 125 mg of Compound I; and wherein

[1243] The first solid dispersion comprises 50 mg of Compound II; and

[1244] The second solid dispersion comprises 75 mg of Compound III; or

[1245] (b) 100 mg of Compound I; and wherein

[1246] The first solid dispersion comprises 50 mg of Compound II; and

[1247] The second solid dispersion comprises 75 mg of Compound III; or

[1248] (c) 200 mg of Compound I; and wherein

[1249] The first solid dispersion comprises 100 mg of Compound II; and

[1250] The second solid dispersion comprises 150 mg of Compound III; or

[1251] (d) 100 mg of Compound I; and wherein

[1252] The first solid dispersion comprises 50 mg of Compound II; and

[1253] The second solid dispersion comprises 150 mg of Compound III; or

[1254] (e) 50 mg of Compound I; and wherein

[1255] The first solid dispersion comprises 25 mg of Compound II; and

[1256] The second solid dispersion comprises 75 mg of Compound III; or

[1257] (f) 100 mg of Compound I; and wherein

[1258] The first solid dispersion comprises 100 mg of Compound II; and

[1259] The second solid dispersion comprises 150 mg of Compound III; or

[1260] (e) 50 mg of Compound I; and wherein

[1261] The first solid dispersion comprises 50 mg of Compound II; and

[1262] The second solid dispersion comprises 75 mg of Compound III; or

[1263] (h) 50 mg of Compound I; and wherein

[1264] The first solid dispersion comprises 50 mg of Compound II; and

[1265] The second solid dispersion comprises 150 mg of Compound III; or

[1266] (i) 25 mg of Compound I; and wherein

[1267] The first solid dispersion comprises 25 mg of Compound II; and

[1268] The second solid dispersion comprises 150 mg of Compound III; or

[1269] (j) 25 mg of Compound I; and wherein

[1270] The first solid dispersion comprises 50 mg of Compound II; and

[1271] The second solid dispersion comprises 150 mg of Compound III; or

[1272] (k) 12.5 mg of Compound I; and wherein

[1273] The first solid dispersion comprises 25 mg of Compound II; and

[1274] The second solid dispersion comprises 75 mg of Compound III; or

[1275] (l) 30 mg to 70 mg of Compound I; and wherein

[1276] The first solid dispersion comprises 15 mg to 40 mg of Compound II; and

[1277] The second solid dispersion contains 20 mg to 55 mg of Compound III; or

[1278] (m) 70 mg to 130 mg of Compound I; and wherein

[1279] The first solid dispersion comprises 30 mg to 70 mg of Compound II; and

[1280] The second solid dispersion contains 50 mg to 100 mg of Compound III.

[1281] 87. The pharmaceutical composition of any one of embodiments 71-86, wherein the second solid dispersion further comprises 0.5% sodium lauryl sulfate relative to the total weight of the second solid dispersion.

[1282] 88. The pharmaceutical composition of any one of embodiments 71-87, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, lubricants, and glidants.

[1283] 89. The pharmaceutical composition of embodiment 88, wherein:

[1284] The filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, starch, maltodextrin, agar and guar gum;

[1285] The disintegrant is selected from cross-linked sodium carboxymethylcellulose, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose and microcrystalline cellulose;

[1286] The lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc; and

[1287] The glidant is selected from colloidal silicon dioxide.

[1288] 90. The pharmaceutical composition of any one of embodiments 71-89, wherein Compound I is substantially crystalline, and wherein Compounds II and III are each independently substantially amorphous.

[1289] 91. The pharmaceutical composition of embodiment 71, further comprising microcrystalline cellulose; croscarmellose sodium; and optionally magnesium stearate.

[1290] 92. The pharmaceutical composition of embodiment 91, wherein the pharmaceutical composition comprises 50 mg to 250 mg microcrystalline cellulose; 10 mg to 45 mg croscarmellose sodium; and optionally 1 mg to 10 mg magnesium stearate.

[1291] 93. A pharmaceutical composition as described in any of embodiments 71-92, wherein the pharmaceutical composition comprises 25 mg to 250 mg of Compound I in (a); the first solid dispersion comprises 20 mg to 150 mg of Compound II in (b); and the second solid dispersion comprises 25 mg to 200 mg of Compound III.

[1292] 94. A pharmaceutical composition as described in any of embodiments 1-23, wherein the weight ratio of Compound I in (a): Compound II in (b): Compound III in (c) is 4:2:3, 2:1:3, 2:2:3, 1:1:3, 1:2:3 or 1:2:6.

[1293] 95. A pharmaceutical composition comprising:

[1294] (a) 10% to 30% by weight of Compound I relative to the total weight of the pharmaceutical composition:

[1295]

[1296] (b) 8 to 30 weight % of the first solid dispersion relative to the total weight of the pharmaceutical composition;

[1297] The first solid dispersion comprises 70% to 90% by weight of Compound II relative to the total weight of the first solid dispersion:

[1298]

[1299] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[1300] (c) 10 wt % to 45 wt % of a second solid dispersion relative to the total weight of the pharmaceutical composition;

[1301] The second solid dispersion comprises 70% to 90% by weight of compound III relative to the total weight of the second solid dispersion:

[1302] and 10 to 30 wt % of a polymer relative to the total weight of the second solid dispersion.

[1303] 96. The pharmaceutical composition of embodiment 95, wherein at least one of the second solid dispersion or the third solid dispersion is a spray-dried dispersion.

[1304] 97. The pharmaceutical composition of embodiment 95, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[1305] 98. A pharmaceutical composition as described in embodiment 95, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[1306] 99. A pharmaceutical composition as described in embodiment 95, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose (HPMC E15); and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate H.

[1307] 100. The pharmaceutical composition of embodiment 95, wherein:

[1308] The first solid dispersion comprises 70 wt % to 85 wt % of Compound II relative to the total weight of the first solid dispersion, and the polymer is hydroxypropyl methylcellulose in an amount of 15 wt % to 30 wt % relative to the total weight of the first solid dispersion; and

[1309] The second solid dispersion comprises 70 to 85 wt% of Compound III relative to the total weight of the second solid dispersion, 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and the polymer is hydroxypropylmethylcellulose acetate succinate in an amount of 14.5 to 29.5 wt% relative to the total weight of the second solid dispersion.

[1310] 101. The pharmaceutical composition of any one of embodiments 95-100, wherein the first solid dispersion comprises 75 wt% to 85 wt% of Compound II relative to the total weight of the first solid dispersion.

[1311] 102. A pharmaceutical composition as described in any of embodiments 95-100, wherein the first solid dispersion comprises 80 weight % of Compound II, relative to the total weight of the first solid dispersion; and 20 weight % of hydroxypropyl methylcellulose, relative to the total weight of the first solid dispersion.

[1312] 103. The pharmaceutical composition of any one of embodiments 95-102, wherein the second solid dispersion comprises 75 wt% to 85 wt% of Compound III relative to the total weight of the second solid dispersion.

[1313] 104. A pharmaceutical composition as described in any of embodiments 95-103, wherein the second solid dispersion comprises 80 weight % of Compound III relative to the total weight of the second solid dispersion; 0.5 weight % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and 19.5 weight % of hydroxypropyl methylcellulose acetate succinate relative to the total weight of the second solid dispersion.

[1314] 105. The pharmaceutical composition of any one of embodiments 95-104, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, and lubricants.

[1315] 106. The pharmaceutical composition according to embodiment 105, wherein:

[1316] The filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, starch, maltodextrin, agar and guar gum;

[1317] The disintegrant is selected from cross-linked sodium carboxymethylcellulose, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose and microcrystalline cellulose; and

[1318] The lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc.

[1319] 107. The pharmaceutical composition of any one of embodiments 95-107, wherein the pharmaceutical composition is a tablet or in the form of granules.

[1320] 108. The pharmaceutical composition of embodiment 95, further comprising microcrystalline cellulose; croscarmellose sodium; and optionally magnesium stearate.

[1321] 109. A pharmaceutical composition as described in embodiment 108, wherein the pharmaceutical composition comprises 15% to 45% by weight of microcrystalline cellulose; 1% to 10% by weight of croscarmellose sodium; and optionally 0.5% to 3% by weight of magnesium stearate, relative to the total weight of the pharmaceutical composition.

[1322] 110. A pharmaceutical composition as described in any of embodiments 95-109, wherein the pharmaceutical composition comprises 10% to 30% by weight of Compound I in (a); 8% to 30% by weight of the first solid dispersion in (b); and 10% to 30% by weight of the second solid dispersion in (c).

[1323] 111. A pharmaceutical composition as described in any of embodiments 95-110, wherein the weight ratio of Compound I in (a): Compound II in (b): Compound III in (c) is 4:2:3, 2:1:3, 2:2:3, 1:1:3, 1:2:3 or 1:2:6.

[1324] 112. A pharmaceutical composition comprising:

[1325] (a) Compound I:

[1326]

[1327] (b) a first solid dispersion, the first solid dispersion comprising 70 wt % to 90 wt % of Compound II relative to the total weight of the first solid dispersion:

[1328]

[1329] and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion; and

[1330] (c) a second solid dispersion, the second solid dispersion comprising 70 wt % to 90 wt % of Compound III relative to the total weight of the second solid dispersion:

[1331] and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion, wherein

[1332] The weight ratio of compound I in (a): compound II in (b): compound III in (c) ranges from 4:2:3-6.

[1333] 113. The pharmaceutical composition of embodiment 112, wherein at least one of the second solid dispersion or the third solid dispersion is a spray-dried dispersion.

[1334] 114. The pharmaceutical composition of embodiment 112, wherein the first solid dispersion and the second solid dispersion are both spray-dried dispersions.

[1335] 115. The pharmaceutical composition of embodiment 112, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

[1336] 116. A pharmaceutical composition as described in embodiment 112, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose (HPMC E15); and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate H.

[1337] 117. The pharmaceutical composition according to embodiment 112, wherein:

[1338] The first solid dispersion comprises 70 wt % to 85 wt % of Compound II relative to the total weight of the first solid dispersion, and the polymer is hydroxypropyl methylcellulose in an amount of 15 wt % to 30 wt % relative to the total weight of the first solid dispersion; and

[1339] The second solid dispersion comprises 70 to 85 wt% of Compound III relative to the total weight of the second solid dispersion, 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and the polymer is hydroxypropylmethylcellulose acetate succinate in an amount of 14.5 to 29.5 wt% relative to the total weight of the second solid dispersion.

[1340] 118. The pharmaceutical composition of any one of embodiments 112-117, wherein the first solid dispersion comprises 75 wt% to 85 wt% of Compound II relative to the total weight of the first solid dispersion.

[1341] 119. A pharmaceutical composition as described in any one of embodiments 112-117, wherein the first solid dispersion comprises 80 weight % of Compound II, relative to the total weight of the first solid dispersion; and 20 weight % of hydroxypropyl methylcellulose, relative to the total weight of the first solid dispersion.

[1342] 120. The pharmaceutical composition of any one of embodiments 112-119, wherein the second solid dispersion comprises 75% to 85% by weight of Compound III relative to the total weight of the second solid dispersion.

[1343] 121. A pharmaceutical composition as described in any of embodiments 112-120, wherein the second solid dispersion comprises 80 weight % of Compound III relative to the total weight of the second solid dispersion; 0.5 weight % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, and 19.5 weight % of hydroxypropyl methylcellulose acetate succinate relative to the total weight of the second solid dispersion.

[1344] 122. The pharmaceutical composition of any one of embodiments 112-121, further comprising one or more pharmaceutically acceptable excipients selected from one or more fillers, disintegrants, and lubricants.

[1345] 123. The pharmaceutical composition of embodiment 122, wherein:

[1346] The filler is selected from microcrystalline cellulose, silicified microcrystalline cellulose, lactose, dicalcium phosphate, mannitol, copovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, starch, maltodextrin, agar and guar gum;

[1347] The disintegrant is selected from cross-linked sodium carboxymethylcellulose, sodium starch glycolate, crospovidone, corn or pregelatinized starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose and microcrystalline cellulose; and

[1348] The lubricant is selected from magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium stearate, stearic acid and talc.

[1349] 124. The pharmaceutical composition of any one of embodiments 112-123, wherein Compound I is substantially crystalline, and wherein Compounds II and III are each independently substantially amorphous.

[1350] 125. The pharmaceutical composition of any one of embodiments 112-124, wherein the pharmaceutical composition is a tablet or in the form of granules.

[1351] 126. The pharmaceutical composition of embodiment 112, further comprising microcrystalline cellulose; croscarmellose sodium; and magnesium stearate.

[1352] 127. A pharmaceutical composition as described in embodiment 58, wherein the pharmaceutical composition comprises 15% to 45% by weight of microcrystalline cellulose; 1% to 10% by weight of croscarmellose sodium; and 0.5% to 3% by weight of magnesium stearate, relative to the total weight of the pharmaceutical composition.

[1353] 128. A pharmaceutical composition as described in embodiment 58, wherein the weight ratio of Compound I in (a): Compound II in (b): Compound III in (c) is 4:2:3, 2:1:3, 2:2:3, 1:1:3, 1:2:3 or 1:2:6.

[1354] 129. A single tablet comprising:

[1355] (a) 25 mg to 125 mg of Compound I:

[1356]

[1357] (b) 60 mg to 65 mg of a first solid dispersion, wherein the first solid dispersion comprises 80 wt % of Compound II relative to the total weight of the first solid dispersion:

[1358]

[1359] and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion; and

[1360] (c) 90 mg to 95 mg or 180 mg to 190 mg of a second solid dispersion, the second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion:

[1361]

[1362] 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt% of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[1363] (d) 85 mg to 275 mg microcrystalline cellulose;

[1364] (e) 10 mg to 35 mg croscarmellose sodium; and

[1365] (f) 2 mg to 7 mg magnesium stearate.

[1366] 130. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1367] (b) 60 mg to 65 mg of the first solid dispersion;

[1368] (c) 180 mg to 190 mg of the second solid dispersion;

[1369] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1370] 131. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1371] (b) 60 mg to 65 mg of the first solid dispersion;

[1372] (c) 180 mg to 190 mg of the second solid dispersion;

[1373] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1374] 132. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1375] (b) 60 mg to 65 mg of the first solid dispersion;

[1376] (c) 180 mg to 190 mg of the second solid dispersion;

[1377] (d) 20 mg to 25 mg of said croscarmellose sodium; (e) 200 mg to 210 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1378] 133. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1379] (b) 60 mg to 65 mg of the first solid dispersion;

[1380] (c) 180 mg to 190 mg of the second solid dispersion;

[1381] (d) 20 mg to 25 mg of the cross-linked sodium carboxymethyl cellulose; (e) 85 mg to 95 mg of the microcrystalline cellulose; and

[1382] (f) 2 mg to 6 mg magnesium stearate.

[1383] 134. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1384] (b) 60 mg to 65 mg of the first solid dispersion;

[1385] (c) 180 mg to 190 mg of the second solid dispersion;

[1386] (d) 20 mg to 25 mg of said croscarmellose sodium; (e) 270 mg to 275 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1387] 135. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1388] (b) 60 mg to 65 mg of the first solid dispersion;

[1389] (c) 180 mg to 190 mg of the second solid dispersion;

[1390] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1391] 136. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1392] (b) 60 mg to 65 mg of the first solid dispersion;

[1393] (c) 180 mg to 190 mg of the second solid dispersion;

[1394] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1395] 137. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1396] (b) 60 mg to 65 mg of the first solid dispersion;

[1397] (c) 180 mg to 190 mg of the second solid dispersion;

[1398] (d) 12 mg to 17 mg of said croscarmellose sodium; (e) 160 mg to 170 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1399] 138. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1400] (b) 60 mg to 65 mg of the first solid dispersion;

[1401] (c) 180 mg to 190 mg of the second solid dispersion;

[1402] (d) 10 mg to 20 mg of said croscarmellose sodium; (e) 260 mg to 270 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1403] 139. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1404] (b) 60 mg to 65 mg of the first solid dispersion;

[1405] (c) 90 mg to 95 mg of the second solid dispersion;

[1406] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1407] 140. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1408] (b) 60 mg to 65 mg of the first solid dispersion;

[1409] (c) 90 mg to 95 mg of the second solid dispersion;

[1410] (d) 20 mg to 25 mg of said croscarmellose sodium; (e) 200 mg to 210 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1411] 141. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1412] (b) 60 mg to 65 mg of the first solid dispersion;

[1413] (c) 90 mg to 95 mg of the second solid dispersion;

[1414] (d) 20 mg to 25 mg of the cross-linked sodium carboxymethyl cellulose; (e) 85 mg to 95 mg of the microcrystalline cellulose; and

[1415] (f) 2 mg to 6 mg magnesium stearate.

[1416] 142. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1417] (b) 60 mg to 65 mg of the first solid dispersion;

[1418] (c) 90 mg to 95 mg of the second solid dispersion;

[1419] (d) 20 mg to 25 mg of said croscarmellose sodium; (e) 270 mg to 275 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1420] 143. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1421] (b) 60 mg to 65 mg of the first solid dispersion;

[1422] (c) 90 mg to 95 mg of the second solid dispersion;

[1423] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1424] 144. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1425] (b) 60 mg to 65 mg of the first solid dispersion;

[1426] (c) 90 mg to 95 mg of the second solid dispersion;

[1427] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 205 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1428] 145. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1429] (b) 60 mg to 65 mg of the first solid dispersion;

[1430] (c) 90 mg to 95 mg of the second solid dispersion;

[1431] (d) 25 mg to 35 mg of said croscarmellose sodium; (e) 195 mg to 200 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1432] 146. A single tablet according to embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1433] (b) 60 mg to 65 mg of the first solid dispersion;

[1434] (c) 90 mg to 95 mg of the second solid dispersion;

[1435] (d) 12 mg to 17 mg of said croscarmellose sodium; (e) 160 mg to 170 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1436] 147. A single tablet as described in embodiment 129, comprising (a) 90 mg to 110 mg of Compound I;

[1437] (b) 60 mg to 65 mg of the first solid dispersion;

[1438] (c) 90 mg to 95 mg of the second solid dispersion;

[1439] (d) 10 mg to 20 mg of said croscarmellose sodium; (e) 260 mg to 270 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1440] 148. A single tablet comprising:

[1441] (a) 10 mg to 110 mg of Compound I:

[1442]

[1443] (b) 25 mg to 70 mg of a first solid dispersion, wherein the first solid dispersion comprises 80 wt % of Compound II relative to the total weight of the first solid dispersion:

[1444]

[1445] and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion; and

[1446] (c) 85 mg to 195 mg of a second solid dispersion, wherein the second solid dispersion comprises 80 wt % of Compound III relative to the total weight of the second solid dispersion:

[1447]

[1448] 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt% of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion;

[1449] (d) 10 mg to 45 mg croscarmellose sodium; and

[1450] (e) 95 mg to 280 mg microcrystalline cellulose; and

[1451] (f) 2 mg to 7 mg magnesium stearate.

[1452] 149. A single tablet as described in embodiment 148, comprising

[1453] (a) 95 mg to 105 mg of Compound I;

[1454] (b) 60 mg to 65 mg of the first solid dispersion;

[1455] (c) 185 mg to 190 mg of the second solid dispersion;

[1456] (d) 35 mg to 45 mg of said croscarmellose sodium; (e) 260 mg to 280 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1457] 150. A single tablet according to embodiment 148, comprising (a) 45 mg to 55 mg of Compound I;

[1458] (b) 25 mg to 55 mg of the first solid dispersion;

[1459] (c) 90 mg to 100 mg of the second solid dispersion;

[1460] (d) 15 mg to 25 mg of said croscarmellose sodium; (e) 125 mg to 145 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1461] 151. A single tablet according to embodiment 148, comprising (a) 45 mg to 55 mg of Compound I;

[1462] (b) 60 mg to 65 mg of the first solid dispersion;

[1463] (c) 185 mg to 190 mg of the second solid dispersion;

[1464] (d) 30 mg to 40 mg of said croscarmellose sodium; (e) 220 mg to 245 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1465] 152. A single tablet as described in embodiment 148, comprising (a) 20 mg to 30 mg of Compound I;

[1466] (b) 30 mg to 35 mg of the first solid dispersion;

[1467] (c) 90 mg to 100 mg of the second solid dispersion;

[1468] (d) 15 mg to 25 mg of the croscarmellose sodium; (e) 110 mg to 120 mg of the microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1469] 153. A single tablet according to embodiment 148, comprising (a) 20 mg to 30 mg of Compound I;

[1470] (b) 60 mg to 65 mg of the first solid dispersion;

[1471] (c) 185 mg to 190 mg of the second solid dispersion;

[1472] (d) 35 mg to 45 mg of said croscarmellose sodium; (e) 200 mg to 220 mg of said microcrystalline cellulose; and (f) 2 mg to 7 mg of magnesium stearate.

[1473] 154. A single tablet according to embodiment 148, comprising (a) 10 mg to 15 mg of Compound I;

[1474] (b) 25 mg to 35 mg of the first solid dispersion;

[1475] (c) 90 mg to 100 mg of the second solid dispersion;

[1476] (d) 10 mg to 20 mg of the cross-linked sodium carboxymethyl cellulose;

[1477] (e) 100 mg to 115 mg of said microcrystalline cellulose; and

[1478] (f) 2 mg to 7 mg magnesium stearate.

[1479] 155. A pharmaceutical composition comprising:

[1480] (a) 12 wt % to 30 wt % of Compound I relative to the total weight of the pharmaceutical composition:

[1481]

[1482] (b) 5 to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[1483]

[1484] (c) 10% to 25% by weight of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition:

[1485]

[1486] (d) 20% to 45% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[1487] (e) 3% to 8% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[1488] (f) 0.5 to 2 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[1489] 156. The pharmaceutical composition according to embodiment 155, wherein the pharmaceutical composition comprises:

[1490] (a) 18 wt % to 23 wt % of Compound I relative to the total weight of the pharmaceutical composition;

[1491] (b) 8 to 12 wt% of Compound II relative to the total weight of the pharmaceutical composition;

[1492] (c) 13% to 18% by weight of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[1493] (d) 35% to 45% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[1494] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[1495] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[1496] 157. The pharmaceutical composition of embodiment 155, wherein the pharmaceutical composition comprises:

[1497] (a) 15% to 25% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[1498] (b) 5 to 10 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[1499] (c) 7 to 15 wt % of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[1500] (d) 30% to 50% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[1501] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[1502] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[1503] 158. The pharmaceutical composition of embodiment 155, wherein the pharmaceutical composition comprises:

[1504] (a) 20% to 25% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[1505] (b) 7 to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[1506] (c) 15 to 20 wt % of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[1507] (d) 15 to 25 weight % of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[1508] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[1509] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[1510] 159. The pharmaceutical composition of embodiment 155, wherein the pharmaceutical composition comprises:

[1511] (a) 20% to 25% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[1512] (b) 7 to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[1513] (c) 15 to 20 wt % of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[1514] (d) 25% to 35% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[1515] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[1516] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[1517] 160. The pharmaceutical composition of embodiment 155, wherein the pharmaceutical composition comprises:

[1518] (a) 22% to 28% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[1519] (b) 10% to 15% by weight of Compound II relative to the total weight of the pharmaceutical composition:

[1520] (c) 15% to 25% by weight of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[1521] (d) 15 to 25 weight % of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[1522] (e) 3% to 7% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[1523] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[1524] 161. The pharmaceutical composition of embodiment 155, wherein the pharmaceutical composition comprises:

[1525] (a) 15% to 20% by weight of Compound I relative to the total weight of the pharmaceutical composition;

[1526] (b) 7 to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[1527] (c) 10% to 15% by weight of Compound III or Compound III-d relative to the total weight of the pharmaceutical composition;

[1528] (d) 45% to 55% by weight of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[1529] (e) 3% to 5% by weight of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[1530] (f) 0.5 to 1.5 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[1531] 162. A pharmaceutical composition comprising

[1532] (a) 12 wt % to 30 wt % of Compound I relative to the total weight of the pharmaceutical composition:

[1533]

[1534] (b) 5 to 15 wt % of Compound II relative to the total weight of the pharmaceutical composition:

[1535]

[1536] (c) 15% to 35% by weight of Compound III relative to the total weight of the pharmaceutical composition:

[1537]

[1538] (d) 15 to 45 wt % of microcrystalline cellulose relative to the total weight of the pharmaceutical composition;

[1539] (e) 1 wt% to 10 wt% of cross-linked carboxymethyl cellulose sodium relative to the total weight of the pharmaceutical composition; and

[1540] (f) 0.5 to 3 wt% of magnesium stearate relative to the total weight of the pharmaceutical composition.

[1541] 163. The pharmaceutical composition of any one of embodiments 155-162, wherein the composition is a tablet.

[1542] 164. The pharmaceutical composition or single tablet of any one of embodiments 1-163, wherein Compound I is in crystalline Form A.

[1543] 165. The pharmaceutical composition or single tablet of embodiment 164, wherein Compound 1 crystalline Form A is in substantially pure form.

[1544] 166. A pharmaceutical composition or single tablet as described in embodiment 164, wherein Compound 1 crystalline Form A is characterized by an X-ray powder diffraction pattern having signals at at least three 2θ values ​​selected from 6.6±0.2, 7.6±0.2, 9.6±0.2, 12.4±0.2, 13.1±0.2, 15.2±0.2, 16.4±0.2, 18.2±0.2 and 18.6±0.2.

[1545] 167. A method of treating cystic fibrosis in a patient, the method comprising orally administering to the patient one or more single tablets or pharmaceutical compositions of any one of embodiments 1-163.

[1546] 168. The method of embodiment 167, wherein one or more of the single tablets or pharmaceutical compositions are administered once daily or twice daily.

[1547] 169. The method of embodiment 168, wherein two tablets are administered once daily.

[1548] 170. The method of any one of embodiments 167-168, wherein the patient with cystic fibrosis is selected from a patient with a F508del / minimal function genotype, a patient with a F508del / F508del genotype, a patient with a F508del / gating genotype, and a patient with a F508del / residual function genotype.

[1549] 171. The method of embodiment 170, wherein the patient with the F508del / minimal functional genotype has a minimal functional mutation selected from:

[1550]

[1551]

[1552] 172. The method of embodiment 170, wherein the patient with the F508del / gating genotype has a gating mutation selected from G178R, S549N, S549R, G551D, G551S, G1244E, S1251N, S1255P, and G1349D.

[1553] 173. The method of embodiment 170, wherein the patient with the F508del / residual function genotype has a gene selected from 2789+5G→A, 3849+10kbC→T, 3272-26A→G, 711+3A→G, E56K, P67L, R74W, D110E, D110H, R117C, L206W, R347H, R352Q, A455E, D579G, E831X, S945L, S Residual function mutations of 977F, F1052V, R1070W, F1074L, D1152H, D1270N, E193K, K1060T, R117H, S1235R, I1027T, R668C, G576A, M470V, L997F, R75Q, R1070Q, R31C, D614G, G1069R, R1162L, E56K, A1067T, E193K, and K1060T.

[1554] 174. A method of preparing a single tablet as described in any one of embodiments 1, 41, 59, 61, 71, 110, 127, 129, 148 or 163, comprising

[1555] (a) mixing Compound 1 with the first solid dispersion and the second solid dispersion to form a first mixture; and

[1556] (b) compressing a tablet mixture comprising the first mixture into tablets.

[1557] 175. The method of embodiment 174, wherein the tablet mixture further comprises one or more pharmaceutically acceptable excipients, and the method further comprises mixing the first mixture with the one or more excipients to form the tablet mixture.

[1558] 176. The method of embodiment 173 or 174, further comprising coating the tablet.

[1559] 177. A method of preparing a single tablet as described in embodiment 61 or 129, comprising

[1560] (a) mixing Compound 1 with the first solid dispersion and the second solid dispersion to form a first mixture;

[1561] (b) mixing the first mixture with the microcrystalline cellulose, croscarmellose sodium and magnesium stearate to form a tablet mixture; and (c) compressing the tablet mixture into tablets.

[1562] 178. The method of embodiment 177, further comprising coating the tablet.

[1563] 179. A pharmaceutical composition having the following formula:

[1564]

[1565]

[1566] 180. The pharmaceutical composition of any one of embodiments 1-60, 71-128, 155-168 or 179, wherein the composition is a tablet.

[1567] Methods of preparing compounds and tablets

[1568] General Experimental Procedure

[1569] Unless otherwise stated, reagents and starting materials were obtained from commercial sources and used without purification. Proton and carbon NMR spectra were acquired at 400 and 100 MHz, respectively. 1 H and 13C resonance frequency operation on a Bruker Biospin DRX 400 MHz FTNMR spectrometer or on a 300 MHz NMR spectrometer. One-dimensional proton and carbon spectra were obtained at 20 Hz sample rotation with a broadband observation (BBFO) probe at a digital resolution of 0.1834 and 0.9083 Hz / Pt, respectively. All proton and carbon spectra were obtained under temperature control at 30°C using standard, previously published pulse sequences and conventional processing parameters.

[1570] The final purity of the compound was determined by reverse phase UPLC using an Acquity UPLC BEH C manufactured by Waters (pn: 186002350). 18 Column (50×2.1 mm, 1.7 μm particles) and 1%-99% mobile phase B over 3.0 minutes dual gradient run. Mobile phase A=H2O (0.05% CF3CO2H). Mobile phase B=CH3CN (0.035% CF3CO2H). Flow rate=1.2 mL / min, injection volume=1.5 μL, and column temperature=60°C. Final purity was calculated by averaging the area under the curve (AUC) of two UV traces (220 nm, 254 nm). Low resolution mass spectra are reported as [M+H] obtained using a single quadrupole mass spectrometer. + The material was a quadrupole mass spectrometer equipped with an electrospray ionization (ESI) source capable of achieving a mass accuracy of 0.1 Da and a minimum resolution of 1000 (no resolution unit) over the entire detection range. The optical purity of (2S)-2,4-dimethyl-4-nitro-pentanoic acid methyl ester was determined by chiral gas chromatography (GC) analysis on an Agilent 7890A / MSD 5975C instrument using a Restek Rt-βDEXcst (30mx 0.25mmx0.25um_df) column at a flow rate of 2.0 mL / min (H2 carrier gas), an injection temperature of 220°C and an oven temperature of 120°C for 15 minutes.

[1571] Powder X-ray diffraction measurements were performed using a PANalytical X-pert Pro diffractometer at room temperature using Cu 2+ radiation. The incident beam optics consisted of a variable divergence slit to ensure a constant illumination length on the sample and on the diffracted beam side; a fast linear solid-state detector was used with an effective length of 2.12 degrees 2θ measured in scanning mode. The powder sample was mounted on a recessed area of ​​a zero-background silicon holder and rotated to achieve better statistics. Symmetric scans were measured from 3-40 degrees 2θ with a step size of 0.017 degrees and a scan step time of 15.5 s.

[1572] Solid-state spectrometers were obtained using a Bruker-Biospin 400 MHz wide-aperture spectrometer equipped with a Bruker-Biospin 4 mm HFX probe. 13 C and 19 F NMR data. The samples were loaded into a 4 mm rotor and spun at a typical rotation speed of 12.5 kHz under Magic Angle Spinning (MAS) conditions. The proton relaxation time was given by 1 The H MAS T1 saturation recovery relaxation experiment was estimated and used to establish 13 The appropriate cycle delay for C cross-polarization (CP) MAS experiments. The fluorine relaxation time is given by 19 F was estimated from the T1 saturation recovery relaxation experiment and used to establish 19 Appropriate recycle delays for F MAS experiments. CP contact time for CPMAS experiments was set to 2 ms. CP proton pulses with linear slope (50% to 100%) were employed. All spectra were externally referenced by adjusting the magnetic field to set the carbon resonance of adamantane to 29.5 ppm. 13 C and 19 For F acquisition, the TPPM15 proton decoupling sequence was used with a field strength of approximately 100 kHz.

[1573] The final purity of the compound was determined by reverse phase UPLC using an Acquity UPLC BEH C manufactured by Waters (pn: 186002350). 18 Column (50×2.1 mm, 1.7 μm particles) and 1%-99% mobile phase B over 3.0 minutes dual gradient run. Mobile phase A=H2O (0.05% CF3CO2H). Mobile phase B=CH3CN (0.035% CF3CO2H). Flow rate=1.2 mL / min, injection volume=1.5 μL, and column temperature=60°C. Final purity was calculated by averaging the area under the curve (AUC) of two UV traces (220 nm, 254 nm). Low resolution mass spectra are reported as [M+H] obtained using a single quadrupole mass spectrometer. + The material was a quadrupole mass spectrometer equipped with an electrospray ionization (ESI) source capable of achieving a mass accuracy of 0.1 Da and a minimum resolution of 1000 (no resolution unit) over the entire detection range. The optical purity of (2S)-2,4-dimethyl-4-nitro-pentanoic acid methyl ester was determined by chiral gas chromatography (GC) analysis on an Agilent 7890A / MSD 5975C instrument using a Restek Rt-βDEXcst (30mx 0.25mmx0.25um_df) column at a flow rate of 2.0 mL / min (H2 carrier gas), an injection temperature of 220°C and an oven temperature of 120°C for 15 minutes.

[1574] Example 1. Synthesis of Compound I: N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound I):

[1575]

[1576] Part A: Synthesis of (4S)-2,2,4-trimethylpyrrolidine hydrochloride

[1577]

[1578] Step 1: 2,4-Dimethyl-4-nitro-pentanoic acid methyl ester

[1579]

[1580] Tetrahydrofuran (THF, 4.5L) was added to a 20L glass reactor and stirred at room temperature under N2. 2-Nitropropane (1.5kg, 16.83mol) and 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) (1.282kg, 8.42mol) were then loaded into the reactor, and the jacket temperature was raised to 50°C. Once the reactor contents approached 50°C, methyl methacrylate (1.854kg, 18.52mol) was slowly added over 100 minutes. The reaction temperature was maintained at or near 50°C for 21 hours. The reaction mixture was concentrated in vacuo, then transferred back into the reactor and diluted with methyl tert-butyl ether (MTBE) (14L). 2M HCl (7.5L) was added, and the mixture was stirred for 5 minutes and then allowed to settle. Two transparent layers were visible - the yellow aqueous phase at the lower layer and the green organic phase at the upper layer. The aqueous layer is removed, and the organic layer is stirred with 2M HCl (3L) again. After separation, the HCl washings are recombined and stirred with MTBE (3L) for 5 minutes. The aqueous layer is removed, and all organic layers are combined in a reactor and stirred with water (3L) for 5 minutes. After separation, the organic layer is concentrated in vacuo to obtain a turbid green oil. The crude product is treated with MgSO4 and filtered to obtain 2,4-dimethyl-4-nitro-pentanoic acid methyl esters (3.16kg, 99% yield) as a clear green oil.

[1581] 1 H NMR (400 MHz, CHLOROFORM-d) δ 3.68 (s, 3H), 2.56–2.35 (m, 2H), 2.11–2.00 (m, 1H), 1.57 (s, 3H), 1.55 (s, 3H), 1.19 (d, J=6.8 Hz, 3H).

[1582] Step 2: Synthesis of (2S)-2,4-dimethyl-4-nitro-pentanoic acid methyl ester

[1583]

[1584] The reactor was charged with purified water (2090 L; 10 volumes) and then potassium dihydrogen phosphate (27 kg, 198.4 mole; 13 g / L for water). The pH of the reactor contents was adjusted to 6.5 (± 0.2) with 20% (w / v) potassium carbonate solution. The reactor was charged with racemic 2,4-dimethyl-4-nitro-pentanoic acid methyl ester (209 kg; 1104.6 mole) and Palatase 20000L lipase (13 L, 15.8 kg; 0.06 volumes).

[1585] The reaction mixture is adjusted to 32 ± 2 ° C and stirred for 15-21 hours, and pH 6.5 is maintained by automatically adding 20% ​​potassium carbonate solution using a pH constant. As determined by chiral GC, when the racemic starting material is converted into the S-enantiomer of >98%ee, external heating is turned off. MTBE (35L) is then loaded into the reactor; 5 volumes), and the aqueous layer is extracted with MTBE (3 times, 400-1000L). The combined organic extracts are washed with Na2CO3 aqueous solution (4 times, 522L, 18%w / w 2.5 volumes), water (523L; 2.5 volumes) and 10%NaCl aqueous solution (314L, 1.5 volumes). The organic layer is concentrated in vacuo to obtain (2S)-2,4-dimethyl-4-nitro-pentanoic acid methyl ester (>98%ee, 94.4kg; 45% yield) as a flowing yellow oil.

[1586] Step 3: Synthesis of (3S)-3,5,5-trimethylpyrrolidin-2-one

[1587]

[1588] The 20L reactor was purged with N2. Deionized water rinsed, wet Ni (2800 grade, 250 g), (2S)-2,4-dimethyl-4-nitro-pentanoic acid methyl ester (1741 g, 9.2 mol) and ethanol (13.9 L, 8 volumes). The reaction was stirred at 900 rpm and the reactor was flushed with H2 and maintained at ~2.5 bar. The reaction mixture was then warmed to 60°C for 5 hours. The reaction mixture was cooled and filtered to remove the Raney nickel, and the solid filter cake was rinsed with ethanol (3.5 L, 2 volumes). The ethanol solution of the product was combined with a second batch of equal size and concentrated in vacuo to reduce to a minimum volume of ethanol (~1.5 volumes). Heptane (2.5 L) was added and the suspension was concentrated again to ~1.5 volumes. Repeat 3 times; the resulting suspension was cooled to 0-5°C, filtered under suction, and washed with heptane (2.5 L). The product was dried under vacuum for 20 minutes, then transferred to a drying tray and dried in a vacuum oven at 40 °C overnight to give (3S)-3,5,5-trimethylpyrrolidin-2-one (2.042 kg, 16.1 mol, 87%) as a white crystalline solid. 1 HNMR (400 MHz, CHLOROFORM-d) δ 6.39 (s, 1H), 2.62 (ddq, J = 9.9, 8.6, 7.1 Hz, 1H), 2.17 (dd, J = 12.4, 8.6 Hz, 1H), 1.56 (dd, J = 12.5, 9.9 Hz, 1H), 1.31 (s, 3H), 1.25 (s, 3H), 1.20 (d, J = 7.1 Hz, 3H).

[1589] Step 4: Synthesis of (4S)-2,2,4-trimethylpyrrolidine hydrochloride

[1590]

[1591] A glass-lined 120 L reactor was charged with lithium aluminum hydride pellets (2.5 kg, 66 mol) and dry THF (60 L) and warmed to 30 ° C. (S)-3,5,5-trimethylpyrrolidin-2-one (7.0 kg, 54 mol) in THF (25 L) was charged to the resulting suspension over 2 hours while maintaining the reaction temperature at 30 to 40 ° C. After the addition was complete, the reaction temperature was raised to 60-63 ° C and maintained overnight. The reaction mixture was cooled to 22 ° C and then carefully quenched by adding ethyl acetate (EtOAc) (1.0 L, 10 mole), followed by a mixture of THF (3.4 L) and water (2.5 kg, 2.0 equivalents), followed by a mixture of water (1.75 kg) and 50% aqueous sodium hydroxide solution (750 g, 2 equivalents of water and 1.4 equivalents of sodium hydroxide relative to aluminum), followed by 7.5 L of water. After the addition is complete, the reaction mixture is cooled to room temperature, and the solid is removed by filtration and washed with THF (3×25L). The filtrate and washings are combined and treated with 5.0L (58mole) 37% HCl aqueous solution (1.05 equivalents) while keeping the temperature below 30°C. The resulting solution is concentrated to a slurry by vacuum distillation. Isopropanol (8L) is added, and the solution is concentrated to near dryness by vacuum distillation. Isopropanol (4L) is added, and the product is slurried by warming to about 50°C. MTBE (6L) is added, and the slurry is cooled to 2-5°C. The product is collected by filtration and rinsed with 12L MTBE, then dried in a vacuum oven (55°C / 300 Torr / N2 purging) to give (4S)-2,2,4-trimethylpyrrolidine HCl (6.21kg, 75% yield) as a white crystalline solid. 1 HNMR(400MHz,DMSO-d6)δ9.34(br d,2H),3.33(dd,J=11.4,8.4Hz,1H),2.75(dd,J=11.4,8.6Hz,1H),2.50–2.39(m,1H),1.97(dd,J= 12.7,7.7Hz,1H),1.42(s,3H),1.38(dd,J=12.8,10.1Hz,1H),1.31(s,3H),1.05(d,J=6.6Hz,3H).

[1592] Part B: Preparation of N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound I):

[1593]

[1594]

[1595] Preparation of starting materials:

[1596] 3,3,3-Trifluoro-2,2-dimethyl-propan-1-ol

[1597]

[1598] A mechanical stirrer, cooling bath, addition funnel and J-Kem temperature probe were assembled on a 1L 3-neck round-bottom flask. Lithium aluminum hydride (LAH) particles (6.3 g, 0.1665 mol) were loaded into the container under a nitrogen atmosphere. Then tetrahydrofuran (200 mL) was added to the container under a nitrogen atmosphere. The mixture was stirred at room temperature for 0.5 hours to dissolve the particles. Crushed ice water was then loaded into the cooling bath, and the reaction temperature was reduced to 0 ° C. A solution of 3,3,3-trifluoro-2,2-dimethyl-propionic acid (20 g, 0.1281 mol) in tetrahydrofuran (60 mL) was loaded into the addition funnel, and a clear light yellow solution was added dropwise within 1 hour. After the addition was completed, the mixture was slowly warmed to room temperature and continued to stir for 24 hours. The suspension was cooled to 0°C with crushed ice-water in a cooling bath and then quenched by very slowly dropping water (6.3 ml), followed by dropping sodium hydroxide solution (15 wt %, 6.3 mL), and then finally with water (18.9 mL). The reaction temperature of the obtained white suspension was recorded as 5°C. The suspension was stirred at 5°C for 30 minutes and then filtered through a 20 mm diatomaceous earth layer. The filter cake was washed with tetrahydrofuran (2×100 mL). The filtrate was dried with sodium sulfate (150 g) and then filtered. The filtrate was concentrated under reduced pressure to obtain a clear colorless oil (15 g) containing a mixture of the product 3,3,3-trifluoro-2,2-dimethyl-propan-1-ol in THF (73 wt % of product ~10.95 g and 27 wt % of THF as determined by 1H-NMR). The distillate obtained by rotary evaporation was distilled at atmospheric pressure using a 30 cm Vigreux column to obtain 8.75 g of residue containing 60 wt % THF and 40 wt % product (~3.5 g). The total amount of product estimated was 14.45 g (79% yield). 1H NMR (400 MHz, DMSO-d6) δ 4.99 (t, J = 5.7 Hz, 1H), 3.38 (dd, J = 5.8, 0.9 Hz, 2H), 1.04 (d, J = 0.9 Hz, 6H).

[1599] 3-Oxo-2,3-dihydro-1H-pyrazole-1-carboxylic acid tert-butyl ester

[1600]

[1601] Start the reactor of 50L Syrris control, and set the jacket to 20 ℃, stir at 150rpm, reflux condenser (10 ℃) and purge with nitrogen.Add MeOH (2.860L) and (E)-3-methoxyprop-2-enoic acid methyl ester (2.643kg, 22.76mol), and cover the reactor.Reaction is heated to 40 ℃ of internal temperature, and the system is set to keep the jacket temperature at 40 ℃.Add hydrazine hydrate (1300g, 55%w / w, 22.31mol) in batches via addition funnel in 30 minutes.Reactant is heated to 60 ℃, keeps for 1 hour.Reaction mixture is cooled to 20 ℃, and triethylamine (2.483kg, 3.420L, 24.54mol) (exothermic) is added in batches, keeps reaction temperature<30 ℃. Boc anhydride (di-tert-butyl dicarbonate) (4.967kg, 5.228L, 22.76mol) in MeOH (2.860L) solution was added in batches, maintaining a certain temperature <45°C. The reaction mixture was stirred at 20°C for 16h. The reaction solution was partially concentrated to remove MeOH to obtain a clear light amber oil. The resulting oil was transferred to a 50L reactor, stirred and added with water (7.150L) and heptane (7.150L). The addition precipitated a small amount of product. The water layer was drained into a clean container, and the interface and heptane layer were filtered to separate the solid (product). The water layer was transferred back to the reactor, and the collected solids were put back into the reactor and mixed with the water layer. A dropping funnel was added to the reactor and acetic acid (1.474kg, 1.396L, 24.54mol) was loaded, and then acid was added dropwise. The jacket was set to 0°C to absorb the quenching exotherm. After the addition was completed (pH=5), the reaction mixture was stirred for 1 hour. The solid was collected by filtration, washed with water (7.150L), washed with water (3.575L) for the second time and dried. The crystalline solid was scooped out from the filter, put into a 20L rotary evaporator bulb, and heptane (7.150L) was added. The mixture was slurried at 45 ° C for 30 minutes, and then 1-2 volume of solvent was distilled out. The slurries in the rotary evaporator flask were filtered, and the solid was washed and dried with heptane (3.575L). The solid was further vacuum dried (50 ° C, 15mbar) to obtain 5-oxo-1H-pyrazole-2-carboxylic acid tert-butyl ester (2921g, 71%) in a crude crystalline solid. 1 H NMR (400MHz, DMSO-d6) δ10.95 (s, 1H), 7.98 (d, J = 2.9 Hz, 1H), 5.90 (d, J = 2.9 Hz, 1H), 1.54 (s, 9H).

[1602] Step A: tert-Butyl 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazole-1-carboxylate

[1603]

[1604] A mixture of 3,3,3-trifluoro-2,2-dimethyl-propan-1-ol (10 g, 70.36 mmol) and tert-butyl 3-hydroxypyrazole-1-carboxylate (12.96 g, 70.36 mmol) in toluene (130 mL) was treated with triphenylphosphine (20.30 g, 77.40 mmol) followed by N-isopropoxycarbonylcarbamic acid isopropyl ester (14.99 mL, 77.40 mmol) and the mixture was stirred for 16 hours at 110° C. The yellow solution was concentrated under reduced pressure, diluted with heptane (100 mL), the precipitated triphenylphosphine oxide was removed by filtration and washed with heptane / toluene 4:1 (100 mL). The yellow filtrate was evaporated and the residue was purified by silica gel chromatography with a linear gradient of ethyl acetate in hexanes (0-40%) to give tert-butyl 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazole-1-carboxylate (12.3 g, 57%) as an off-white solid. ESI-MS m / z calculated value 308.13477, found value 309.0 (M+1) + ; Retention time: 1.84 minutes. 1 HNMR (400MHz, DMSO-d6) δ8.10 (d, J = 3.0 Hz, 1H), 6.15 (d, J = 3.0 Hz, 1H), 4.18 (s, 2H), 1.55 (s, 9H), 1.21 (s, 6H).

[1605] Step B: 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)-1H-pyrazole

[1606]

[1607] 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazole-1-carboxylic acid tert-butyl ester (13.5g, 43.79mmol) was treated with 4M hydrogen chloride (54.75mL, 219.0mmol) in dioxane, and the mixture was stirred at 45°C for 1 hour. The reaction mixture was evaporated to dryness, and the residue was extracted with 1M NaOH aqueous solution (100ml) and methyl tert-butyl ether (100ml), washed with brine (50ml), and extracted with methyl tert-butyl ether (50ml). The combined organic phase was dried, filtered and evaporated to give 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)-1H-pyrazole (9.0g, 96%) as an off-white waxy solid. ESI-MS m / z calculated value 208.08235, found value 209.0 (M+1) + ; Retention time 1.22 minutes. 1HNMR (400MHz, DMSO-d6) δ11.91 (s, 1H), 7.52 (d, J = 2.2Hz, 1H), 5.69 (t, J = 2.3Hz, 1H), 4.06 (s, 2H), 1.19 (s, 6H).

[1608] Step C: tert-Butyl 2,6-dichloropyridine-3-carboxylate

[1609]

[1610] A solution of 2,6-dichloropyridine-3-carboxylic acid (10 g, 52.08 mmol) in THF (210 mL) was treated with di-tert-butyl dicarbonate (17 g, 77.89 mmol) and 4-(dimethylamino)pyridine (3.2 g, 26.19 mmol) in sequence and stirred at room temperature overnight. At this point, HCl 1N (400 mL) was added, and the mixture was stirred vigorously for about 10 minutes. The product was extracted with ethyl acetate (2×300 mL), and the combined organic layer was washed with water (300 mL) and brine (150 mL), dried over sodium sulfate and concentrated under reduced pressure to give 12.94 g (96% yield) of tert-butyl 2,6-dichloropyridine-3-carboxylate as a colorless oil. ESI-MS m / z calculated value 247.01668, found value 248.1 (M+1) + ; Retention time: 2.27 minutes. 1 HNMR (300MHz, CDCl3) ppm 1.60 (s, 9H), 7.30 (d, J = 7.9 Hz, 1H), 8.05 (d, J = 8.2 Hz, 1H).

[1611] Step D: 2-Chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxylic acid tert-butyl ester

[1612]

[1613] Potassium carbonate (7.53g, 54.5mmol) and 1,4-diazabicyclo [2.2.2] octane (706mg, 6.29mmol) were added to a DMF (110mL) solution of 2,6-dichloropyridine-3-carboxylic acid tert-butyl ester (10.4g, 41.9mmol) and 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)-1H-pyrazole (9.0g, 41.93mmol), and the mixture was stirred at room temperature for 16 hours. The cream suspension was cooled in a cold water bath, and cold water (130mL) was slowly added. The thick suspension was stirred at room temperature for 1 hour, filtered and washed with plenty of water to obtain 2-chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy) pyrazole-1-yl] pyridine-3-carboxylic acid tert-butyl ester (17.6g, 99%) as an off-white solid. ESI-MS m / z calculated value 419.12234, found value 420.0 (M+1) + ; Retention time: 2.36 minutes. 1 HNMR(400MHz,DMSO-d6)δ8.44(d,J=2.9Hz,1H),8.31(d,J=8.4Hz,1H),7.76(d ,J=8.4Hz,1H),6.26(d,J=2.9Hz,1H),4.27(s,2H),1.57(s,9H),1.24(s,6H).

[1614] Step E: 2-Chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxylic acid

[1615]

[1616] 2-Chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy) pyrazole-1-yl] pyridine-3-carboxylic acid tert-butyl ester (17.6g, 40.25mmol) was suspended in isopropanol (85mL) treated with hydrochloric acid (34mL, 6M, 201mmol) and heated to reflux for 3 hours (almost completely dissolved in the solution at reflux and began to precipitate again). The suspension was diluted with water (51mL) at reflux and cooled to room temperature for 2.5 hours under stirring. The solid was collected by filtration, washed with isopropanol / water 1: 1 (50mL), a large amount of water, and dried overnight in a drying oven under vacuum at 45-50°C with nitrogen purging to obtain 2-chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy) pyrazole-1-yl] pyridine-3-carboxylic acid (13.7g, 91%) as an off-white solid. ESI-MS m / z calculated value 363.05975, found value 364.0 (M+1) + ; Retention time: 1.79 minutes.1 HNMR(400MHz,DMSO-d6)δ13.61(s,1H),8.44(d,J=2.9Hz,1H),8.39(d,J=8.4H z, 1H), 7.77 (d, J = 8.4Hz, 1H), 6.25 (d, J = 2.9Hz, 1H), 4.28 (s, 2H), 1.24 (s, 6H).

[1617] Step F: 2-Chloro-N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxamide

[1618]

[1619] 2-Chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxylic acid (100 mg, 0.2667 mmol) and CDI (512 mg, 3.158 mmol) were combined in THF (582.0 μL), and the mixture was stirred at room temperature. At the same time, 1,3-dimethylpyrazole-4-sulfonyl chloride (62 mg, 0.3185 mmol) was combined with ammonia (in methanol) in a separate vial, and a white solid was immediately formed. After stirring for an additional 20 minutes, the volatiles were removed by evaporation, and 1 mL of dichloromethane was added to the solid residue and also evaporated. DBU (100 μL, 0.6687 mmol) was then added, and the mixture was stirred at 60 ° C for 5 minutes, and then THF (1 mL) was added and then evaporated. The contents of the vial containing the CDI activated carboxylic acid in THF were then added to the vial containing the newly formed sulfonamide and DBU, and the reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with 10 mL of ethyl acetate and washed with 10 mL of citric acid solution (1 M). The aqueous layer was extracted with ethyl acetate (2 × 10 mL), and the combined organics were washed with brine, dried over sodium sulfate, and concentrated to give the product as a white solid (137 mg, 99%), which was used in the next step without further purification. ESI-MS m / z calculated value 520.09076, found value 521.1 (M+1) + ; Retention time: 0.68 minutes.

[1620] Step G: N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide

[1621]

[1622] 2-Chloro-N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxamide (137 mg, 0.2630 mmol), (4S)-2,2,4-trimethylpyrrolidine (hydrochloride) (118 mg, 0.7884 mmol) and potassium carbonate (219 mg, 1.585 mmol) were mixed in DMSO (685.0 μL) and the mixture was heated at 130 °C for 16 hours. The reaction was cooled to room temperature and 1 mL of water was added. After stirring for 15 minutes, the contents of the vial were allowed to settle and the liquid portion was removed via a pipette and the remaining solid was dissolved with 20 mL of ethyl acetate and washed with 1 M citric acid (15 mL). The layers were separated and the aqueous layer was extracted twice more with 15 mL of ethyl acetate. The organics were combined, washed with brine, dried over sodium sulfate and concentrated. The obtained solid was further purified by silica gel chromatography with a methanol / dichloromethane (0-10%) gradient elution to give N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (72 mg, 41%) as a white solid. ESI-MS m / z calculated value 597.2345, found value 598.3 (M+1) + ; Retention time: 2.1 minutes. 1 HNMR (400MHz, DMSO) δ12.36(s,1H),8.37(s,1H),8.22(d,J=2.8Hz,1H),7.74(d,J=8.2Hz,1H ),6.93(d,J=8.2Hz,1H),6.17(d,J=2.8Hz,1H),4.23(s,2H),3.81(s,3H),2.56(d,J=10.4Hz ,1H),2.41(t,J=8.7Hz,1H),2.32(s,3H),2.18(dd,J=12.4,6.1Hz,1H),1.87(dd,J=11.7,5. 5Hz, 1H), 1.55 (d, J = 11.2Hz, 6H), 1.42 (t, J = 12.0Hz, 1H), 1.23 (s, 6H), 0.81 (d, J = 6.2Hz, 3H).

[1623] Alternative steps F and G:

[1624] Alternative Step F: 2-Chloro-N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)nicotinamide

[1625]

[1626] To a suspension of 2-chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxylic acid (20.0 g, 53.89 mmol) in THF (78.40 mL) was added solid carbonyldiimidazole (about 10.49 g, 64.67 mmol) portionwise and the resulting solution was stirred at room temperature (a slight exotherm from 18-21 °C was observed). After 1 hour, solid 1,3-dimethylpyrazole-4-sulfonamide (about 11.33 g, 64.67 mmol) was added, followed by DBU (about 9.845 g, 9.671 mL, 64.67 mmol) in two equal portions over 1 minute (exotherm from 19 °C to 35 °C). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with ethyl acetate (118 mL) and then diluted with HCl (2M, about 107.8 mL, 215.6 mmol). The phases were separated and the aqueous phase was extracted with ethyl acetate (78 mL). The combined organics were washed with water (39.2 mL), then brine (40 mL), dried over sodium sulfate and concentrated. The resulting foam was crystallized from a 1:1 isopropanol:heptane mixture (80 mL) to give 2-chloro-N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)nicotinamide (26.1 g, 93%) as a white solid. ESI-MS m / z calculated value 520.0, found value 520.9 (M+1) + ; Retention time: 1.83 minutes.

[1627] Alternative Step G: N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide

[1628]

[1629] In a 500-mL flask with a reflux condenser, 2-chloro-N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxamide (20.0 g, 38.39 mmol), (4S)-2,2,4-trimethylpyrrolidine (hydrochloride) (about 14.36 g, 95.98 mmol) and K2CO3 (about 26.54 g, 192.0 mmol) were combined in DMSO (80.00 mL) and 1,2-diethoxyethane (20.00 mL). The reaction mixture was heated at 120 °C for 16 hours and then cooled to room temperature. The reaction was diluted with DCM (200.0 mL) and HCl (2M, about 172.8 mL, 345.5 mmol); the aqueous solution pH ~1. The phases were separated and the aqueous phase was extracted with DCM (100.0 mL). The organic phases were combined, washed (3×) with water (100.0 mL), and dried (Na2SO4) to give an amber solution. The solution was filtered through a bed of silica gel (80 g; 4 g / g) filled with DCM and washed with 20% EtOAc / DCM (5×200 mL). The combined filtrate / washings were concentrated to give 22.2 g of an off-white powder. The powder was slurried in MTBE (140 mL) for 30 minutes. The solids were collected by filtration (paper / sintered glass) and air-dried to give 24 g. The solids were transferred to a drying pan and dried under vacuum (40°C / 200 Torr / N2 purge) overnight to give 20.70 g (90%) of a white powder. ESI-MS m / z calculated value 597.2345, found value 598.0 (M+1)+; retention time 2.18 minutes.

[1630] 1 H NMR (400 MHz, chloroform-d) δ 13.85 (s, 1H), 8.30 (d, J = 8.6 Hz, 1H), 8.23 ​​(d, J = 2.8 Hz, 1H), 8.08 (s, 1H), 7.55 (d, J = 8.5 Hz, 1H), 5.98 (d, J = 2.8 Hz, 1H), 4.24 (s, 2H), 3.86 (s, 3H), 3.44 (dd, J = 10.3, 8 .4Hz,1H),3.09(dd,J=10.3,7.8Hz,1H),2.67–2.52(m,1H),2.47(s,3H),2.12(dd,J=12.3,7 .8Hz,1H),1.70(dd,J=12.4,9.6Hz,1H),1.37(s,3H),1.33(s,3H),1.27(s,6H),1.20(d,3H).

[1631] Alternative Synthesis of 3-(3,3,3-Trifluoro-2,2-dimethyl-propoxy)-1H-pyrazole

[1632]

[1633] Step 1: Preparation of 3,3,3-trifluoro-2,2-dimethylpropan-1-ol

[1634]

[1635] Toluene (300mL) and 3,3,3-trifluoro-2,2-dimethylpropionic acid (30g, 192.2mmol) were loaded into the reactor, capped and purged under nitrogen. The reaction was set to control the internal temperature to 40°C. Red aluminum (Vitride) solution (65% in toluene, about 119.6g of 65% w / w, 115.4mL of 65% w / w, 384.4mmol) was added by syringe, and the addition was started at 40°C, with a target addition temperature of 40-50°C. The reaction was stirred at 40°C for 90 minutes. The reaction was cooled to 10°C, and the remaining red aluminum was quenched by slowly adding water (6mL). 15% NaOH aqueous solution (30mL) was added portionwise, and solids were precipitated halfway through the addition process by adding alkali. Water (60.00mL) was added. The mixture was warmed to 30°C and maintained for at least 15 minutes. The mixture was then cooled to 20°C. The water layer was removed. The organic layer was washed with water (60 mL×3) and then with brine (60 mL). The washed organic layer was dried over Na2SO4 and then over MgSO4. The mixture was filtered through celite, and the filter cake was washed with toluene (60.00 mL) and dried. The product 3,3,3-trifluoro-2,2-dimethyl-propan-1-ol (22.5 g, 82%) was obtained as a clear colorless solution.

[1636] Step 2: Preparation of 1-(tert-butyl)4-ethyl 3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazole-1,4-dicarboxylate

[1637]

[1638] The reactor was charged with a solution of 3,3,3-trifluoro-2,2-dimethylpropan-1-ol (17.48 g, 123.0 mmol) in toluene (250 g), 1-(tert-butyl)-4-ethyl 3-hydroxy-1H-pyrazole-1,4-dicarboxylate (30.0 g, 117.1 mmol), and PPh3 (35.33 g, 134.7 mmol). The reaction was heated to 40°C. DIAD (26.09 mL, 134.7 mmol) was weighed into a syringe and added over 10 minutes while maintaining the internal temperature between 40 and 50°C. The reaction was then heated to 100°C over 30 minutes. After 30 minutes at 100°C, the reaction was complete and the mixture was cooled to 70°C over 15 minutes. Heptane (180.0 mL) was added and the jacket was cooled to 15°C over 1 hour. (TPPO begins to crystallize at ~35°C). The stirred mixture at 15°C was filtered (quickly) and the filter cake was washed with a premixed solution of toluene (60 mL) and heptane (60 mL) and then dried. The clear solution was concentrated to a waxy solid (45°C, vacuum, rotary evaporator). Crude 3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazole-1,4-dicarboxylic acid 1-(tert-butyl) 4-ethyl ester (53.49 g) was obtained as a waxy solid (~120% theoretical mass recovery).

[1639] Step 3: Preparation of 3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazole-4-carboxylic acid

[1640]

[1641] A solution of 3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazole-1,4-dicarboxylic acid 1-(tert-butyl) 4-ethyl ester (50.0 g, 131 mmol) in 2-methyltetrahydrofuran (500 mL) was prepared in a reactor and stirred at 40°C. A portion of KOt-Bu (80.85 g, 720.5 mmol) was then added over 30 minutes. The addition was exothermic. After 2053.49 g UPLC-MS showed complete removal of the Boc group, water (3.53 g, 3.53 mL, 196 mmol) was added dropwise via a syringe over 20 minutes to maintain the reaction temperature between 40-50°C. The mixture was then stirred for 17 hours to complete the reaction. The mixture was then cooled to 20°C and water (400 mL) was added. Stirring was stopped and the layers were separated. The desired product in the aqueous layer was returned to the reactor and the organic layer was discarded. The aqueous layer was washed with 2-Me-THF (200 mL). Isopropanol (50. mL) was added, followed by a dropwise addition of HCl aqueous solution (6.0 M, 131 mL, 786.0 mmol) to adjust the pH to <3 while maintaining the temperature below 30 ° C. The resulting solid was then separated by filtration, and the filter cake was washed with water (100 mL) and then dried until a sticky filter cake was obtained. The solid was then dried in vacuo at 55 ° C to obtain 3- (3,3,3- trifluoro-2,2-dimethylpropoxy) -1H- pyrazole -4- carboxylic acid (23.25 g) as an off-white fine solid.

[1642] Step 4: Preparation of 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)-1H-pyrazole

[1643] 3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazole-4-carboxylic acid (1.0 equiv) was added to the reactor, followed by DMF (6.0 vol, 2.6 wt equiv). The mixture was stirred at 18–22°C. DBU (0.2 equiv) was charged to the reaction mixture at a rate of about 45 mL / min. The reaction temperature was then raised to 98–102°C over 45 minutes. The reaction mixture was stirred at 98–102°C for no less than 10 hours. The reaction mixture was then cooled to -2°C to 2°C over about 1 hour and used without isolation to prepare ethyl 2-chloro-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)nicotinate.

[1644] Alternative Procedure for the Preparation of 2-Chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxylic acid

[1645]

[1646] Step 1. 2-Chloro-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)nicotinate

[1647]

[1648] A solution of ethyl 2,6-dichloronicotinate (256 g, 1.16 mol) and 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)-1H-pyrazole (242 g, 1.16 mol) in DMF (1.53 L) was treated with potassium carbonate (209 g, 1.51 mol) and DABCO (19.6 g, 174 mmol). The resulting suspension was stirred, exothermed from 14°C to 25°C, and then kept externally cooled at 20-25°C for 3 days. The suspension was cooled to below 10°C while water (2.0 L) was added in a thin stream, while keeping the temperature below 25°C. After the addition was complete, the suspension was stirred for another hour. The solid was collected by filtration (sintered glass / polypad), and the filter cake was washed with water (2×500-mL) and dried under vacuum for 2 h to give water-wet ethyl 2-chloro-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)nicotinate (512 g; 113% yield) as a white powder, which was used in the subsequent reaction without further steps.

[1649] Step 2. 2-Chloro-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)nicotinic acid

[1650]

[1651]

[0136] Water-wet ethyl 2-chloro-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)nicotinate (455 g, 1.16 mol; assumed 100% yield from previous step) in EtOH (1.14 L) and THF (455 mL) was stirred at ambient temperature (17°C) upon addition of 1 M NaOH (1.16 L, 1.16 mol). The reaction mixture was allowed to exotherm to 30°C and further warmed at 40°C for 2 h. The solution was quenched with 1 M HCl (1.39 L, 1.39 mol), which resulted in an immediate precipitation that became thicker as the acid was added. The creamy suspension was allowed to cool to room temperature and stirred overnight. The solid was collected by filtration (sintered glass / poly pad). The filter cake was washed with water (2 x 500-mL). The filter cake was dried by suction for 1 h, but remained wet. The wet solid was transferred to a 10-L Buchi flask for further drying (50°C / 20 Torr), but further efforts to dry by adding i-PrOH were ineffective. After the wet solid was backfilled with i-PrOAc (3 L), successful drying was completed, the suspension was heated at 60°C (homogenized), and reconcentrated to dryness (50°C / 20 Torr) to give dry 2-chloro-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1h-pyrazol-1-yl)nicotinic acid (408 g; 97% yield for two steps) as a fine white powder. The product was further dried in a vacuum oven (50°C / 10 Torr / N2 purge) for 2 hours, but a slight weight loss was observed. 1H NMR (400 MHz, DMSO-d6) δ13.64 (s, 1H), 8.49–8.36 (m, 2H), 7.77 (d, J=8.4 Hz, 1H), 6.26 (d, J=2.8 Hz, 1H), 4.28 (s, 2H), 1.24 (s, 6H). 19F NMR (376 MHz, DMSO-d6) δ-75.2. KF analysis: 0.04% water.

[1652] Preparation of Form A of Compound I

[1653] Crystalline Form A of Compound I was obtained by the following synthesis. In a 1-L RB flask with a reflux condenser, combined 2-chloro-N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxamide (108 g, 207.3 mmol), (4S)-2,2,4-trimethylpyrrolidine (hydrochloride) (77.55 g, 518.2 mmol) and K2CO3 (143.2 g, 1.036 mol) in DMSO (432.0 mL) and 1,2-diethoxyethane (108.0 mL) were combined. The resulting suspension was heated at 120° C. and stirred at this temperature overnight. The reactant was then diluted with DCM (1.080 L), and HCl (2M, 933.0 mL, 1.866 mol) was slowly added. The liquid phase was separated, and the aqueous phase was extracted with DCM (540.0 mL). The organic phases were combined, washed with water (540.0 mL) (3x), and then dried with (Na2SO4) to give an amber solution. Silica gel (25 g) was added, and the desiccant / silica gel was filtered out. The filter bed was washed with DCM (3×50 mL). The organic phases were combined and concentrated (40°C / 40 Torr) to give crude N-(1,3-dimethylpyrazole-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (198.6 g, 160% theoretical value) as an off-white solid. The solid was diluted with MTBE (750 mL), warmed at 60° C. (external temperature), and mixed to a homogeneous suspension. The suspension was cooled to 30° C. with stirring, and the solid was collected by filtration, air-dried, and dried in vacuo to give Compound I (111.1 g; 90%) as a fine white powder.

[1654] Crystalline Form A of Compound I was also obtained by the following steps. A suspension of Compound I (150.0 g, 228.1 mmol) in iPrOH (480 mL) and water (120 mL) was heated at 82 ° C to obtain a solution. The solution was cooled with a J-Kem controller at a cooling rate of 10 ° C / h. Once the temperature reached 74 ° C, the solution was seeded with a sample of Compound I in crystalline Form A. Crystallization occurred immediately. The sample was cooled to ~ 5 ° C, stirred for 1 hour, and then the solid was collected by filtration (sintered glass / paper). The filter cake was washed with i-PrOH (75 mL) (2x), air-dried, air-dried in a drying pan (mostly dried to 120.6 g), vacuum dried (55 ° C / 300 Torr / N2 purge) for 4 hours, and then overnight at room temperature. Overnight drying gave 118.3 g (87% yield) of white powder.

[1655] A suspension of compound I (116 g, 176.3 mmol) in iPrOH (371 mL) and water (93 mL) was heated at 82 ° C to obtain a solution. The solution was cooled to 20 ° C with a J-Kem controller at a cooling rate of 10 ° C / h. Once the temperature reached 74 ° C, the solution was seeded with a sample of compound I in crystalline form A. Crystallization occurred immediately. Cooling was stopped at 20 ° C, and the mixture was stirred overnight. The solid was collected by filtration, washed with i-PrOH (2x 75 mL), evacuated and air-dried, and vacuum dried (55 ° C / 300 Torr / N2 purged) to obtain Compound I Form A (103.3 g) as a white powder.

[1656] Example 2: Compound II: Synthesis of (R)-1-(2,2-difluorobenzo[d][1,3]dioxazol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

[1657]

[1658] Step 1: (R)-benzyl 2-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-nitro-1H-indol-2-yl)-2-methylpropanoate and ((S)-2-(1-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-nitro-1H-indol-2-yl)-2-methylpropanoate

[1659] Cesium carbonate (8.23 g, 25.3 mmol) was added to a mixture of 2-(6-fluoro-5-nitro-1H-indol-2-yl)-2-methylpropionic acid benzyl ester (3.0 g, 8.4 mmol) and (S)-4-methylbenzenesulfonic acid (2,2-dimethyl-1,3-dioxolane-4-yl) methyl ester (7.23 g, 25.3 mmol) in DMF (N,N-dimethylformamide) (17 mL). The reaction was stirred at 80 ° C under a nitrogen atmosphere for 46 hours. The mixture was then distributed between ethyl acetate and water. The water layer was extracted with ethyl acetate. The combined ethyl acetate layer was washed with brine, dried over MgSO4, filtered and concentrated. The crude product (a viscous brown oil containing the above two products) can be directly used in the next step without further purification. (R)-2-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-nitro-1H-indol-2-yl)-2-methylpropanoic acid benzyl ester, ESI-MS m / z calculated value 470.2, found value 471.5 (M+1) +. Retention time 2.20 minutes. ((S)-2-(1-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-nitro-1H-indol-2-yl)-2-methylpropanoic acid 2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester, ESI-MS m / z calculated value 494.5, found value 495.7 (M+1) + . Retention time 2.01 minutes.

[1660] Step 2: (R)-2-(1-((2,2-dimethyl-1,3-dioxol-4-yl)methyl)-6-fluoro-5-nitro-1H-indol-2-yl)-2-methylpropan-1-ol

[1661] The crude reaction mixture obtained in step (A) is dissolved in THF (tetrahydrofuran) (42mL), and cooled in an ice-water bath. LiAlH4 (16.8mL 1M solution, 16.8mmol) is added dropwise. After the addition is completed, the mixture is stirred for another 5 minutes. The reaction is quenched by adding water (1mL), 15% NaOH solution (1mL), and then adding water (3mL). The mixture is filtered through diatomaceous earth, and the solid is washed with THF and ethyl acetate. The filtrate is concentrated, and purified by column chromatography (30%-60% ethyl acetate-hexane) to obtain (R) -2- (1- ((2,2- dimethyl -1,3- dioxolane -4- bases) methyl) -6- fluoro-5- nitro -1H- indol -2- bases) -2- methyl propan-1-ol (through 2 steps 2.68g, 87%) as a brown oil. ESI-MS m / z calculated value 366.4, found value 367.3 (M+1) + . Retention time 1.68 minutes. 1 H NMR (400 MHz, DMSO-d6) δ 8.34 (d, J = 7.6 Hz, 1H), 7.65 (d, J = 13.4 Hz, 1H), 6.57 (s, 1H), 4.94 (t, J = 5.4 Hz, 1H), 4.64-4.60 (m, 1H), 4.52-4.42 (m, 2H), 4.16-4.14 (m, 1H), 3.76-3.74 (m, 1H), 3.63-3.53 (m, 2H), 1.42 (s, 3H), 1.38-1.36 (m, 6H) and 1.19 (s, 3H) ppm. (DMSO is dimethyl sulfoxide).

[1662] Step 3: (R)-2-(5-amino-1-((2,2-dimethyl-1,3-dioxol-4-yl)methyl)-6-fluoro-1H-indol-2-yl)-2-methylpropan-1-ol

[1663] (R)-2-(1-((2,2-dimethyl-1,3-dioxol-4-yl)methyl)-6-fluoro-5-nitro-1H-indol-2-yl)-2-methylpropan-1-ol (2.5 g, 6.82 mmol) was dissolved in ethanol (70 mL) and the reaction was flushed with N2. Pd—C (250 mg, 5% by weight) was ...

Claims

1. A single tablet comprising: (a) 12.5 mg to 100 mg of Compound I: (b) a first solid dispersion comprising 25 mg to 50 mg of Compound II: and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion, wherein the polymer is selected from a cellulose-based polymer and a vinyl-based polymer; and (c) a second solid dispersion comprising 37.5 mg to 150 mg of Compound III: and 10 to 30 wt% of a polymer relative to the total weight of the second solid dispersion, wherein the polymer is selected from a cellulose-based polymer and a vinyl-based polymer.

2. A single tablet as claimed in claim 1, comprising 12.5 mg to 25 mg of Compound I.

3. A single tablet comprising: (a) 4 to 27 wt% of Compound I relative to the total weight of the single tablet: (b) 9 wt % to 17 wt % of the first solid dispersion relative to the total weight of the single tablet, The first solid dispersion comprises 70% to 90% by weight of Compound II relative to the total weight of the first solid dispersion: and 10 wt % to 30 wt % of a polymer relative to the total weight of the first solid dispersion, wherein the polymer is selected from a cellulose-based polymer and a vinyl-based polymer; and (c) 18 wt % to 40 wt % of a second solid dispersion relative to the total weight of the single tablet; The second solid dispersion comprises 70% to 90% by weight of compound III relative to the total weight of the second solid dispersion: and 10 to 30 wt% of a polymer relative to the total weight of the second solid dispersion, wherein the polymer is selected from a cellulose-based polymer and a vinyl-based polymer.

4. A single tablet as described in claim 1 or 3, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose; and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate.

5. The single tablet of claim 1 or 3, wherein the polymer in the first solid dispersion is hydroxypropyl methylcellulose (HPMC E15); and the polymer in the second solid dispersion is hydroxypropyl methylcellulose acetate succinate H.

6. A single tablet comprising: (a) 12.5 mg to 125 mg of Compound I: (b) 60 mg to 65 mg of a first solid dispersion, wherein the first solid dispersion comprises 80 wt % of Compound II relative to the total weight of the first solid dispersion: and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion; and (c) 90 mg to 95 mg or 180 mg to 190 mg of a second solid dispersion, the second solid dispersion comprising 80 wt % of Compound III relative to the total weight of the second solid dispersion: 0.5 wt% of sodium lauryl sulfate relative to the total weight of the second solid dispersion; and 19.5 wt% of hydroxypropylmethylcellulose acetate succinate relative to the total weight of the second solid dispersion; (d) 85 mg to 275 mg microcrystalline cellulose; (e) 10 mg to 35 mg croscarmellose sodium; and (f) 2 mg to 7 mg magnesium stearate.

7. A single tablet comprising: (a) 4 to 27 wt% of Compound I relative to the total weight of the single tablet: (b) 7 to 14 wt% of Compound II relative to the total weight of the single tablet: (c) 14 wt % to 33 wt % of Compound III relative to the total weight of the single tablet: (d) 20% to 41% by weight of microcrystalline cellulose relative to the total weight of the single tablet; (e) 4.5 wt% to 6 wt% of croscarmellose sodium relative to the total weight of the single tablet; and (f) 0.5 wt% to 1.0 wt% of magnesium stearate relative to the total weight of the single tablet.

8. A single tablet comprising: (a) 4 to 27 wt% of Compound I relative to the total weight of the single tablet: (b) 7 to 14 wt% of Compound II relative to the total weight of the single tablet: (c) 15% to 33% by weight of Compound III relative to the total weight of the single tablet: (d) 19 wt % to 41 wt % of microcrystalline cellulose relative to the total weight of the single tablet; (e) 4.5 wt% to 6 wt% of croscarmellose sodium relative to the total weight of the single tablet; and (f) 0.5 wt% to 1 wt% of magnesium stearate relative to the total weight of the single tablet.

9. Use of a single tablet according to any one of claims 1 to 8 in the preparation of a medicament for treating cystic fibrosis in a patient.

10. A method for preparing a single tablet as claimed in claim 6, the method comprising (a) mixing Compound 1 with the first solid dispersion and the second solid dispersion to form a first mixture; and (b) compressing a tablet mixture comprising the first mixture into tablets.

11. A method for preparing a single tablet as claimed in claim 6, the method comprising (a) mixing Compound 1 with the first solid dispersion and the second solid dispersion to form a first mixture; (b) mixing the first mixture with the microcrystalline cellulose, croscarmellose sodium and magnesium stearate to form a tableting mixture; and (c) compressing the tablet mixture into tablets.